<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="urn:hl7-org:v3" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="31bc3385-44c4-6a3a-e063-6294a90aaad0"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>
      <content styleCode="bold">These highlights do not include all the information needed to use</content>
      <content styleCode="bold">MYCOPHENOLATE MOFETIL</content>
      <content styleCode="bold">safely and effectively. See full prescribing information for MYCOPHENOLATE MOFETIL.</content>
      <content styleCode="bold">MYCOPHENOLATE</content>
      <content styleCode="bold">MOFETIL</content>
      <content styleCode="bold">capsules, for oral use</content>
      <content styleCode="bold">MYCOPHENOLATE</content>
      <content styleCode="bold">MOFETIL</content>
      <content styleCode="bold">tablets, for oral use</content>
      <br/>
      <br/>
      <br/>
      <br/>
      <content styleCode="bold">Initial U.S. Approval: 1995</content>
   </title>
   <effectiveTime value="20250401"/>
   <setId root="90336570-e701-4f50-a19f-b5e7d6f2d293"/>
   <versionNumber value="8"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id root="1.3.6.1.4.1.519.1" extension="829572556"/>
            <name>REMEDYREPACK INC.</name>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="31bc2fd6-1be2-cdd8-e063-6394a90a6ac5"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20250401"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="70518-2835" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>mycophenolate mofetil</name>
                        <formCode code="C25158" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>mycophenolate mofetil</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <asEquivalentEntity classCode="EQUIV">
                           <code code="C64637" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <definingMaterialKind>
                              <code code="16729-094" codeSystem="2.16.840.1.113883.6.69"/>
                           </definingMaterialKind>
                        </asEquivalentEntity>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="M28OL1HH48" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CROSCARMELLOSE SODIUM</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CELLULOSE, MICROCRYSTALLINE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="RDH86HJV5Z" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POVIDONE K90</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="UKE75GEA7F" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYDROXYPROPYL CELLULOSE (90000 WAMW)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7SEV7J4R1U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TALC</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="L06K8R7DQK" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FD&amp;C BLUE NO. 2</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="2G86QN327L" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>GELATIN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="1K09F3G675" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FERRIC OXIDE RED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="368GB5141J" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM LAURYL SULFATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EX438O2MRT" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FERRIC OXIDE YELLOW</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="46N107B71O" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SHELLAC</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="WZH3C48M4T" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POTASSIUM HYDROXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="XM0M87F357" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FERROSOFERRIC OXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="250"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="9242ECW6R0" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MYCOPHENOLATE MOFETIL</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="HU9DX48N0T" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>MYCOPHENOLIC ACID</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="1" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="70518-2835-1" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43200" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="POUCH"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="100" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="70518-2835-0" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43178" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOX"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20200818"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA090253" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20200818"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48333" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="blue" xsi:type="CE">
                              <originalText>light blue</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48331" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="orange" xsi:type="CE">
                              <originalText>peach</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">GC1</value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48336" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="19" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="BOX">
               <id root="130317dd-7114-69c9-e063-6394a90adc55"/>
               <code code="34066-1" codeSystem="2.16.840.1.113883.6.1" displayName="BOXED WARNING SECTION"/>
               <title>WARNING: EMBRYOFETAL TOXICITY, MALIGNANCIES and SERIOUS INFECTIONS</title>
               <text>
                  <list listType="unordered">
                     <item>
                        <content styleCode="bold">Use during pregnancy is associated with increased risks of first trimester pregnancy loss and congenital malformations. Avoid if safer treatment options are available. Females of reproductive potential must be counseled regarding pregnancy prevention and planning
   
    <content styleCode="italics">[see
    
     <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>,
    
     <linkHtml href="#S8.1">Use in Special Populations (8.1</linkHtml>,
    
     <linkHtml href="#S8.3">8.3)</linkHtml>]
   
    </content>.
  
   </content>
                     </item>
                     <item>
                        <content styleCode="bold">Increased risk of development of lymphoma and other malignancies, particularly of the skin
   
    <content styleCode="italics">[see
    
     <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>]
   
    </content>.
  
   </content>
                     </item>
                     <item>
                        <content styleCode="bold">Increased susceptibility to bacterial, viral, fungal and protozoal infections, including opportunistic infections and viral reactivation of hepatitis B and C, which may lead to hospitalizations and fatal outcomes
   
    <content styleCode="italics">[see
    
     <linkHtml href="#S5.3">Warnings and Precautions (5.3)</linkHtml>]
   
    </content>.
  
   </content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20240306"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>WARNING: EMBRYOFETAL TOXICITY, MALIGNANCIES and SERIOUS INFECTIONS</paragraph>
                        <paragraph>
                           <content styleCode="italics">See full prescribing information for complete boxed warning</content>
                        </paragraph>
                        <list listType="unordered">
                           <item>
                              <content styleCode="bold">Use during pregnancy is associated with increased risks of first trimester pregnancy loss and congenital malformations. Avoid if safer treatment options are available. Females of reproductive potential must be counseled regarding pregnancy prevention and planning
   
      <content styleCode="italics">[see
    
       <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>].
   
      </content>
                              </content>
                           </item>
                           <item>
                              <content styleCode="bold">Increased risk of development of lymphoma and other malignancies, particularly of the skin
   
      <content styleCode="italics">[see
    
       <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>]
   
      </content>.
  
     </content>
                           </item>
                           <item>
                              <content styleCode="bold">Increased susceptibility to infections, including opportunistic infections and severe infections with fatal outcomes
   
      <content styleCode="italics">[see
    
       <linkHtml href="#S5.3">Warnings and Precautions (5.3)</linkHtml>].
   
      </content>
                              </content>
                           </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="sRMC">
               <id root="1311f590-ce30-dec5-e063-6294a90a4440"/>
               <code code="43683-2" codeSystem="2.16.840.1.113883.6.1" displayName="RECENT MAJOR CHANGES SECTION"/>
               <text/>
               <effectiveTime value="20240306"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Indications and Usage, Pediatric Heart or Liver Transplants ( 1) 6/2022
    <br/>
Dosage and Administration, Dosage Recommendations for Heart Transplant Patients ( 2.3) 6/2022
    <br/>
Dosage and Administration, Dosage Recommendations for Liver Transplant Patients ( 2.4) 6/2022
    <br/>
Warnings and Precautions, Serious Infections ( 5.3) 10/2021
    <br/>
Warnings and Precautions, Acute Inflammatory Syndrome Associated with Mycophenolate Products ( 5.11) 10/2021
   </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S1">
               <id root="130317dd-7116-69c9-e063-6394a90adc55"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>
                     <content styleCode="xmChange">Mycophenolate mofetil (MMF) is indicated for the prophylaxis of organ rejection, in adult and pediatric recipients 3 months of age and older of allogeneic kidney
 
   <content styleCode="italics">[see
  
    <linkHtml href="#S14.1">Clinical Studies (14.1)</linkHtml>]
 
   </content>, heart
 
   <content styleCode="italics">[see
  
    <linkHtml href="#S14.2">Clinical Studies (14.2)</linkHtml>]
 
   </content>or liver transplants
 
   <content styleCode="italics">[see
  
    <linkHtml href="#S14.3">Clinical Studies (14.3)</linkHtml>],
 
   </content>in combination with other immunosuppressants.

  </content>
                  </paragraph>
               </text>
               <effectiveTime value="20240306"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Mycophenolate mofetil is an antimetabolite immunosuppressant indicated for the prophylaxis of organ rejection in adult and pediatric recipients 3 months of age and older of allogeneic kidney, heart or liver transplants, in combination with other immunosuppressants (
 
    <linkHtml href="#S1">1</linkHtml>)

   </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S2">
               <id root="130317dd-7117-69c9-e063-6394a90adc55"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <effectiveTime value="20240306"/>
               <excerpt>
                  <highlight>
                     <text>
                        <table width="100%">
                           <col width="50%" align="center" valign="top"/>
                           <col width="50%" align="left" valign="top"/>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td align="left" styleCode="Lrule Rrule">
                                    <content styleCode="bold">ADULTS</content>
                                 </td>
                                 <td align="left" styleCode="Rrule">
                                    <content styleCode="bold">DOSAGE</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="underline">Kidney Transplant</content>
                                 </td>
                                 <td styleCode="Rrule">1 g twice daily, orally (
    
       <linkHtml href="#S2.2">2.2</linkHtml>)
   
      </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="underline">Heart Transplant</content>
                                 </td>
                                 <td styleCode="Rrule">1.5 g twice daily orally (
    
       <linkHtml href="#S2.3">2.3</linkHtml>)
   
      </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="underline">Liver Transplant</content>
                                 </td>
                                 <td styleCode="Rrule">1.5 g twice daily orally (
    
       <linkHtml href="#S2.4">2.4</linkHtml>)
   
      </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="left" styleCode="Lrule Rrule">
                                    <content styleCode="bold">PEDIATRICS</content>
                                 </td>
                                 <td styleCode="Rrule"/>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Botrule">
                                    <content styleCode="underline">Kidney Transplant</content>
                                 </td>
                                 <td styleCode="Rrule Botrule">600 mg/m
    
       <sup>2</sup>orally twice daily, up to maximum of 2 g daily (
    
       <linkHtml href="#S2.2">2.2</linkHtml>)
   
      </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Botrule">
                                    <content styleCode="underline">Heart Transplant</content>
                                 </td>
                                 <td styleCode="Rrule Botrule">600 mg/m
    
       <sup>2</sup>orally twice daily, (starting dose) up to a maximum of 900 mg/m
    
       <sup>2</sup>twice daily (3 g) (
    
       <linkHtml href="#S2.3">2.3</linkHtml>)
   
      </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Botrule">
                                    <content styleCode="underline">Liver Transplant</content>
                                 </td>
                                 <td styleCode="Rrule Botrule">600 mg/m
    
       <sup>2</sup>orally twice daily,daily (starting dose) up to a maximum of 900 mg/m
    
       <sup>2</sup>twice daily (3 g) (
    
       <linkHtml href="#S2.2">2.4</linkHtml>)
   
      </td>
                              </tr>
                           </tbody>
                        </table>
                        <list listType="unordered">
                           <item>Reduce or interrupt dosing in the event of neutropenia. (
  
     <linkHtml href="#S2.5">2.5</linkHtml>)
 
    </item>
                           <item>See full prescribing information (FPI) for: adjustments for renal impairment and neutropenia (
  
     <linkHtml href="#S2.5">2.5</linkHtml>)
 
    </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S2.1">
                     <id root="130317dd-7118-69c9-e063-6394a90adc55"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1 Important Administration Instructions</title>
                     <text>
                        <paragraph>Mycophenolate mofetil should not be used without the supervision of a physician with experience in immunosuppressive therapy.</paragraph>
                     </text>
                     <effectiveTime value="20240306"/>
                     <component>
                        <section>
                           <id root="130317dd-7119-69c9-e063-6394a90adc55"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Mycophenolate Mofetil Capsules and Tablets</content>
                              </paragraph>
                              <paragraph>Mycophenolate mofetil oral dosage forms (capsules or tablets)
 
  <content styleCode="bold">should not be used interchangeably with mycophenolic acid delayed-release tablets without supervision of a physician with experience in immunosuppressive therapy</content>because the rates of absorption following the administration of mycophenolate mofetil oral dosage forms and mycophenolic acid delayed-release tablets are not equivalent.

 </paragraph>
                              <paragraph>Mycophenolate mofetil tablets should not be crushed and mycophenolate mofetil capsules should not be opened or crushed. Patients should avoid inhalation or contact of the skin or mucous membranes with the powder contained in mycophenolate mofetil capsules and oral suspension. If such contact occurs, they must wash the area of contact thoroughly with soap and water. In case of ocular contact, rinse eyes with plain water.</paragraph>
                              <paragraph>The initial oral dose of mycophenolate mofetil should be given as soon as possible following kidney, heart or liver transplant. It is recommended that mycophenolate mofetil be administered on an empty stomach. In stable transplant patients, however, mycophenolate mofetil may be administered with food if necessary
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]
 
  </content>.

 </paragraph>
                              <paragraph>Patients should be instructed to take a missed dose as soon as they remember, except if it is closer than 2 hours to the next scheduled dose; in this case, they should continue to take mycophenolate mofetil at the usual times.</paragraph>
                           </text>
                           <effectiveTime value="20240306"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S2.2">
                     <id root="130317dd-711a-69c9-e063-6394a90adc55"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2 Dosage Recommendations for Kidney Transplant Patients</title>
                     <effectiveTime value="20240306"/>
                     <component>
                        <section>
                           <id root="130317dd-711b-69c9-e063-6394a90adc55"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Adults</content>
                              </paragraph>
                              <paragraph>The recommended dosage for adult kidney transplant patients is 1 g orally or intravenously infused over no less than 2 hours, twice daily (total daily dose of 2 g).</paragraph>
                           </text>
                           <effectiveTime value="20240306"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="130317dd-711c-69c9-e063-6394a90adc55"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Pediatrics (3 months and olderer)</content>
                              </paragraph>
                              <paragraph>Pediatric dosing is based on body surface area (BSA).The recommended dosage of mycophenolate mofetil oral suspension for pediatric kidney transplant patients 3 months and older is 600 mg/m
 
  <sup>2</sup>, administered twice daily (maximum total daily dose of 2 g or 10 mL of the oral suspension). Pediatric patients with BSA ≥1.25 m
 
  <sup>2</sup>may be dosed with capsules or tablets as follows:

 </paragraph>
                              <table width="100%" ID="Table1">
                                 <caption>Table 1 Pediatric Kidney Transplant: Dosage Using Capsules or Tablets</caption>
                                 <col width="25%" align="left" valign="top"/>
                                 <col width="75%" align="left" valign="top"/>
                                 <thead>
                                    <tr>
                                       <th styleCode="Lrule Rrule">Body Surface Area</th>
                                       <th styleCode="Rrule">Dosage</th>
                                    </tr>
                                 </thead>
                                 <tbody>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">1.25 m
    
     <sup>2</sup>to &lt;1.5 m
    
     <sup>2</sup>
                                       </td>
                                       <td styleCode="Rrule">Mycophenolate mofetil capsule 750 mg twice daily (1.5 g total daily dose)</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">≥ 1.5 m
    
     <sup>2</sup>
                                       </td>
                                       <td styleCode="Rrule">Mycophenolate mofetil capsules or tablets 1 g twice daily (2 g total daily dose)</td>
                                    </tr>
                                 </tbody>
                              </table>
                           </text>
                           <effectiveTime value="20240306"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S2.3">
                     <id root="130317dd-711d-69c9-e063-6394a90adc55"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.3 Dosage Recommendations for Heart Transplant Patients</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Adults</content>
                        </paragraph>
                        <paragraph>The recommended dosage of mycophenolate mofetil for adult heart transplant patients is 1.5 g orally twice daily (total daily dose of 3 g).</paragraph>
                        <paragraph>
                           <content styleCode="xmChange">Pediatric patients with BSA ≥1.25 m
 
   <sup>2</sup>may be started on therapy with capsules or tablets as follows:

  </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">
                              <content styleCode="bold">Table 2 Pediatric Heart Transplant: Pediatric Starting Dosage Using Capsules or Tablets</content>
                           </content>
                        </paragraph>
                        <table width="100%" ID="Table2">
                           <col width="25%" align="left" valign="top"/>
                           <col width="75%" align="left" valign="top"/>
                           <thead>
                              <tr>
                                 <th styleCode="Lrule Rrule">Body Surface Area</th>
                                 <th styleCode="Rrule">Starting Dosage
    
     <footnote ID="t1f1">Maximum maintenance dose: 3 g total daily.</footnote>
                                 </th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">1.25 m
    
     <sup>2</sup>to &lt;1.5 m
    
     <sup>2</sup>
                                 </td>
                                 <td styleCode="Rrule">Mycophenolate mofetil capsule 750 mg twice daily (1.5 g total daily dose)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">≥ 1.5 m
    
     <sup>2</sup>
                                 </td>
                                 <td styleCode="Rrule">Mycophenolate mofetil capsules or tablets 1 g twice daily (2 g total daily dose)</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20240306"/>
                  </section>
               </component>
               <component>
                  <section ID="S2.4">
                     <id root="130317dd-711e-69c9-e063-6394a90adc55"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.4 Dosage Recommendations for Liver Transplant Patients</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Adults</content>
                        </paragraph>
                        <paragraph>The recommended dosage of mycophenolate mofetil for adult liver transplant patients is 1.5 g administered orally twice daily (total daily dose of 3 g).</paragraph>
                        <paragraph>
                           <content styleCode="xmChange">Pediatric patients with BSA ≥1.25 m
 
   <sup>2</sup>may be started on therapy with capsules or tablets as follows:

  </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">
                              <content styleCode="bold">Table 3 Pediatric Liver Transplant: Pediatric Starting Dosage Using Capsules or Tablets</content>
                           </content>
                        </paragraph>
                        <table width="100%" ID="Table3">
                           <col width="25%" align="left" valign="top"/>
                           <col width="75%" align="left" valign="top"/>
                           <thead>
                              <tr>
                                 <th styleCode="Lrule Rrule">Body Surface Area</th>
                                 <th styleCode="Rrule">Starting Dosage
    
     <footnote ID="t1f2">Maximum maintenance dose: 3 g total daily.</footnote>
                                 </th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">1.25 m
    
     <sup>2</sup>to &lt;1.5 m
    
     <sup>2</sup>
                                 </td>
                                 <td styleCode="Rrule">Mycophenolate mofetil capsule 750 mg twice daily (1.5 g total daily dose)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">≥ 1.5 m
    
     <sup>2</sup>
                                 </td>
                                 <td styleCode="Rrule">Mycophenolate mofetil capsules or tablets 1 g twice daily (2 g total daily dose)</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20240306"/>
                  </section>
               </component>
               <component>
                  <section ID="S2.5">
                     <id root="130317dd-711f-69c9-e063-6394a90adc55"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.5 Dosage Modifications: Patients with Renal Impairment, Neutropenia</title>
                     <effectiveTime value="20240306"/>
                     <component>
                        <section>
                           <id root="130317dd-7120-69c9-e063-6394a90adc55"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Renal Impairment</content>
                              </paragraph>
                              <paragraph>No dosage modifications are needed in kidney transplant patients with delayed graft function postoperatively
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]
 
  </content>. In
 
  <content styleCode="underline">kidney transplant patients with severe chronic impairment of the graft</content>(GFR &lt;25 mL/min/1.73 m
 
  <sup>2</sup>), do not administer doses of mycophenolate mofetil greater than 1 g twice a day. These patients should be carefully monitored
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]
 
  </content>.

 </paragraph>
                           </text>
                           <effectiveTime value="20240306"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="130317dd-7121-69c9-e063-6394a90adc55"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Neutropenia</content>
                              </paragraph>
                              <paragraph>If neutropenia develops (ANC &lt;1.3 × 10
 
  <sup>3</sup>/µL), dosing with mycophenolate mofetil should be interrupted or reduced, appropriate diagnostic tests performed, and the patient managed appropriately
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S5.4">Warnings and Precautions (5.4)</linkHtml>and
  
   <linkHtml href="#S6.1">Adverse Reactions (6.1)</linkHtml>]
 
  </content>.

 </paragraph>
                           </text>
                           <effectiveTime value="20240306"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S3">
               <id root="13032314-2555-68dc-e063-6394a90a8c11"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>Mycophenolate Mofetil Capsules, USP are available containing 250 mg of mycophenolate mofetil, USP.</paragraph>
                  <list listType="unordered">
                     <item>The 250 mg capsules are light blue/ peach, size ‘1’ hard gelatin capsules, printed in black with ‘GC1’ on body containing white to off white powder.</item>
                  </list>
               </text>
               <effectiveTime value="20240306"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>Capsules: 250 mg</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S4">
               <id root="130317dd-7123-69c9-e063-6394a90adc55"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph>Allergic reactions to mycophenolate mofetil have been observed; therefore, mycophenolate mofetil is contraindicated in patients with a hypersensitivity to mycophenolate mofetil (MMF), mycophenolic acid (MPA) or any component of the drug product.</paragraph>
               </text>
               <effectiveTime value="20240306"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>Hypersensitivity to mycophenolate mofetil, mycophenolic acid or any component of the drug product (
  
     <linkHtml href="#S4">4</linkHtml>)
 
    </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S5">
               <id root="130317dd-7124-69c9-e063-6394a90adc55"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20240306"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>Blood Dyscrasias (Neutropenia, Red Blood Cell Aplasia): Monitor with blood tests; consider treatment interruption or dose reduction. (
  
     <linkHtml href="#S5.4">5.4</linkHtml>)
 
    </item>
                           <item>Gastrointestinal Complications: Monitor for complications such as bleeding, ulceration and perforations, particularly in patients with underlying gastrointestinal disorders. (
  
     <linkHtml href="#S5.5">5.5</linkHtml>)
 
    </item>
                           <item>Hypoxanthine-Guanine Phosphoribosyl-Transferase Deficiency: Avoid use of mycophenolate mofetil. (
  
     <linkHtml href="#S5.6">5.6</linkHtml>)
 
    </item>
                           <item>Acute Inflammatory Syndrome Associated with Mycophenolate Products: Monitor for this paradoxical inflammatory reaction. (
  
     <linkHtml href="#S5.7">5.7</linkHtml>)
 
    </item>
                           <item>Immunizations: Avoid live attenuated vaccines. (
  
     <linkHtml href="#S5.8">5.8</linkHtml>)
 
    </item>
                           <item>Blood Donation: Avoid during therapy and for 6 weeks thereafter. (
  
     <linkHtml href="#S5.11">5.11</linkHtml>)
 
    </item>
                           <item>Semen Donation: Avoid during therapy and for 90 days thereafter. (
  
     <linkHtml href="#S5.12">5.12</linkHtml>)
 
    </item>
                           <item>Potential Impairment on Driving and Use of Machinery: Mycophenolate mofetil may affect ability to drive or operate machinery. (
  
     <linkHtml href="#S5.14">5.14</linkHtml>)
 
    </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S5.1">
                     <id root="130317dd-7125-69c9-e063-6394a90adc55"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1 Embryofetal Toxicity</title>
                     <text>
                        <paragraph>Use of MMF during pregnancy is associated with an increased risk of first trimester pregnancy loss and an increased risk of congenital malformations, especially external ear and other facial abnormalities including cleft lip and palate, and anomalies of the distal limbs, heart, esophagus, kidney and nervous system. Females of reproductive potential must be made aware of these risks and must be counseled regarding pregnancy prevention and planning. Avoid use of MMF during pregnancy if safer treatment options are available
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S8.1">Use in Specific Populations (8.1</linkHtml>,
  
   <linkHtml href="#S8.3">8.3)</linkHtml>].
 
  </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240306"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.2">
                     <id root="130317dd-7126-69c9-e063-6394a90adc55"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2 Lymphoma and Other Malignancies</title>
                     <text>
                        <paragraph>Patients receiving immunosuppressants, including mycophenolate mofetil, are at increased risk of developing lymphomas and other malignancies, particularly of the skin
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S6.1">Adverse Reactions (6.1)</linkHtml>]
 
  </content>. The risk appears to be related to the intensity and duration of immunosuppression rather than to the use of any specific agent. For patients with increased risk for skin cancer, exposure to sunlight and UV light should be limited by wearing protective clothing and using a broad-spectrum sunscreen with a high protection factor.

 </paragraph>
                        <paragraph>Post-transplant lymphoproliferative disorder (PTLD) developed in 0.4% to 1% of patients receiving mycophenolate mofetil (2 g or 3 g) with other immunosuppressive agents in controlled clinical trials of kidney, heart and liver transplant patients
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S6.1">Adverse Reactions (6.1)</linkHtml>]
 
  </content>. The majority of PTLD cases appear to be related to Epstein Barr Virus (EBV) infection. The risk of PTLD appears greatest in those individuals who are EBV seronegative, a population which includes many young children. In pediatric patients, no other malignancies besides PTLD were observed in clinical trials
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S6.1">Adverse Reactions (6.1)</linkHtml>].
 
  </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240306"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.3">
                     <id root="130317dd-7127-69c9-e063-6394a90adc55"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3 Serious Infections</title>
                     <text>
                        <paragraph>Patients receiving immunosuppressants, including mycophenolate mofetil, are at increased risk of developing bacterial, fungal, protozoal and new or reactivated viral infections, including opportunistic infections. The risk increases with the total immunosuppressive load. These infections may lead to serious outcomes, including hospitalizations and death
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S6.1">Adverse Reactions (6.1,</linkHtml>
                              <linkHtml href="#S6.2">6.2)</linkHtml>].
 
  </content>
                        </paragraph>
                        <paragraph>Serious viral infections reported include:</paragraph>
                        <list listType="unordered">
                           <item>Polyomavirus-associated nephropathy (PVAN), especially due to BK virus infection</item>
                           <item>JC virus-associated progressive multifocal leukoencephalopathy (PML), and</item>
                           <item>Cytomegalovirus (CMV) infections: CMV seronegative transplant patients who receive an organ from a CMV seropositive donor are at highest risk of CMV viremia and CMV disease.</item>
                           <item>Viral reactivation in patients infected with Hepatitis B and C</item>
                           <item>
                              <content styleCode="xmChange">COVID-19</content>
                           </item>
                        </list>
                        <paragraph>
                           <content styleCode="xmChange">Consider dose reduction or discontinuation of mycophenolate mofetil in patients who develop new infections or reactivate viral infections, weighing the risk that reduced immunosuppression represents to the functioning allograft.</content>
                        </paragraph>
                        <paragraph>PVAN, especially due to BK virus infection, is associated with serious outcomes, including deteriorating renal function and renal graft loss
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S6.2">Adverse Reactions (6.2)</linkHtml>].
 
  </content>Patient monitoring may help detect patients at risk for PVAN.

 </paragraph>
                        <paragraph>PML, which is sometimes fatal, commonly presents with hemiparesis, apathy, confusion, cognitive deficiencies, and ataxia
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S6.2">Adverse Reactions (6.2)</linkHtml>]
 
  </content>. In immunosuppressed patients, physicians should consider PML in the differential diagnosis in patients reporting neurological symptoms.

 </paragraph>
                        <paragraph>The risk of CMV viremia and CMV disease is highest among transplant recipients seronegative for CMV at time of transplant who receive a graft from a CMV seropositive donor. Therapeutic approaches to limiting CMV disease exist and should be routinely provided. Patient monitoring may help detect patients at risk for CMV disease.</paragraph>
                        <paragraph>Viral reactivation has been reported in patients infected with HBV or HCV. Monitoring infected patients for clinical and laboratory signs of active HBV or HCV infection is recommended.</paragraph>
                     </text>
                     <effectiveTime value="20240306"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.4">
                     <id root="130317dd-7128-69c9-e063-6394a90adc55"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.4 Blood Dyscrasias: Neutropenia and Pure Red Cell Aplasia (PRCA)</title>
                     <text>
                        <paragraph>Severe neutropenia [absolute neutrophil count (ANC) &lt;0.5 × 10
 
  <sup>3</sup>/µL] developed in transplant patients receiving mycophenolate mofetil 3 g daily
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S6.1">Adverse Reactions (6.1)</linkHtml>]
 
  </content>. Patients receiving mycophenolate mofetil should be monitored for neutropenia. Neutropenia has been observed most frequently in the period from 31 to 180 days post-transplant in patients treated for prevention of kidney, heart and liver rejection. The development of neutropenia may be related to mycophenolate mofetil itself, concomitant medications, viral infections, or a combination of these causes. If neutropenia develops (ANC &lt;1.3 × 10
 
  <sup>3</sup>/µL), dosing with mycophenolate mofetil should be interrupted or the dose reduced, appropriate diagnostic tests performed, and the patient managed appropriately
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S2.5">Dosage and Administration (2.5)</linkHtml>].
 
  </content>
                        </paragraph>
                        <paragraph>Patients receiving mycophenolate mofetil should be instructed to report immediately any evidence of infection, unexpected bruising, bleeding or any other manifestation of bone marrow depression.</paragraph>
                        <paragraph>Consider monitoring with complete blood counts weekly for the first month, twice monthly for the second and third months, and monthly for the remainder of the first year.</paragraph>
                        <paragraph>Cases of pure red cell aplasia (PRCA) have been reported in patients treated with mycophenolate mofetil in combination with other immunosuppressive agents. In some cases, PRCA was found to be reversible with dose reduction or cessation of mycophenolate mofetil therapy. In transplant patients, however, reduced immunosuppression may place the graft at risk.</paragraph>
                     </text>
                     <effectiveTime value="20240306"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.5">
                     <id root="130317dd-7129-69c9-e063-6394a90adc55"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.5 Gastrointestinal Complications</title>
                     <text>
                        <paragraph>Gastrointestinal bleeding requiring hospitalization, ulceration and perforations were observed in clinical trials. Physicians should be aware of these serious adverse effects particularly when administering mycophenolate mofetil to patients with a gastrointestinal disease.</paragraph>
                     </text>
                     <effectiveTime value="20240306"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.6">
                     <id root="130317dd-712a-69c9-e063-6394a90adc55"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.6 Patients with Hypoxanthine-Guanine Phosphoribosyl-Transferase Deficiency (HGPRT)</title>
                     <text>
                        <paragraph>Mycophenolate mofetil is an inosine monophosphate dehydrogenase (IMPDH) inhibitor; therefore it should be avoided in patients with hereditary deficiencies of hypoxanthine-guanine phosphoribosyl-transferase (HGPRT) such as Lesch-Nyhan and Kelley-Seegmiller syndromes because it may cause an exacerbation of disease symptoms characterized by the overproduction and accumulation of uric acid leading to symptoms associated with gout such as acute arthritis, tophi, nephrolithiasis or urolithiasis and renal disease including renal failure.</paragraph>
                     </text>
                     <effectiveTime value="20240306"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.7">
                     <id root="130317dd-712b-69c9-e063-6394a90adc55"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.7 Acute Inflammatory Syndrome Associated with Mycophenolate Products</title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange">Acute inflammatory syndrome (AIS) has been reported with the use of MMF and mycophenolate products, and some cases have resulted in hospitalization. AIS is a paradoxical pro-inflammatory reaction characterized by fever, arthralgias, arthritis, muscle pain and elevated inflammatory markers including, C-reactive protein and erythrocyte sedimentation rate, without evidence of infection or underlying disease recurrence. Symptoms occur within weeks to months of initiation of treatment or a dose increase. After discontinuation, improvement of symptoms and inflammatory markers are usually observed within 24 to 48 hours.</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">Monitor patients for symptoms and laboratory parameters of AIS when starting treatment with mycophenolate products or when increasing the dosage. Discontinue treatment and consider other treatment alternatives based on the risk and benefit for the patient.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240306"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.8">
                     <id root="130317dd-712c-69c9-e063-6394a90adc55"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.8 Immunizations</title>
                     <text>
                        <paragraph>During treatment with mycophenolate mofetil, the use of live attenuated vaccines should be avoided (e.g., intranasal influenza, measles, mumps, rubella, oral polio, BCG, yellow fever, varicella, and TY21a typhoid vaccines) and patients should be advised that vaccinations may be less effective. Advise patients to discuss with the physician before seeking any immunizations.</paragraph>
                     </text>
                     <effectiveTime value="20240306"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.10">
                     <id root="130317dd-712d-69c9-e063-6394a90adc55"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.11 Blood Donation</title>
                     <text>
                        <paragraph>Patients should not donate blood during therapy and for at least 6 weeks following discontinuation of mycophenolate mofetil because their blood or blood products might be administered to a female of reproductive potential or a pregnant woman.</paragraph>
                     </text>
                     <effectiveTime value="20240306"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.11">
                     <id root="130317dd-712e-69c9-e063-6394a90adc55"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.12 Semen Donation</title>
                     <text>
                        <paragraph>Based on animal data, men should not donate semen during therapy and for 90 days following discontinuation of mycophenolate mofetil
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S8.3">Use In Specific Populations (8.3)</linkHtml>]
 
  </content>.

 </paragraph>
                     </text>
                     <effectiveTime value="20240306"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.12">
                     <id root="130317dd-712f-69c9-e063-6394a90adc55"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.13 Effect of Concomitant Medications on Mycophenolic Acid Concentrations</title>
                     <text>
                        <paragraph>A variety of drugs have potential to alter systemic MPA exposure when co-administered with mycophenolate mofetil. Therefore, determination of MPA concentrations in plasma before and after making any changes to immunosuppressive therapy, or when adding or discontinuing concomitant medications, may be appropriate to ensure MPA concentrations remain stable.</paragraph>
                     </text>
                     <effectiveTime value="20240306"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.13">
                     <id root="130317dd-7130-69c9-e063-6394a90adc55"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.14 Potential Impairment of Ability to Drive or Operate Machinery</title>
                     <text>
                        <paragraph>Mycophenolate mofetil may impact the ability to drive and use machines. Patients should avoid driving or using machines if they experience somnolence, confusion, dizziness, tremor, or hypotension during treatment with mycophenolate mofetil
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S6.1">Adverse Reactions (6.1)</linkHtml>]
 
  </content>.

 </paragraph>
                     </text>
                     <effectiveTime value="20240306"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S6">
               <id root="130317dd-7131-69c9-e063-6394a90adc55"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <text>
                  <paragraph>The following adverse reactions are discussed in greater detail in other sections of the label:</paragraph>
                  <list listType="unordered">
                     <item>Embryofetal Toxicity
  
   <content styleCode="italics">[see
   
    <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]
  
   </content>
                     </item>
                     <item>Lymphomas and Other Malignancies
  
   <content styleCode="italics">[see
   
    <linkHtml href="#S5.2">Warnings and Precautions 5.2)</linkHtml>]
  
   </content>
                     </item>
                     <item>Serious Infections
  
   <content styleCode="italics">[see
   
    <linkHtml href="#S5.3">Warnings and Precautions (5.3)</linkHtml>]
  
   </content>
                     </item>
                     <item>Blood Dyscrasias: Neutropenia, Pure Red Cell Aplasia
  
   <content styleCode="italics">[see
   
    <linkHtml href="#S5.4">Warnings and Precautions (5.4)</linkHtml>]
  
   </content>
                     </item>
                     <item>Gastrointestinal Complications
  
   <content styleCode="italics">[see
   
    <linkHtml href="#S5.5">Warnings and Precautions (5.5)</linkHtml>]
  
   </content>
                     </item>
                     <item>Acute Inflammatory Syndrome Associated with Mycophenolate Products s
  
   <content styleCode="italics">[see
   
    <linkHtml href="#S5.5">Warnings and Precautions (5.7)</linkHtml>]
  
   </content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20240306"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>The most common adverse reactions in clinical trials (20 % or greater) include diarrhea, leukopenia, infection, vomiting, and there is evidence of a higher frequency of certain types of infections e.g., opportunistic infection. (
 
    <linkHtml href="#S6.1">6.1</linkHtml>)

   </paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Accord Healthcare Inc. at 1-866-941-7875 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.com</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S6.1">
                     <id root="130317dd-7132-69c9-e063-6394a90adc55"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.1 Clinical Trials Experience</title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</paragraph>
                        <paragraph>An estimated total of 1557 adult patients received mycophenolate mofetil during pivotal clinical trials in the prevention of acute organ rejection. Of these, 991 were included in the three renal studies, 277 were included in one hepatic study, and 289 were included in one cardiac study. Patients in all study arms also received cyclosporine and corticosteroids.</paragraph>
                        <paragraph>The data described below primarily derive from five randomized, active-controlled double-blind 12-month trials of mycophenolate mofetil in
 
  <content styleCode="italics">de novo</content>kidney (3) heart (1) and liver (1) transplant patients
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S14.1">Clinical Studies (14.1</linkHtml>,
  
   <linkHtml href="#S14.2">14.2,</linkHtml>and
  
   <linkHtml href="#S14.3">14.3)</linkHtml>]
 
  </content>.

 </paragraph>
                     </text>
                     <effectiveTime value="20240306"/>
                     <component>
                        <section>
                           <id root="130317dd-7133-69c9-e063-6394a90adc55"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Mycophenolate Mofetil Oral</content>
                              </paragraph>
                              <paragraph>The incidence of adverse reactions for mycophenolate mofetil was determined in five randomized, comparative, double-blind trials in the prevention of rejection in kidney, heart and liver transplant patients (two active- and one placebo-controlled trials, one active-controlled trial, and one active-controlled trial, respectively)
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S14.1">Clinical Studies (14.1</linkHtml>,
  
   <linkHtml href="#S14.2">14.2</linkHtml>and
  
   <linkHtml href="#S14.3">14.3)</linkHtml>]
 
  </content>.

 </paragraph>
                              <paragraph>The three
 
  <content styleCode="italics">de novo</content>kidney studies with 12-month duration compared two dose levels of oral mycophenolate mofetil (1 g twice daily and 1.5 g twice daily) with azathioprine (2 studies) or placebo (1 study) when administered in combination with cyclosporine (Sandimmune
 
  <sup>®</sup>) and corticosteroids to prevent acute rejection episodes. One study also included anti-thymocyte globulin (ATGAM
 
  <sup>®)</sup>induction therapy.

 </paragraph>
                              <paragraph>In the
 
  <content styleCode="italics">de novo</content>heart transplantation study with 12-month duration, patients received mycophenolate mofetil 1.5 g twice daily (n=289) or azathioprine 1.5 to 3 mg/kg/day (n=289), in combination with cyclosporine (Sandimmune
 
  <sup>®</sup>or Neoral
 
  <sup>®</sup>) and corticosteroids as maintenance immunosuppressive therapy.

 </paragraph>
                              <paragraph>In the
 
  <content styleCode="italics">de novo</content>liver transplantation study with 12-month duration, patients received mycophenolate mofetil 1 g twice daily intravenously for up to 14 days followed by mycophenolate mofetil 1.5 g twice daily orally or azathioprine 1 to 2 mg/kg/day intravenously followed by azathioprine 1 to 2 mg/kg/day orally, in combination with cyclosporine (Neoral
 
  <sup>®</sup>) and corticosteroids as maintenance immunosuppressive therapy. The total number of patients enrolled was 565.

 </paragraph>
                              <paragraph>Approximately 53% of the kidney transplant patients, 65% of the heart transplant patients, and 48% of the liver transplant patients were treated for more than 1 year. Adverse reactions reported in ≥ 20% of patients in the mycophenolate mofetil treatment groups are presented below. The safety data of three kidney transplantation studies are pooled together.</paragraph>
                              <table width="100%" ID="table5">
                                 <caption>Table 5 Adverse Reactions in Controlled Studies of De Novo Kidney, Heart or Liver Transplantation Reported in ≥20% of Patients in the Mycophenolate Mofetil Group</caption>
                                 <col width="30%" align="left" valign="middle"/>
                                 <col width="10%" align="center" valign="middle"/>
                                 <col width="10%" align="center" valign="middle"/>
                                 <col width="10%" align="center" valign="middle"/>
                                 <col width="10%" align="center" valign="middle"/>
                                 <col width="10%" align="center" valign="middle"/>
                                 <col width="10%" align="center" valign="middle"/>
                                 <col width="10%" align="center" valign="middle"/>
                                 <thead>
                                    <tr>
                                       <th rowspan="2" styleCode="Lrule Rrule">Adverse drug reaction</th>
                                       <th colspan="3" styleCode="Rrule Botrule">Kidney Studies</th>
                                       <th colspan="2" styleCode="Rrule Botrule">Heart Study</th>
                                       <th colspan="2" styleCode="Rrule Botrule">Liver Study</th>
                                    </tr>
                                    <tr>
                                       <th align="center" styleCode="Rrule Botrule" valign="top">Mycophenolate mofetil 2g/day 
     <br/>  (n=501) 
     <br/>  or 3g/day 
     <br/>  (n=490)
    </th>
                                       <th styleCode="Rrule Botrule">AZA 
     <br/>  1 to 2 mg/kg/day 
     <br/>  or 100 to 150 mg/day
    </th>
                                       <th styleCode="Rrule Botrule" valign="bottom">Placebo</th>
                                       <th styleCode="Rrule Botrule" valign="bottom">Mycophenolate mofetil 
     <br/>  3g/day
    </th>
                                       <th styleCode="Rrule Botrule" valign="bottom">AZA 
     <br/>  1.5 to 3 mg/kg/day
    </th>
                                       <th styleCode="Rrule Botrule" valign="bottom">Mycophenolate mofetil 
     <br/>  3g/day
    </th>
                                       <th styleCode="Rrule Botrule" valign="bottom">AZA 
     <br/>  1 to 2 mg/kg/day
    </th>
                                    </tr>
                                    <tr>
                                       <th styleCode="Lrule Rrule" valign="top"/>
                                       <th styleCode="Rrule Botrule">(n=991)</th>
                                       <th styleCode="Rrule Botrule">(n=326)</th>
                                       <th styleCode="Rrule Botrule">(n=166)</th>
                                       <th styleCode="Rrule Botrule">(n=289)</th>
                                       <th styleCode="Rrule Botrule">(n=289)</th>
                                       <th styleCode="Rrule Botrule">(n=277)</th>
                                       <th styleCode="Rrule Botrule">(n=287)</th>
                                    </tr>
                                    <tr>
                                       <th styleCode="Lrule Rrule">System Organ Class</th>
                                       <th styleCode="Rrule Botrule">%</th>
                                       <th styleCode="Rrule Botrule">%</th>
                                       <th styleCode="Rrule Botrule">%</th>
                                       <th styleCode="Rrule Botrule">%</th>
                                       <th styleCode="Rrule Botrule">%</th>
                                       <th styleCode="Rrule Botrule">%</th>
                                       <th styleCode="Rrule Botrule">%</th>
                                    </tr>
                                 </thead>
                                 <tbody>
                                    <tr styleCode="Botrule">
                                       <td colspan="8" styleCode="Lrule Rrule">
                                          <content styleCode="bold">Infections and infestations</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Bacterial infections</td>
                                       <td styleCode="Rrule">39.9</td>
                                       <td styleCode="Rrule">33.7</td>
                                       <td styleCode="Rrule">37.3</td>
                                       <td styleCode="Rrule">-</td>
                                       <td styleCode="Rrule">-</td>
                                       <td styleCode="Rrule">27.4</td>
                                       <td styleCode="Rrule">26.5</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Viral infections</td>
                                       <td styleCode="Rrule">-
    
     <footnote ID="K2210">a ."-" Indicates that the incidence was below the cutoff value of 20% for inclusion in the table. </footnote>
                                       </td>
                                       <td styleCode="Rrule">-</td>
                                       <td styleCode="Rrule">-</td>
                                       <td styleCode="Rrule">31.1</td>
                                       <td styleCode="Rrule">24.9</td>
                                       <td styleCode="Rrule">-</td>
                                       <td styleCode="Rrule">-</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td colspan="8" styleCode="Lrule Rrule">
                                          <content styleCode="bold">Blood and lymphatic system disorders</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Anemia</td>
                                       <td styleCode="Rrule">20.0</td>
                                       <td styleCode="Rrule">23.6</td>
                                       <td styleCode="Rrule">2.4</td>
                                       <td styleCode="Rrule">45.0</td>
                                       <td styleCode="Rrule">47.1</td>
                                       <td styleCode="Rrule">43.0</td>
                                       <td styleCode="Rrule">53.0</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Ecchymosis</td>
                                       <td styleCode="Rrule">-</td>
                                       <td styleCode="Rrule">-</td>
                                       <td styleCode="Rrule">-</td>
                                       <td styleCode="Rrule">20.1</td>
                                       <td styleCode="Rrule">9.7</td>
                                       <td styleCode="Rrule">-</td>
                                       <td styleCode="Rrule">-</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Leukocytosis</td>
                                       <td styleCode="Rrule">-</td>
                                       <td styleCode="Rrule">-</td>
                                       <td styleCode="Rrule">-</td>
                                       <td styleCode="Rrule">42.6</td>
                                       <td styleCode="Rrule">37.4</td>
                                       <td styleCode="Rrule">22.4</td>
                                       <td styleCode="Rrule">21.3</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Leukopenia</td>
                                       <td styleCode="Rrule">28.6</td>
                                       <td styleCode="Rrule">24.8</td>
                                       <td styleCode="Rrule">4.2</td>
                                       <td styleCode="Rrule">34.3</td>
                                       <td styleCode="Rrule">43.3</td>
                                       <td styleCode="Rrule">45.8</td>
                                       <td styleCode="Rrule">39.0</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Thrombocytopenia</td>
                                       <td styleCode="Rrule">-</td>
                                       <td styleCode="Rrule">-</td>
                                       <td styleCode="Rrule">-</td>
                                       <td styleCode="Rrule">24.2</td>
                                       <td styleCode="Rrule">28.0</td>
                                       <td styleCode="Rrule">38.3</td>
                                       <td styleCode="Rrule">42.2</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td colspan="8" styleCode="Lrule Rrule">
                                          <content styleCode="bold">Metabolism and nutrition disorders</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Hypercholesterolemia</td>
                                       <td styleCode="Rrule">-</td>
                                       <td styleCode="Rrule">-</td>
                                       <td styleCode="Rrule">-</td>
                                       <td styleCode="Rrule">46.0</td>
                                       <td styleCode="Rrule">43.9</td>
                                       <td styleCode="Rrule">-</td>
                                       <td styleCode="Rrule">-</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Hyperglycemia</td>
                                       <td styleCode="Rrule">-</td>
                                       <td styleCode="Rrule">-</td>
                                       <td styleCode="Rrule">-</td>
                                       <td styleCode="Rrule">48.4</td>
                                       <td styleCode="Rrule">53.3</td>
                                       <td styleCode="Rrule">43.7</td>
                                       <td styleCode="Rrule">48.8</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Hyperkalemia</td>
                                       <td styleCode="Rrule">-</td>
                                       <td styleCode="Rrule">-</td>
                                       <td styleCode="Rrule">-</td>
                                       <td styleCode="Rrule">-</td>
                                       <td styleCode="Rrule">-</td>
                                       <td styleCode="Rrule">22.0</td>
                                       <td styleCode="Rrule">23.7</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Hypocalcemia</td>
                                       <td styleCode="Rrule">-</td>
                                       <td styleCode="Rrule">-</td>
                                       <td styleCode="Rrule">-</td>
                                       <td styleCode="Rrule">-</td>
                                       <td styleCode="Rrule">-</td>
                                       <td styleCode="Rrule">30.0</td>
                                       <td styleCode="Rrule">30.0</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Hypokalemia</td>
                                       <td styleCode="Rrule">-</td>
                                       <td styleCode="Rrule">-</td>
                                       <td styleCode="Rrule">-</td>
                                       <td styleCode="Rrule">32.5</td>
                                       <td styleCode="Rrule">26.3</td>
                                       <td styleCode="Rrule">37.2</td>
                                       <td styleCode="Rrule">41.1</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Hypomagnesemia</td>
                                       <td styleCode="Rrule">-</td>
                                       <td styleCode="Rrule">-</td>
                                       <td styleCode="Rrule">-</td>
                                       <td styleCode="Rrule">20.1</td>
                                       <td styleCode="Rrule">14.2</td>
                                       <td styleCode="Rrule">39.0</td>
                                       <td styleCode="Rrule">37.6</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td colspan="8" styleCode="Lrule Rrule">
                                          <content styleCode="bold">Psychiatric disorders</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Depression</td>
                                       <td styleCode="Rrule">-</td>
                                       <td styleCode="Rrule">-</td>
                                       <td styleCode="Rrule">-</td>
                                       <td styleCode="Rrule">20.1</td>
                                       <td styleCode="Rrule">15.2</td>
                                       <td styleCode="Rrule">-</td>
                                       <td styleCode="Rrule">-</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Insomnia</td>
                                       <td styleCode="Rrule">-</td>
                                       <td styleCode="Rrule">-</td>
                                       <td styleCode="Rrule">-</td>
                                       <td styleCode="Rrule">43.3</td>
                                       <td styleCode="Rrule">39.8</td>
                                       <td styleCode="Rrule">52.3</td>
                                       <td styleCode="Rrule">47.0</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td colspan="8" styleCode="Lrule Rrule">
                                          <content styleCode="bold">Nervous system disorders</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Dizziness</td>
                                       <td styleCode="Rrule">-</td>
                                       <td styleCode="Rrule">-</td>
                                       <td styleCode="Rrule">-</td>
                                       <td styleCode="Rrule">34.3</td>
                                       <td styleCode="Rrule">33.9</td>
                                       <td styleCode="Rrule">-</td>
                                       <td styleCode="Rrule">-</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Headache</td>
                                       <td styleCode="Rrule">-</td>
                                       <td styleCode="Rrule">-</td>
                                       <td styleCode="Rrule">-</td>
                                       <td styleCode="Rrule">58.5</td>
                                       <td styleCode="Rrule">55.4</td>
                                       <td styleCode="Rrule">53.8</td>
                                       <td styleCode="Rrule">49.1</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Tremor</td>
                                       <td styleCode="Rrule">-</td>
                                       <td styleCode="Rrule">-</td>
                                       <td styleCode="Rrule">-</td>
                                       <td styleCode="Rrule">26.3</td>
                                       <td styleCode="Rrule">25.6</td>
                                       <td styleCode="Rrule">33.9</td>
                                       <td styleCode="Rrule">35.5</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td colspan="8" styleCode="Lrule Rrule">
                                          <content styleCode="bold">Cardiac disorders</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Tachycardia</td>
                                       <td styleCode="Rrule">-</td>
                                       <td styleCode="Rrule">-</td>
                                       <td styleCode="Rrule">-</td>
                                       <td styleCode="Rrule">22.8</td>
                                       <td styleCode="Rrule">21.8</td>
                                       <td styleCode="Rrule">22.0</td>
                                       <td styleCode="Rrule">15.7</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td colspan="8" styleCode="Lrule Rrule">
                                          <content styleCode="bold">Vascular disorders</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Hypertension</td>
                                       <td styleCode="Rrule">27.5</td>
                                       <td styleCode="Rrule">32.2</td>
                                       <td styleCode="Rrule">19.3</td>
                                       <td styleCode="Rrule">78.9</td>
                                       <td styleCode="Rrule">74.0</td>
                                       <td styleCode="Rrule">62.1</td>
                                       <td styleCode="Rrule">59.6</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Hypotension</td>
                                       <td styleCode="Rrule">-</td>
                                       <td styleCode="Rrule">-</td>
                                       <td styleCode="Rrule">-</td>
                                       <td styleCode="Rrule">34.3</td>
                                       <td styleCode="Rrule">40.1</td>
                                       <td styleCode="Rrule">-</td>
                                       <td styleCode="Rrule">-</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td colspan="8" styleCode="Lrule Rrule">
                                          <content styleCode="bold">Respiratory, thoracic and mediastinal disorders</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Cough</td>
                                       <td styleCode="Rrule">-</td>
                                       <td styleCode="Rrule">-</td>
                                       <td styleCode="Rrule">-</td>
                                       <td styleCode="Rrule">40.5</td>
                                       <td styleCode="Rrule">32.2</td>
                                       <td styleCode="Rrule">-</td>
                                       <td styleCode="Rrule">-</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Dyspnea</td>
                                       <td styleCode="Rrule">-</td>
                                       <td styleCode="Rrule">-</td>
                                       <td styleCode="Rrule">-</td>
                                       <td styleCode="Rrule">44.3</td>
                                       <td styleCode="Rrule">44.3</td>
                                       <td styleCode="Rrule">31.0</td>
                                       <td styleCode="Rrule">30.3</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Pleural effusion</td>
                                       <td styleCode="Rrule">-</td>
                                       <td styleCode="Rrule">-</td>
                                       <td styleCode="Rrule">-</td>
                                       <td styleCode="Rrule">-</td>
                                       <td styleCode="Rrule">-</td>
                                       <td styleCode="Rrule">34.3</td>
                                       <td styleCode="Rrule">35.9</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td colspan="8" styleCode="Lrule Rrule">
                                          <content styleCode="bold">Gastrointestinal disorders</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Abdominal pain</td>
                                       <td styleCode="Rrule">22.4</td>
                                       <td styleCode="Rrule">23.0</td>
                                       <td styleCode="Rrule">11.4</td>
                                       <td styleCode="Rrule">41.9</td>
                                       <td styleCode="Rrule">39.4</td>
                                       <td styleCode="Rrule">62.5</td>
                                       <td styleCode="Rrule">51.2</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Constipation</td>
                                       <td styleCode="Rrule">-</td>
                                       <td styleCode="Rrule">-</td>
                                       <td styleCode="Rrule">-</td>
                                       <td styleCode="Rrule">43.6</td>
                                       <td styleCode="Rrule">38.8</td>
                                       <td styleCode="Rrule">37.9</td>
                                       <td styleCode="Rrule">38.3</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Decreased appetite</td>
                                       <td styleCode="Rrule">-</td>
                                       <td styleCode="Rrule">-</td>
                                       <td styleCode="Rrule">-</td>
                                       <td styleCode="Rrule">-</td>
                                       <td styleCode="Rrule">-</td>
                                       <td styleCode="Rrule">25.3</td>
                                       <td styleCode="Rrule">17.1</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Diarrhea</td>
                                       <td styleCode="Rrule">30.4</td>
                                       <td styleCode="Rrule">20.9</td>
                                       <td styleCode="Rrule">13.9</td>
                                       <td styleCode="Rrule">52.6</td>
                                       <td styleCode="Rrule">39.4</td>
                                       <td styleCode="Rrule">51.3</td>
                                       <td styleCode="Rrule">49.8</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Dyspepsia</td>
                                       <td styleCode="Rrule">-</td>
                                       <td styleCode="Rrule">-</td>
                                       <td styleCode="Rrule">-</td>
                                       <td styleCode="Rrule">22.1</td>
                                       <td styleCode="Rrule">22.1</td>
                                       <td styleCode="Rrule">22.4</td>
                                       <td styleCode="Rrule">20.9</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Nausea</td>
                                       <td styleCode="Rrule">-</td>
                                       <td styleCode="Rrule">-</td>
                                       <td styleCode="Rrule">-</td>
                                       <td styleCode="Rrule">56.1</td>
                                       <td styleCode="Rrule">60.2</td>
                                       <td styleCode="Rrule">54.5</td>
                                       <td styleCode="Rrule">51.2</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Vomiting</td>
                                       <td styleCode="Rrule">-</td>
                                       <td styleCode="Rrule">-</td>
                                       <td styleCode="Rrule">-</td>
                                       <td styleCode="Rrule">39.1</td>
                                       <td styleCode="Rrule">34.6</td>
                                       <td styleCode="Rrule">32.9</td>
                                       <td styleCode="Rrule">33.4</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td colspan="8" styleCode="Lrule Rrule">
                                          <content styleCode="bold">Hepatobiliary disorders</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Blood lactate dehydrogenase increased</td>
                                       <td styleCode="Rrule">-</td>
                                       <td styleCode="Rrule">-</td>
                                       <td styleCode="Rrule">-</td>
                                       <td styleCode="Rrule">23.5</td>
                                       <td styleCode="Rrule">18.3</td>
                                       <td styleCode="Rrule">-</td>
                                       <td styleCode="Rrule">-</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Hepatic enzyme increased</td>
                                       <td styleCode="Rrule">-</td>
                                       <td styleCode="Rrule">-</td>
                                       <td styleCode="Rrule">-</td>
                                       <td styleCode="Rrule">-</td>
                                       <td styleCode="Rrule">-</td>
                                       <td styleCode="Rrule">24.9</td>
                                       <td styleCode="Rrule">19.2</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td colspan="8" styleCode="Lrule Rrule">
                                          <content styleCode="bold">Skin and subcutaneous tissues disorders</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Rash</td>
                                       <td styleCode="Rrule">-</td>
                                       <td styleCode="Rrule">-</td>
                                       <td styleCode="Rrule">-</td>
                                       <td styleCode="Rrule">26.0</td>
                                       <td styleCode="Rrule">20.8</td>
                                       <td styleCode="Rrule">-</td>
                                       <td styleCode="Rrule">-</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td colspan="8" styleCode="Lrule Rrule">
                                          <content styleCode="bold">Renal and urinary disorders</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Blood creatinine increased</td>
                                       <td styleCode="Rrule">-</td>
                                       <td styleCode="Rrule">-</td>
                                       <td styleCode="Rrule">-</td>
                                       <td styleCode="Rrule">42.2</td>
                                       <td styleCode="Rrule">39.8</td>
                                       <td styleCode="Rrule">-</td>
                                       <td styleCode="Rrule">-</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Blood urea increased</td>
                                       <td styleCode="Rrule">-</td>
                                       <td styleCode="Rrule">-</td>
                                       <td styleCode="Rrule">-</td>
                                       <td styleCode="Rrule">36.7</td>
                                       <td styleCode="Rrule">34.3</td>
                                       <td styleCode="Rrule">-</td>
                                       <td styleCode="Rrule">-</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td colspan="8" styleCode="Lrule Rrule">
                                          <content styleCode="bold">General disorders and administration site conditions</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Asthenia</td>
                                       <td styleCode="Rrule">-</td>
                                       <td styleCode="Rrule">-</td>
                                       <td styleCode="Rrule">-</td>
                                       <td styleCode="Rrule">49.1</td>
                                       <td styleCode="Rrule">41.2</td>
                                       <td styleCode="Rrule">35.4</td>
                                       <td styleCode="Rrule">33.8</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Edema
    
     <footnote ID="K3241">b."Edema" includes peripheral edema, facial edema, scrotal edema.</footnote>
                                       </td>
                                       <td styleCode="Rrule">21.0</td>
                                       <td styleCode="Rrule">28.2</td>
                                       <td styleCode="Rrule">8.4</td>
                                       <td styleCode="Rrule">67.5</td>
                                       <td styleCode="Rrule">55.7</td>
                                       <td styleCode="Rrule">48.4</td>
                                       <td styleCode="Rrule">47.7</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Pain
    
     <footnote ID="K3269">c."Pain" includes musculoskeletal pain (myalgia, neck pain, back pain).</footnote>
                                       </td>
                                       <td styleCode="Rrule">24.8</td>
                                       <td styleCode="Rrule">32.2</td>
                                       <td styleCode="Rrule">9.6</td>
                                       <td styleCode="Rrule">79.2</td>
                                       <td styleCode="Rrule">77.5</td>
                                       <td styleCode="Rrule">74.0</td>
                                       <td styleCode="Rrule">77.5</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Pyrexia</td>
                                       <td styleCode="Rrule">-</td>
                                       <td styleCode="Rrule">-</td>
                                       <td styleCode="Rrule">-</td>
                                       <td styleCode="Rrule">56.4</td>
                                       <td styleCode="Rrule">53.6</td>
                                       <td styleCode="Rrule">52.3</td>
                                       <td styleCode="Rrule">56.1</td>
                                    </tr>
                                 </tbody>
                              </table>
                              <paragraph>In the three
 
  <content styleCode="italics">de novo</content>kidney studies, patients receiving 2 g/day of mycophenolate mofetil had an overall better safety profile than did patients receiving 3 g/day of mycophenolate mofetil.

 </paragraph>
                              <paragraph>Post-transplant lymphoproliferative disease (PTLD, pseudolymphoma) developed in 0.4% to 1% of patients receiving mycophenolate mofetil (2 g or 3 g daily) with other immunosuppressive agents in controlled clinical trials of kidney, heart and liver transplant patients followed for at least 1 year
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>].
 
  </content>Non-melanoma skin carcinomas occurred in 1.6% to 4.2% of patients, other types of malignancy in 0.7% to 2.1% of patients. Three-year safety data in kidney and heart transplant patients did not reveal any unexpected changes in incidence of malignancy compared to the 1-year data. In pediatric patients, PTLD was observed in 1.35% (2/148) by 12 months post-transplant.

 </paragraph>
                              <paragraph>Cytopenias, including leukopenia, anemia, thrombocytopenia and pancytopenia are a known risk associated with mycophenolate and may lead or contribute to the occurrence of infections and hemorrhages
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S5.3">Warnings and Precautions (5.3)</linkHtml>]
 
  </content>. Severe neutropenia (ANC &lt;0.5 × 10
 
  <sup>3</sup>/µL) developed in up to 2% of kidney transplant patients, up to 2.8% of heart transplant patients and up to 3.6% of liver transplant patients receiving mycophenolate mofetil 3 g daily
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S5.4">Warnings and Precautions (5.4)</linkHtml>and
  
   <linkHtml href="#S2.5">Dosage and Administration (2.5)</linkHtml>].
 
  </content>
                              </paragraph>
                              <paragraph>The most common opportunistic infections in patients receiving mycophenolate mofetil with other immunosuppressants were mucocutaneous candida, CMV viremia/syndrome, and herpes simplex. The proportion of patients with CMV viremia/syndrome was 13.5%. In patients receiving mycophenolate mofetil (2 g or 3 g) in controlled studies for prevention of kidney, heart or liver rejection, fatal infection/sepsis occurred in approximately 2% of kidney and heart patients and in 5% of liver patients
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S5.3">Warnings and Precautions (5.3)</linkHtml>].
 
  </content>
                              </paragraph>
                              <paragraph>The most serious gastrointestinal disorders reported were ulceration and hemorrhage, which are known risks associated with mycophenolate mofetil. Mouth, esophageal, gastric, duodenal, and intestinal ulcers often complicated by hemorrhage, as well as hematemesis, melena, and hemorrhagic forms of gastritis and colitis were commonly reported during the pivotal clinical trials, while the most common gastrointestinal disorders were diarrhea, nausea and vomiting. Endoscopic investigation of patients with mycophenolate mofetil-related diarrhea revealed isolated cases of intestinal villous atrophy
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S5.5">Warnings and Precautions (5.5)</linkHtml>]
 
  </content>. The following adverse reactions were reported with 3% to &lt;20% incidence in kidney, heart, and liver transplant patients treated with mycophenolate mofetil, in combination with cyclosporine and corticosteroids.

 </paragraph>
                              <table width="100%" ID="Table6">
                                 <caption>Table 6 Adverse Reactions in Controlled Studies of De Novo Kidney, Heart or Liver Transplantation Reported in 3% to &lt;20% of Patients Treated with Mycophenolate Mofetil in Combination with Cyclosporine and Corticosteroids</caption>
                                 <col width="20%" align="left" valign="top"/>
                                 <col width="80%" align="left" valign="top"/>
                                 <thead>
                                    <tr>
                                       <th styleCode="Lrule Rrule">Body System</th>
                                       <th styleCode="Rrule">Adverse Reactions</th>
                                    </tr>
                                 </thead>
                                 <tbody>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Body as a Whole</td>
                                       <td styleCode="Rrule">cellulitis, chills, hernia, malaise</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Infections and Infestations</td>
                                       <td styleCode="Rrule">fungal infections</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Hematologic and Lymphatic</td>
                                       <td styleCode="Rrule">coagulation disorder, ecchymosis, pancytopenia</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Urogenital</td>
                                       <td styleCode="Rrule">hematuria</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Cardiovascular</td>
                                       <td styleCode="Rrule">hypotension</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Metabolic and Nutritional</td>
                                       <td styleCode="Rrule">acidosis, alkaline phosphatase increased, hyperlipemia, hypophosphatemia, weight loss</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Digestive</td>
                                       <td styleCode="Rrule">esophagitis, flatulence, gastritis, gastrointestinal hemorrhage, hepatitis, ileus, nausea and vomiting, stomach ulcer, stomatitis</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Neoplasm benign, malignant and unspecified</td>
                                       <td styleCode="Rrule">neoplasm</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Skin and Appendages</td>
                                       <td styleCode="Rrule">skin benign neoplasm, skin carcinoma</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Psychiatric</td>
                                       <td styleCode="Rrule">confusional state</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Nervous</td>
                                       <td styleCode="Rrule">hypertonia, paresthesia, somnolence</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Musculoskeletal</td>
                                       <td styleCode="Rrule">arthralgia, myasthenia</td>
                                    </tr>
                                 </tbody>
                              </table>
                           </text>
                           <effectiveTime value="20240306"/>
                           <component>
                              <section>
                                 <id root="130317dd-7134-69c9-e063-6394a90adc55"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Pediatrics</content>
                                    </paragraph>
                                    <paragraph>The type and frequency of adverse events in a clinical study for prevention of kidney allograft rejection in 100 pediatric patients 3 months to 18 years of age dosed with mycophenolate mofetil oral suspension 600 mg/m
 
  <sup>2</sup>twice daily (up to 1 g twice daily) were generally similar to those observed in adult patients dosed with mycophenolate mofetil capsules at a dose of 1 g twice daily with the exception of abdominal pain, fever, infection, pain, sepsis, diarrhea, vomiting, pharyngitis, respiratory tract infection, hypertension, leukopenia, and anemia, which were observed in a higher proportion in pediatric patients. 
  <br/>  Safety information in pediatric heart transplant or pediatric liver transplant patients treated with mycophenolate mofetil is supported by an open-label study in pediatric liver transplant patients and publications; the type and frequency of the reported adverse reactions are consistent with those observed in pediatric patients following renal transplant and in adults.

 </paragraph>
                                 </text>
                                 <effectiveTime value="20240306"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="130317dd-7135-69c9-e063-6394a90adc55"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Geriatrics</content>
                                    </paragraph>
                                    <paragraph>Geriatric patients (≥65 years), particularly those who are receiving mycophenolate mofetil as part of a combination immunosuppressive regimen, may be at increased risk of certain infections (including cytomegalovirus [CMV] tissue invasive disease) and possibly gastrointestinal hemorrhage and pulmonary edema, compared to younger individuals
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S5.3">Warnings and Precautions (5.3)</linkHtml>and
  
   <linkHtml href="#S6.1">Adverse Reactions (6.1)</linkHtml>].
 
  </content>
                                    </paragraph>
                                 </text>
                                 <effectiveTime value="20240306"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S6.2">
                     <id root="130317dd-7136-69c9-e063-6394a90adc55"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.2 Postmarketing Experience</title>
                     <text>
                        <paragraph>The following adverse reactions have been identified during post-approval use of mycophenolate mofetil. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure:</paragraph>
                        <list listType="unordered">
                           <item>
                              <content styleCode="underline">Embryo-Fetal Toxicity</content>: Congenital malformations and spontaneous abortions, mainly in the first trimester, have been reported following exposure to mycophenolate mofetil (MMF) in combination with other immunosuppressants during pregnancy
  
   <content styleCode="italics">[see
   
    <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>, and
   
    <linkHtml href="#S8.1">Use in Specific Populations (8.1)</linkHtml>,
   
    <linkHtml href="#S8.3">(8.3)</linkHtml>].
  
   </content>Congenital malformations include:
  
   <list listType="unordered">
                                 <item>Facial malformations: cleft lip, cleft palate, micrognathia, hypertelorism of the orbits</item>
                                 <item>Abnormalities of the ear and eye: abnormally formed or absent external/middle ear, coloboma, microphthalmos</item>
                                 <item>Malformations of the fingers: polydactyly, syndactyly, brachydactyly</item>
                                 <item>Cardiac abnormalities: atrial and ventricular septal defects</item>
                                 <item>Esophageal malformations: esophageal atresia</item>
                                 <item>Nervous system malformations: such as spina bifida
    
     <content styleCode="italics">.</content>
                                 </item>
                              </list>
                           </item>
                           <item>
                              <content styleCode="underline">Cardiovascular:</content>Venous thrombosis has been reported in patients treated with mycophenolate mofetil administered intravenously.
 
  </item>
                           <item>
                              <content styleCode="underline">Digestive</content>: Colitis, pancreatitis.
 
  </item>
                           <item>
                              <content styleCode="underline">Hematologic and Lymphatic</content>: Bone marrow failure, cases of pure red cell aplasia (PRCA) and hypogammaglobulinemia have been reported in patients treated with mycophenolate mofetil in combination with other immunosuppressive agents
  
   <content styleCode="italics">[see
   
    <linkHtml href="#S5.4">Warnings and Precautions (5.4)</linkHtml>]
  
   </content>.
 
  </item>
                           <item>
                              <content styleCode="underline">Immune:</content>Hypersensitivity, hypogammaglobinemia.
 
  </item>
                           <item>
                              <content styleCode="underline">Infections</content>: Meningitis , infectious endocarditis, tuberculosis, atypical mycobacterial infection, progressive multifocal leukoencephalopathy, BK virus infection, viral reactivation of hepatitis B and hepatitis C, protozoal infections
  
   <content styleCode="italics">[see
   
    <linkHtml href="#S5.3">Warnings and Precautions (5.3)</linkHtml>]
  
   </content>.
 
  </item>
                           <item>
                              <content styleCode="underline">Respiratory</content>: Bronchiectasis, interstitial lung disease, fatal pulmonary fibrosis, have been reported rarely and should be considered in the differential diagnosis of pulmonary symptoms ranging from dyspnea to respiratory failure in post-transplant patients receiving mycophenolate mofetil.
 
  </item>
                           <item>
                              <content styleCode="underline">Vascular:</content>Lymphocele
 
  </item>
                        </list>
                     </text>
                     <effectiveTime value="20240306"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S7">
               <id root="130317dd-7137-69c9-e063-6394a90adc55"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS</title>
               <effectiveTime value="20240306"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>See FPI for drugs that may interfere with systemic exposure and reduce mycophenolate mofetil efficacy: antacids with magnesium or aluminum hydroxide, proton pump inhibitors, drugs that interfere with enterohepatic recirculation, telmisartan, calcium-free phosphate binders. (
  
     <linkHtml href="#S7.1">7.1</linkHtml>)
 
    </item>
                           <item>Mycophenolate mofetil may reduce effectiveness of oral contraceptives. Use of additional barrier contraceptive methods is recommended. (
  
     <linkHtml href="#S7.2">7.2</linkHtml>)
 
    </item>
                           <item>See FPI for other important drug interactions. (
  
     <linkHtml href="#S7">7</linkHtml>)
 
    </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S7.1">
                     <id root="130317dd-7138-69c9-e063-6394a90adc55"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.1 Effect of Other Drugs on Mycophenolate Mofetil</title>
                     <text>
                        <table width="100%" ID="Table5">
                           <caption>Table 7 Drug Interactions with Mycophenolate mofetil that Affect Mycophenolic Acid (MPA) Exposure</caption>
                           <col width="25%" align="right" valign="middle"/>
                           <col width="75%" align="left" valign="middle"/>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td colspan="2" align="left" styleCode="Lrule Rrule">
                                    <content styleCode="bold">Antacids with Magnesium or Aluminum Hydroxide</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="italics">Clinical Impact</content>
                                 </td>
                                 <td styleCode="Rrule">Concomitant use with an antacid containing magnesium or aluminum hydroxide decreases MPA systemic exposure
    
     <content styleCode="italics">[see
     
      <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]
    
     </content>, which may reduce mycophenolate mofetil efficacy.
   
    </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="italics">Prevention or Management</content>
                                 </td>
                                 <td styleCode="Rrule">Administer magnesium or aluminum hydroxide containing antacids at least 2h after mycophenolate mofetil administration.</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="2" align="left" styleCode="Lrule Rrule">
                                    <content styleCode="bold">Proton Pump Inhibitors (PPIs)</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="italics">Clinical Impact</content>
                                 </td>
                                 <td styleCode="Rrule">Concomitant use with PPIs decreases MPA systemic exposure
    
     <content styleCode="italics">[see
     
      <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]
    
     </content>, which may reduce mycophenolate mofetil efficacy.
   
    </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="italics">Prevention or Management</content>
                                 </td>
                                 <td styleCode="Rrule">Monitor patients for alterations in efficacy when PPIs are co-administered with mycophenolate mofetil.</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="italics">Examples</content>
                                 </td>
                                 <td styleCode="Rrule">Lansoprazole, pantoprazole</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="2" align="left" styleCode="Lrule Rrule">
                                    <content styleCode="bold">Drugs that Interfere with Enterohepatic Recirculation</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="italics">Clinical Impact</content>
                                 </td>
                                 <td styleCode="Rrule">Concomitant use with drugs that directly interfere with enterohepatic recirculation, or indirectly interfere with enterohepatic recirculation by altering the gastrointestinal flora, can decrease MPA systemic exposure
    
     <content styleCode="italics">[see
     
      <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]
    
     </content>, which may reduce mycophenolate mofetil efficacy.
   
    </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="italics">Prevention or Management</content>
                                 </td>
                                 <td styleCode="Rrule">Monitor patients for alterations in efficacy or mycophenolate mofetil related adverse reactions when these drugs are co-administered with mycophenolate mofetil.</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="italics">Examples</content>
                                 </td>
                                 <td styleCode="Rrule">Cyclosporine A,trimethoprim/sulfamethoxazole, bile acid sequestrants (cholestyramine), rifampin as well as aminoglycoside, cephalosporin, fluoroquinolone and penicillin classes of antimicrobials</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="2" align="left" styleCode="Lrule Rrule">
                                    <content styleCode="bold">Drugs Modulating Glucuronidation</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="italics">Clinical Impact</content>
                                 </td>
                                 <td styleCode="Rrule">Concomitant use with drugs inducing glucuronidation decreases MPA systemic exposure, potentially reducing mycophenolate mofetil efficacy, while use with drugs inhibiting glucuronidation increases MPA systemic exposure
    
     <content styleCode="italics">[see
     
      <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]
    
     </content>, which may increase the risk of mycophenolate mofetil related adverse reactions.
   
    </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="italics">Prevention or Management</content>
                                 </td>
                                 <td styleCode="Rrule">Monitor patients for alterations in efficacy or mycophenolate mofetil related adverse reactions when these drugs are co-administered with mycophenolate mofetil.</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="italics">Examples</content>
                                 </td>
                                 <td styleCode="Rrule">Telmisartan (induces glucuronidation); isavuconazole (inhibits glucuronidation).</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="2" align="left" styleCode="Lrule Rrule">
                                    <content styleCode="bold">Calcium Free Phosphate Binders</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="italics">Clinical Impact</content>
                                 </td>
                                 <td styleCode="Rrule">Concomitant use with calcium free phosphate binders decrease MPA systemic exposure
    
     <content styleCode="italics">[see
     
      <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]
    
     </content>, which may reduce mycophenolate mofetil efficacy.
   
    </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="italics">Prevention or Management</content>
                                 </td>
                                 <td styleCode="Rrule">Administer calcium free phosphate binders at least 2 hours after mycophenolate mofetil.</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="italics">Examples</content>
                                 </td>
                                 <td styleCode="Rrule">Sevelamer</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20240306"/>
                  </section>
               </component>
               <component>
                  <section ID="S7.2">
                     <id root="130317dd-7139-69c9-e063-6394a90adc55"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.2 Effect of Mycophenolate Mofetil on Other Drugs</title>
                     <text>
                        <table width="100%" ID="Table8">
                           <caption>Table 8 Drug Interactions with Mycophenolate mofetil that Affect Other Drugs</caption>
                           <col width="25%" align="right" valign="middle"/>
                           <col width="75%" align="left" valign="middle"/>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td colspan="2" align="left" styleCode="Lrule Rrule">
                                    <content styleCode="bold">Drugs that Undergo Renal Tubular Secretion</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="italics">Clinical Impact</content>
                                 </td>
                                 <td styleCode="Rrule">When concomitantly used with mycophenolate mofetil, its metabolite MPAG, may compete with drugs eliminated by renal tubular secretion which may increase plasma concentrations and/or adverse reactions associated with these drugs.</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="italics">Prevention or Management</content>
                                 </td>
                                 <td styleCode="Rrule">Monitor for drug-related adverse reactions in patients with renal impairment.</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="bottom">
                                    <content styleCode="italics">Examples</content>
                                 </td>
                                 <td styleCode="Rrule">Acyclovir, ganciclovir, probenecid, valacyclovir, valganciclovir</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="2" align="left" styleCode="Lrule Rrule">
                                    <content styleCode="bold">Combination Oral Contraceptives</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="italics">Clinical Impact</content>
                                 </td>
                                 <td styleCode="Rrule">Concomitant use with mycophenolate mofetil decreased the systemic exposure to levonorgestrel, but did not affect the systemic exposure to ethinylestradiol
    
     <content styleCode="italics">[see
     
      <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]
    
     </content>, which may result in reduced combination oral contraceptive effectiveness.
   
    </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="italics">Prevention or Management</content>
                                 </td>
                                 <td styleCode="Rrule">Use additional barrier contraceptive methods.</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20240306"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S8">
               <id root="130317dd-713a-69c9-e063-6394a90adc55"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20240306"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>Pediatric Use: Safety and effectiveness in allogenic heart or liver transplants has not been established (
  
     <linkHtml href="#S8.4">8.4</linkHtml>)
 
    </item>
                           <item>Male Patients: Sexually active male patients and/or their female partners are recommended to use effective contraception during treatment of the male patient and for at least 90 days after cessation of treatment (
  
     <linkHtml href="#S8.3">8.3</linkHtml>)
 
    </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S8.1">
                     <id root="130317dd-713b-69c9-e063-6394a90adc55"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <effectiveTime value="20240306"/>
                     <component>
                        <section>
                           <id root="130317dd-713c-69c9-e063-6394a90adc55"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Pregnancy Exposure Registry</content>
                              </paragraph>
                              <paragraph>There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to mycophenolate during pregnancy and those becoming pregnant within 6 weeks of discontinuing mycophenolate mofetil treatment. To report a pregnancy or obtain information about the registry, visit www.mycophenolateREMS.com or call 1-800-617-8191.</paragraph>
                           </text>
                           <effectiveTime value="20240306"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="130317dd-713d-69c9-e063-6394a90adc55"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>Use of mycophenolate mofetil (MMF) during pregnancy is associated with an increased risk of first trimester pregnancy loss and an increased risk of multiple congenital malformations in multiple organ systems
 
  <content styleCode="italics">[see
  
   <linkHtml href="#Human">Human Data</linkHtml>].
 
  </content>Oral administration of mycophenolate to rats and rabbits during the period of organogenesis produced congenital malformations and pregnancy loss at doses less than the recommended clinical dose (0.01 to 0.05 times the recommended clinical doses in kidney and heart transplant patients)
 
  <content styleCode="italics">[see
  
   <linkHtml href="#Animal">Animal Data</linkHtml>]
 
  </content>.

 </paragraph>
                              <paragraph>Consider alternative immunosuppressants with less potential for embryofetal toxicity. Risks and benefits of mycophenolate mofetil should be discussed with the pregnant woman.</paragraph>
                              <paragraph>The estimated background risk of pregnancy loss and congenital malformations in organ transplant populations is not clear. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.</paragraph>
                           </text>
                           <effectiveTime value="20240306"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="130317dd-713e-69c9-e063-6394a90adc55"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Data</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20240306"/>
                           <component>
                              <section ID="Human">
                                 <id root="130317dd-713f-69c9-e063-6394a90adc55"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Human Data</content>
                                    </paragraph>
                                    <paragraph>A spectrum of congenital malformations (including multiple malformations in individual newborns) has been reported in 23 to 27% of live births in MMF exposed pregnancies, based on published data from pregnancy registries. Malformations that have been documented include external ear, eye, and other facial abnormalities including cleft lip and palate, and anomalies of the distal limbs, heart, esophagus, kidney, and nervous system.</paragraph>
                                    <paragraph>Based on published data from pregnancy registries, the risk of first trimester pregnancy loss has been reported at 45 to 49% following MMF exposure.</paragraph>
                                 </text>
                                 <effectiveTime value="20240306"/>
                              </section>
                           </component>
                           <component>
                              <section ID="Animal">
                                 <id root="130317dd-7140-69c9-e063-6394a90adc55"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Animal Data</content>
                                    </paragraph>
                                    <paragraph>In animal reproductive toxicology studies, there were increased rates of fetal resorptions and malformations in the absence of maternal toxicity. Oral administration of MMF to pregnant rats from Gestational Day 7 to Day 16 produced increased embryofetal lethality and fetal malformations including anophthalmia, agnathia, and hydrocephaly at doses equivalent to 0.015 and 0.01 times the recommended human doses for renal and cardiac transplant patients, respectively, when corrected for BSA. Oral administration of MMF to pregnant rabbits from Gestational Day 7 to Day 19 produced increased embryofetal lethality and fetal malformations included ectopia cordis, ectopic kidneys, diaphragmatic hernia, and umbilical hernia at dose equivalents as low as 0.05 and 0.03 times the recommended human doses for renal and cardiac transplant patients, respectively, when corrected for BSA.</paragraph>
                                 </text>
                                 <effectiveTime value="20240306"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.2">
                     <id root="130317dd-7141-69c9-e063-6394a90adc55"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2 Lactation</title>
                     <effectiveTime value="20240306"/>
                     <component>
                        <section>
                           <id root="130317dd-7142-69c9-e063-6394a90adc55"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>There are no data on the presence of mycophenolate in human milk, or the effects on milk production. There are limited data in the National Transplantation Pregnancy Registry on the effects of mycophenolate on a breastfed child
 
  <content styleCode="italics">[see
  
   <linkHtml href="#Data">Data</linkHtml>]
 
  </content>. Studies in rats treated with MMF have shown mycophenolic acid (MPA) to be present in milk. Because available data are limited, it is not possible to exclude potential risks to a breastfeeding infant.

 </paragraph>
                              <paragraph>The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for mycophenolate mofetil and any potential adverse effects on the breastfed infant from mycophenolate mofetil or from the underlying maternal condition.</paragraph>
                           </text>
                           <effectiveTime value="20240306"/>
                        </section>
                     </component>
                     <component>
                        <section ID="Data">
                           <id root="130317dd-7143-69c9-e063-6394a90adc55"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Data</content>
                              </paragraph>
                              <paragraph>Limited information is available from the National Transplantation Pregnancy Registry. Of seven infants reported by the National Transplantation Pregnancy Registry to have been breastfed while the mother was taking mycophenolate, all were born at 34 to 40 weeks gestation, and breastfed for up to 14 months. No adverse events were reported.</paragraph>
                           </text>
                           <effectiveTime value="20240306"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.3">
                     <id root="130317dd-7144-69c9-e063-6394a90adc55"/>
                     <code code="77291-3" codeSystem="2.16.840.1.113883.6.1" displayName="FEMALES &amp; MALES OF REPRODUCTIVE POTENTIAL SECTION"/>
                     <title>8.3 Females and Males of Reproductive Potential</title>
                     <text>
                        <paragraph>Females of reproductive potential must be made aware of the increased risk of first trimester pregnancy loss and congenital malformations and must be counseled regarding pregnancy prevention and planning.</paragraph>
                     </text>
                     <effectiveTime value="20240306"/>
                     <component>
                        <section>
                           <id root="130317dd-7145-69c9-e063-6394a90adc55"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Pregnancy Planning</content>
                              </paragraph>
                              <paragraph>For patients who are considering pregnancy, consider alternative immunosuppressants with less potential for embryofetal toxicity whenever possible. Risks and benefits of mycophenolate mofetil should be discussed with the patient.</paragraph>
                           </text>
                           <effectiveTime value="20240306"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="130317dd-7146-69c9-e063-6394a90adc55"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Pregnancy Testing</content>
                              </paragraph>
                              <paragraph>To prevent unplanned exposure during pregnancy, all females of reproductive potential should have a serum or urine pregnancy test with a sensitivity of at least 25 mIU/mL immediately before starting mycophenolate mofetil. Another pregnancy test with the same sensitivity should be done 8 to 10 days later. Repeat pregnancy tests should be performed during routine follow-up visits. Results of all pregnancy tests should be discussed with the patient. In the event of a positive pregnancy test, consider alternative immunosuppressants with less potential for embryofetal toxicity whenever possible.</paragraph>
                           </text>
                           <effectiveTime value="20240306"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="130317dd-7147-69c9-e063-6394a90adc55"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Contraception</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20240306"/>
                           <component>
                              <section>
                                 <id root="130317dd-7148-69c9-e063-6394a90adc55"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Female Patients</content>
                                    </paragraph>
                                    <paragraph>Females of reproductive potential taking mycophenolate mofetil must receive contraceptive counseling and use acceptable contraception (see
 
  <content styleCode="bold">
                                          <linkHtml href="#Table7">Table 9</linkHtml>
                                       </content>for acceptable contraception methods). Patients must use acceptable birth control during the entire mycophenolate mofetil therapy, and for 6 weeks after stopping mycophenolate mofetil, unless the patient chooses abstinence.

 </paragraph>
                                    <paragraph>Patients should be aware that mycophenolate mofetil reduces blood levels of the hormones from the oral contraceptive pill and could theoretically reduce its effectiveness
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S7.2">Drug Interactions (7.2)</linkHtml>]
 
  </content>.

 </paragraph>
                                    <table width="100%" ID="Table7" styleCode="Noautorules">
                                       <caption>Table 9 Acceptable Contraception Methods for Females of Reproductive Potential Pick from the following birth control options:</caption>
                                       <col width="15%" align="left" valign="top"/>
                                       <col width="37%" align="left" valign="top"/>
                                       <col width="11%" align="left" valign="top"/>
                                       <col width="37%" align="left" valign="top"/>
                                       <tbody>
                                          <tr styleCode="Botrule">
                                             <td colspan="4">
                                                <content styleCode="bold">Pick from the following birth control options:</content>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Lrule Rrule">
                                                <content styleCode="bold">Option 1</content>
                                             </td>
                                             <td colspan="3" styleCode="Rrule"/>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">
                                                <content styleCode="bold">Methods to Use Alone</content>
                                             </td>
                                             <td colspan="3" styleCode="Rrule">
                                                <list listType="unordered">
                                                   <item>Intrauterine devices (IUDs)</item>
                                                   <item>Tubal sterilization</item>
                                                   <item>Patient's partner vasectomy</item>
                                                </list>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td colspan="4">
                                                <content styleCode="bold">OR</content>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">
                                                <content styleCode="bold">Option 2</content>
                                             </td>
                                             <td styleCode="Rrule">
                                                <content styleCode="bold">Hormone Methods</content>
                                                <br/>  choose 1
   
    </td>
                                             <td styleCode="Rrule"/>
                                             <td styleCode="Rrule">
                                                <content styleCode="bold">Barrier Methods</content>
                                                <br/>  choose 1
   
    </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">
                                                <content styleCode="bold">Choose One Hormone Method</content>
                                                <content styleCode="italics">AND</content>
                                                <content styleCode="bold">One Barrier Method</content>
                                             </td>
                                             <td styleCode="Rrule" valign="middle">
                                                <content styleCode="bold">Estrogen and Progesterone</content>
                                                <list listType="unordered">
                                                   <item>Oral Contraceptive Pill</item>
                                                   <item>Transdermal patch</item>
                                                   <item>Vaginal ring</item>
                                                </list>
                                                <content styleCode="bold">Progesterone-only</content>
                                                <list listType="unordered">
                                                   <item>Injection</item>
                                                   <item>Implant</item>
                                                </list>
                                             </td>
                                             <td styleCode="Rrule" valign="middle">
                                                <content styleCode="italics">AND</content>
                                             </td>
                                             <td styleCode="Rrule" valign="middle">
                                                <list listType="unordered">
                                                   <item>Diaphragm with spermicide</item>
                                                   <item>Cervical cap with spermicide</item>
                                                   <item>Contraceptive sponge</item>
                                                   <item>Male condom</item>
                                                   <item>Female condom</item>
                                                </list>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td colspan="4">
                                                <content styleCode="bold">OR</content>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">
                                                <content styleCode="bold">Option 3</content>
                                             </td>
                                             <td styleCode="Rrule">
                                                <content styleCode="bold">Barrier Methods</content>
                                                <br/>  choose 1
   
    </td>
                                             <td styleCode="Rrule"/>
                                             <td styleCode="Rrule">
                                                <content styleCode="bold">Barrier Methods</content>
                                                <br/>  choose 1
   
    </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">
                                                <content styleCode="bold">Choose One Barrier Method from each column</content>
                                                <content styleCode="italics">(must choose two methods)</content>
                                             </td>
                                             <td styleCode="Rrule" valign="middle">
                                                <list listType="unordered">
                                                   <item>Diaphragm with spermicide</item>
                                                   <item>Cervical cap with spermicide</item>
                                                   <item>Contraceptive sponge</item>
                                                </list>
                                             </td>
                                             <td styleCode="Rrule" valign="middle">
                                                <content styleCode="italics">AND</content>
                                             </td>
                                             <td styleCode="Rrule" valign="middle">
                                                <list listType="unordered">
                                                   <item>Male condom</item>
                                                   <item>Female condom</item>
                                                </list>
                                             </td>
                                          </tr>
                                       </tbody>
                                    </table>
                                 </text>
                                 <effectiveTime value="20240306"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="130317dd-7149-69c9-e063-6394a90adc55"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Male Patients</content>
                                    </paragraph>
                                    <paragraph>Genotoxic effects have been observed in animal studies at exposures exceeding the human therapeutic exposures by approximately 1.25 times. Thus, the risk of genotoxic effects on sperm cells cannot be excluded. Based on this potential risk, sexually active male patients and/or their female partners are recommended to use effective contraception during treatment of the male patient and for at least 90 days after cessation of treatment. Also, based on the potential risk of genotoxic effects, male patients should not donate sperm during treatment with mycophenolate mofetil and for at least 90 days after cessation of treatment
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S8.1">Use in Special Populations (8.1)</linkHtml>,
  
   <linkHtml href="#S13.1">Nonclinical Toxicology (13.1)</linkHtml>,
  
   <linkHtml href="#S17.9">Patient Counseling Information (17.9)</linkHtml>]
 
  </content>.

 </paragraph>
                                 </text>
                                 <effectiveTime value="20240306"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.4">
                     <id root="130317dd-714a-69c9-e063-6394a90adc55"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph>Safety and effectiveness have been established in pediatric patients 3 months and older for the prophylaxis of organ rejection of allogenic kidney, heart or liver transplants.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Kidney Transplant</content>
                        </paragraph>
                        <paragraph>Use of mycophenolate mofetil in this population is supported by evidence from adequate and well-controlled studies of mycophenolate mofetil in adults with additional data from one open-label, pharmacokinetic and safety study of mycophenolate mofetil in pediatric patients after receiving allogeneic kidney transplant (100 patients, 3 months to 18 years of age)
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S2.2">Dosage and Administration (2.2)</linkHtml>,
  
   <linkHtml href="#S6.1">Adverse Reactions (6.1)</linkHtml>,
  
   <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>,
  
   <linkHtml href="#S14.1">Clinical Studies (14.1)</linkHtml>].
 
  </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="underline">Heart Transplant and Liver Transplant</content>
                        </paragraph>
                        <paragraph>Use of mycophenolate mofetil in pediatric heart transplant and liver transplant patients is supported by adequate and well controlled studies and pharmacokinetic data in adult heart transplant and liver transplant patients. Additional supportive data include pharmacokinetic data in pediatric kidney transplant and pediatric liver transplant patients (8 liver transplant patients, 9 months to 5 years of age, in an open-label, pharmacokinetic and safety study) and published evidence of clinical efficacy and safety in pediatric heart transplant and pediatric liver transplant patients
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S2.2">Dosage and Administration (2.3,2.4)</linkHtml>,
  
   <linkHtml href="#S6.1">Adverse Reactions (6.1)</linkHtml>,
  
   <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>,
  
   <linkHtml href="#S14.1">Clinical Studies (14.1)</linkHtml>].
 
  </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240306"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.5">
                     <id root="130317dd-714b-69c9-e063-6394a90adc55"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph>Clinical studies of mycophenolate mofetil did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between geriatric and younger patients. In general, dose selection for a geriatric patient should take into consideration the presence of decreased hepatic, renal or cardiac function and of concomitant drug therapies
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S6.1">Adverse Reactions (6.1)</linkHtml>,
  
   <linkHtml href="#S7">Drug Interactions (7)</linkHtml>].
 
  </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240306"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.6">
                     <id root="130317dd-714c-69c9-e063-6394a90adc55"/>
                     <code code="88828-9" codeSystem="2.16.840.1.113883.6.1" displayName="RENAL IMPAIRMENT SUBSECTION"/>
                     <title>8.6 Patients with Renal Impairment</title>
                     <effectiveTime value="20240306"/>
                     <component>
                        <section>
                           <id root="130317dd-714d-69c9-e063-6394a90adc55"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Patients with Kidney Transplant</content>
                              </paragraph>
                              <paragraph>No dosage adjustments are needed in kidney transplant patients experiencing delayed graft function postoperatively but patients should be carefully monitored
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>].
 
  </content>
                                 <content styleCode="underline">In kidney transplant patients with severe chronic impairment of the graft</content>(GFR &lt;25 mL/min/1.73 m
 
  <sup>2</sup>), no dose adjustments are necessary; however, doses greater than 1 g administered twice a day should be avoided.

 </paragraph>
                           </text>
                           <effectiveTime value="20240306"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="130317dd-714e-69c9-e063-6394a90adc55"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Patients with Heart and Liver Transplant</content>
                              </paragraph>
                              <paragraph>No data are available for heart or liver transplant patients with severe chronic renal impairment. Mycophenolate mofetil may be used for heart or liver transplant patients with severe chronic renal impairment if the potential benefits outweigh the potential risks.</paragraph>
                           </text>
                           <effectiveTime value="20240306"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.7">
                     <id root="130317dd-714f-69c9-e063-6394a90adc55"/>
                     <code code="88829-7" codeSystem="2.16.840.1.113883.6.1" displayName="HEPATIC IMPAIRMENT SUBSECTION"/>
                     <title>8.7 Patients with Hepatic Impairment</title>
                     <effectiveTime value="20240306"/>
                     <component>
                        <section>
                           <id root="130317dd-7150-69c9-e063-6394a90adc55"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Patients with Kidney Transplant</content>
                              </paragraph>
                              <paragraph>No dosage adjustments are recommended for kidney transplant patients with severe hepatic parenchymal disease. However, it is not known whether dosage adjustments are needed for hepatic disease with other etiologies
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>].
 
  </content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20240306"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="130317dd-7151-69c9-e063-6394a90adc55"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Patients with Heart Transplant</content>
                              </paragraph>
                              <paragraph>No data are available for heart transplant patients with severe hepatic parenchymal disease.</paragraph>
                           </text>
                           <effectiveTime value="20240306"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S10">
               <id root="130317dd-7152-69c9-e063-6394a90adc55"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE</title>
               <text>
                  <paragraph>Possible signs and symptoms of acute overdose include hematological abnormalities such as leukopenia and neutropenia, and gastrointestinal symptoms such as abdominal pain, diarrhea, nausea, vomiting, and dyspepsia.</paragraph>
                  <paragraph>The experience with overdose of mycophenolate mofetil in humans is limited. The reported effects associated with overdose fall within the known safety profile of the drug. The highest dose administered to kidney transplant patients in clinical trials has been 4 g/day. In limited experience with heart and liver transplant patients in clinical trials, the highest doses used were 4 g/day or 5 g/day. At doses of 4 g/day or 5 g/day, there appears to be a higher rate, compared to the use of 3 g/day or less, of gastrointestinal intolerance (nausea, vomiting, and/or diarrhea), and occasional hematologic abnormalities, particularly neutropenia
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S5.4">Warnings and Precautions (5.4)</linkHtml>]
 
  </content>.

 </paragraph>
               </text>
               <effectiveTime value="20240306"/>
               <component>
                  <section>
                     <id root="130317dd-7153-69c9-e063-6394a90adc55"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Treatment and Management</content>
                        </paragraph>
                        <paragraph>MPA and the phenolic glucuronide metabolite of MPA (MPAG) are usually not removed by hemodialysis. However, at high MPAG plasma concentrations (&gt;100 µg/mL), small amounts of MPAG are removed. By increasing excretion of the drug, MPA can be removed by bile acid sequestrants, such as cholestyramine
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>].
 
  </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240306"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S11">
               <id root="130317dd-7154-69c9-e063-6394a90adc55"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph>Mycophenolate mofetil is an antimetabolite immunosuppressant. It is the 2-morpholinoethyl ester of mycophenolic acid (MPA), an immunosuppressive agent; inosine monophosphate dehydrogenase (IMPDH) inhibitor.</paragraph>
                  <paragraph>The chemical name for mycophenolate mofetil (MMF) is 2-morpholinoethyl (E)-6-(1, 3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-4-hexenoate. It has an empirical formula of C
 
  <sub>23</sub>H
 
  <sub>31</sub>NO
 
  <sub>7</sub>, a molecular weight of 433.50, and the following structural formula:

 </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM1"/>
                  </paragraph>
                  <paragraph>MMF is a white to off-white crystalline powder. It is slightly soluble in water (43 µg/mL at pH 7.4); the solubility increases in acidic medium (4.27 mg/mL at pH 3.6). It is freely soluble in acetone, soluble in methanol, and sparingly soluble in ethanol. The apparent partition coefficient in 1-octanol/water (pH 7.4) buffer solution is 238. The pKa values for MMF are 5.6 for the morpholino group and 8.5 for the phenolic group.</paragraph>
                  <paragraph>MMF hydrochloride has a solubility of 65.8 mg/mL in 5% Dextrose Injection USP (D5W). The pH of the reconstituted solution is 2.4 to 4.1.</paragraph>
                  <paragraph>Mycophenolate mofetil is available for oral administration as capsules containing 250 mg of MMF, tablets containing 500 mg of MMF.</paragraph>
                  <paragraph>Inactive ingredients in mycophenolate mofetil 250 mg capsules include croscarmellose sodium, magnesium stearate, povidone (K-90) microcrystalline cellulose, hydroxy propyl cellulose and talc. The capsule shells contain FD&amp;C blue #2, gelatin, red iron oxide, sodium lauryl sulfate, titanium dioxide, and yellow iron oxide. The imprinting ink contains shellac, iron oxide black and potassium hydroxide.</paragraph>
                  <paragraph>Inactive ingredients in mycophenolate mofetil 500 mg tablets include iron oxide black, croscarmellose sodium, FD&amp;C blue #2 aluminum Lake, hydroxypropyl cellulose, hypromellose, magnesium stearate, microcrystalline cellulose, polyethylene glycol 400, povidone (K-90), iron oxide red, talc, and titanium dioxide.</paragraph>
                  <paragraph>Mycophenolate Mofetil Tablets meets USP Dissolution Test 3 and Mycophenolate Mofetil Capsules meets USP Dissolution Test 2.</paragraph>
               </text>
               <effectiveTime value="20240306"/>
               <component>
                  <observationMedia ID="MM1">
                     <text>Chemical Structure</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="mycophenolate-mofetil.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="S12">
               <id root="130317dd-7155-69c9-e063-6394a90adc55"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20240306"/>
               <component>
                  <section ID="S12.1">
                     <id root="130317dd-7156-69c9-e063-6394a90adc55"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph>Mycophenolate mofetil (MMF) is absorbed following oral administration and hydrolyzed to mycophenolic acid (MPA), the active metabolite. MPA is a selective uncompetitive inhibitor of the two isoforms (type I and type II) of inosine monophosphate dehydrogenase (IMPDH) leading to inhibition of the
 
  <content styleCode="italics">de novo</content>pathway of guanosine nucleotide synthesis and blocks DNA synthesis. The mechanism of action of MPA is multifaceted and includes effects on cellular checkpoints responsible for metabolic programming of lymphocytes. MPA shifts transcriptional activities in lymphocytes from a proliferative state to catabolic processes. In vitro studies suggest that MPA modulates transcriptional activities in human CD4+ T-lymphocytes by suppressing the Akt/mTOR and STAT5 pathways that are relevant to metabolism and survival, leading to an anergic state of T-cells whereby the cells become less responsive to antigenic stimulation. Additionally, MPA enhanced the expression of negative co-stimulators such as CD70, PD-1, CTLA-4, and transcription factor FoxP3 as well as decreased the expression of positive co-stimulators CD27 and CD28. 
  <br/>  MPA decreases proliferative responses of T- and B-lymphocytes to both mitogenic and allo-antigenic stimulation, antibody responses, as well as the production of cytokines from lymphocytes and monocytes such as GM-CSF, IFN-ɣ, IL-17, and TNF-α. Additionally, MPA prevents the glycosylation of lymphocyte and monocyte glycoproteins that are involved in intercellular adhesion to endothelial cells and may inhibit recruitment of leukocytes into sites of inflammation and graft rejection. 
  <br/>  Overall, the effect of MPA is cytostatic and reversible.

 </paragraph>
                     </text>
                     <effectiveTime value="20240306"/>
                  </section>
               </component>
               <component>
                  <section ID="S12.2">
                     <id root="130317dd-7157-69c9-e063-6394a90adc55"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics</title>
                     <text>
                        <paragraph>There is a lack of information regarding the pharmacodynamic effects of MMF.</paragraph>
                     </text>
                     <effectiveTime value="20240306"/>
                  </section>
               </component>
               <component>
                  <section ID="S12.3">
                     <id root="130317dd-7158-69c9-e063-6394a90adc55"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <effectiveTime value="20240306"/>
                     <component>
                        <section>
                           <id root="130317dd-7159-69c9-e063-6394a90adc55"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Absorption</content>
                              </paragraph>
                              <paragraph>Following oral and intravenous administration, MMF undergoes complete conversion to MPA, the active metabolite. In 12 healthy volunteers, the mean absolute bioavailability of oral MMF relative to intravenous MMF was 94%. Two 500 mg mycophenolate mofetil tablets have been shown to be bioequivalent to four 250 mg mycophenolate mofetil capsules. Five mL of the 200 mg/mL constituted mycophenolate mofetil oral suspension have been shown to be bioequivalent to four 250 mg capsules.</paragraph>
                              <paragraph>The mean (± SD) pharmacokinetic parameters estimates for MPA following the administration of MMF given as single doses to healthy volunteers, and multiple doses to kidney, heart, and liver transplant patients, are shown in
 
  <content styleCode="bold">
                                    <linkHtml href="#Table10">Table 10</linkHtml>
                                 </content>. The area under the plasma-concentration time curve (AUC) for MPA appears to increase in a dose-proportional fashion in kidney transplant patients receiving multiple oral doses of MMF up to a daily dose of 3 g (1.5 g twice daily) (see
 
  <content styleCode="bold">
                                    <linkHtml href="#Table10">Table 10</linkHtml>
                                 </content>).

 </paragraph>
                              <table width="100%" ID="Table10">
                                 <caption>Table 10 Pharmacokinetic Parameters for MPA [mean (±SD)] Following Administration of MMF to Healthy Volunteers (Single Dose), and Kidney, Heart, and Liver Transplant Patients (Multiple Doses)</caption>
                                 <col width="25%" align="left" valign="top"/>
                                 <col width="16%" align="center" valign="top"/>
                                 <col width="17%" align="center" valign="top"/>
                                 <col width="17%" align="center" valign="top"/>
                                 <col width="25%" align="center" valign="top"/>
                                 <tbody>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" valign="middle">
                                          <content styleCode="bold">Healthy Volunteers</content>
                                       </td>
                                       <td styleCode="Rrule" valign="middle">
                                          <content styleCode="bold">Dose/Route</content>
                                       </td>
                                       <td styleCode="Rrule" valign="middle">
                                          <content styleCode="bold">T
     
      <sub>max</sub>
                                             <br/>  (h)
    
     </content>
                                       </td>
                                       <td styleCode="Rrule" valign="middle">
                                          <content styleCode="bold">C
     
      <sub>max</sub>
                                             <br/>  (mcg/mL)
    
     </content>
                                       </td>
                                       <td styleCode="Rrule" valign="middle">
                                          <content styleCode="bold">Total AUC 
      <br/>  (mcg∙h/mL)
     </content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Single dose</td>
                                       <td styleCode="Rrule">1 g/oral</td>
                                       <td styleCode="Rrule">0.80 
     <br/>  (±0.36) 
     <br/>  (n=129)
    </td>
                                       <td styleCode="Rrule">24.5 
     <br/>  (±9.5) 
     <br/>  (n=129)
    </td>
                                       <td styleCode="Rrule">63.9 
     <br/>  (±16.2) 
     <br/>  (n=117)
    </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" valign="middle">
                                          <content styleCode="bold">Kidney Transplant Patients (twice daily dosing) Time After Transplantation</content>
                                       </td>
                                       <td styleCode="Rrule" valign="middle">
                                          <content styleCode="bold">Dose/Route</content>
                                       </td>
                                       <td styleCode="Rrule" valign="middle">
                                          <content styleCode="bold">T
     
      <sub>max</sub>
                                             <br/>  (h)
    
     </content>
                                       </td>
                                       <td styleCode="Rrule" valign="middle">
                                          <content styleCode="bold">C
     
      <sub>max</sub>
                                             <br/>  (mcg/mL)
    
     </content>
                                       </td>
                                       <td styleCode="Rrule" valign="middle">
                                          <content styleCode="bold">Interdosing Interval AUC
     
      <sub>(0 to 12h)</sub>
                                             <br/>  (mcg∙h/mL)
    
     </content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">5 days</td>
                                       <td styleCode="Rrule">1 g/iv</td>
                                       <td styleCode="Rrule">1.58 
     <br/>  (±0.46) 
     <br/>  (n=31)
    </td>
                                       <td styleCode="Rrule">12.0 
     <br/>  (±3.82) 
     <br/>  (n=31)
    </td>
                                       <td styleCode="Rrule">40.8 
     <br/>  (±11.4) 
     <br/>  (n=31)
    </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">6 days</td>
                                       <td styleCode="Rrule">1 g/oral</td>
                                       <td styleCode="Rrule">1.33 
     <br/>  (±1.05) 
     <br/>  (n=31)
    </td>
                                       <td styleCode="Rrule">10.7 
     <br/>  (±4.83) 
     <br/>  (n=31)
    </td>
                                       <td styleCode="Rrule">32.9 
     <br/>  (±15.0) 
     <br/>  (n=31)
    </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Early (Less than 40 days)</td>
                                       <td styleCode="Rrule">1 g/oral</td>
                                       <td styleCode="Rrule">1.31 
     <br/>  (±0.76) 
     <br/>  (n=25)
    </td>
                                       <td styleCode="Rrule">8.16 
     <br/>  (±4.50) 
     <br/>  (n=25)
    </td>
                                       <td styleCode="Rrule">27.3 
     <br/>  (±10.9) 
     <br/>  (n=25)
    </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Early (Less than 40 days)</td>
                                       <td styleCode="Rrule">1.5 g/oral</td>
                                       <td styleCode="Rrule">1.21 
     <br/>  (±0.81) 
     <br/>  (n=27)
    </td>
                                       <td styleCode="Rrule">13.5 
     <br/>  (±8.18) 
     <br/>  (n=27)
    </td>
                                       <td styleCode="Rrule">38.4 
     <br/>  (±15.4) 
     <br/>  (n=27)
    </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Late (Greater than 3 months)</td>
                                       <td styleCode="Rrule">1.5 g/oral</td>
                                       <td styleCode="Rrule">0.90 
     <br/>  (±0.24) 
     <br/>  (n=23)
    </td>
                                       <td styleCode="Rrule">24.1 
     <br/>  (±12.1) 
     <br/>  (n=23)
    </td>
                                       <td styleCode="Rrule">65.3 
     <br/>  (±35.4) 
     <br/>  (n=23)
    </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" valign="middle">
                                          <content styleCode="bold">Heart transplant Patients (twice daily dosing) Time After Transplantation</content>
                                       </td>
                                       <td styleCode="Rrule" valign="middle">
                                          <content styleCode="bold">Dose/Route</content>
                                       </td>
                                       <td styleCode="Rrule" valign="middle">
                                          <content styleCode="bold">T
     
      <sub>max</sub>
                                             <br/>  (h)
    
     </content>
                                       </td>
                                       <td styleCode="Rrule" valign="middle">
                                          <content styleCode="bold">C
     
      <sub>max</sub>
                                             <br/>  (mcg/mL)
    
     </content>
                                       </td>
                                       <td styleCode="Rrule" valign="middle">
                                          <content styleCode="bold">Interdosing Interval AUC (0 to 12h) 
      <br/>  (mcg∙h/mL)
     </content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Early (Day before discharge)</td>
                                       <td styleCode="Rrule">1.5 g/oral</td>
                                       <td styleCode="Rrule">1.8 
     <br/>  (±1.3) 
     <br/>  (n=11)
    </td>
                                       <td styleCode="Rrule">11.5 
     <br/>  (±6.8) 
     <br/>  (n=11)
    </td>
                                       <td styleCode="Rrule">43.3 
     <br/>  (±20.8) 
     <br/>  (n=9)
    </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Late (Greater than 6 months)</td>
                                       <td styleCode="Rrule">1.5 g/oral</td>
                                       <td styleCode="Rrule">1.1 
     <br/>  (±0.7) 
     <br/>  (n=52)
    </td>
                                       <td styleCode="Rrule">20.0 
     <br/>  (±9.4) 
     <br/>  (n=52)
    </td>
                                       <td styleCode="Rrule">54.1
    
     <footnote ID="K5368">AUC(0 to 12h) values quoted are extrapolated from data from samples collected over 4 hours.</footnote>
                                          <br/>  (±20.4) 
     <br/>  (n=49)
   
    </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" valign="middle">
                                          <content styleCode="bold">Liver transplant Patients (twice daily dosing) Time After Transplantation</content>
                                       </td>
                                       <td styleCode="Rrule" valign="middle">
                                          <content styleCode="bold">Dose/Route</content>
                                       </td>
                                       <td styleCode="Rrule" valign="middle">
                                          <content styleCode="bold">T
     
      <sub>max</sub>
                                             <br/>  (h)
    
     </content>
                                       </td>
                                       <td styleCode="Rrule" valign="middle">
                                          <content styleCode="bold">C
     
      <sub>max</sub>
                                             <br/>  (mcg/mL)
    
     </content>
                                       </td>
                                       <td styleCode="Rrule" valign="middle">
                                          <content styleCode="bold">Interdosing Interval AUC(0 to 12h) 
      <br/>  (mcg∙h/mL)
     </content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">4 to 9 days</td>
                                       <td styleCode="Rrule">1 g/iv</td>
                                       <td styleCode="Rrule">1.50 
     <br/>  (±0.517) 
     <br/>  (n=22)
    </td>
                                       <td styleCode="Rrule">17.0 
     <br/>  (±12.7) 
     <br/>  (n=22)
    </td>
                                       <td styleCode="Rrule">34.0 
     <br/>  (±17.4) 
     <br/>  (n=22)
    </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Early (5 to 8 days)</td>
                                       <td styleCode="Rrule">1.5 g/oral</td>
                                       <td styleCode="Rrule">1.15 
     <br/>  (±0.432) 
     <br/>  (n=20)
    </td>
                                       <td styleCode="Rrule">13.1 
     <br/>  (±6.76) 
     <br/>  (n=20)
    </td>
                                       <td styleCode="Rrule">29.2 
     <br/>  (±11.9) 
     <br/>  (n=20)
    </td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Late (Greater than 6 months)</td>
                                       <td styleCode="Rrule">1.5 g/oral</td>
                                       <td styleCode="Rrule">1.54 
     <br/>  (±0.51) 
     <br/>  (n=6)
    </td>
                                       <td styleCode="Rrule">19.3 
     <br/>  (±11.7) 
     <br/>  (n=6)
    </td>
                                       <td styleCode="Rrule">49.3 
     <br/>  (±14.8) 
     <br/>  (n=6)
    </td>
                                    </tr>
                                 </tbody>
                              </table>
                              <paragraph>In the early post-transplant period (less than 40 days post-transplant), kidney, heart, and liver transplant patients had mean MPA AUCs approximately 20% to 41% lower and mean C
 
  <sub>max</sub>approximately 32% to 44% lower compared to the late transplant period (i.e., 3 to 6 months post-transplant) (non-stationarity in MPA pharmacokinetics).

 </paragraph>
                              <paragraph>Mean MPA AUC values following administration of 1 g twice daily intravenous mycophenolate mofetil over 2 hours to kidney transplant patients for 5 days were about 24% higher than those observed after oral administration of a similar dose in the immediate post-transplant phase.</paragraph>
                              <paragraph>In liver transplant patients, administration of 1 g twice daily intravenous mycophenolate mofetil followed by 1.5 g twice daily oral mycophenolate mofetil resulted in mean MPA AUC estimates similar to those found in kidney transplant patients administered 1 g mycophenolate mofetil twice daily.</paragraph>
                           </text>
                           <effectiveTime value="20240306"/>
                           <component>
                              <section>
                                 <id root="130317dd-715a-69c9-e063-6394a90adc55"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Effect of Food</content>
                                    </paragraph>
                                    <paragraph>Food (27 g fat, 650 calories) had no effect on the extent of absorption (MPA AUC) of MMF when administered at doses of 1.5 g twice daily to kidney transplant patients. However, MPA C
 
  <sub>max</sub>was decreased by 40% in the presence of food
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S2.1">Dosage and Administration (2.1)</linkHtml>]
 
  </content>.

 </paragraph>
                                 </text>
                                 <effectiveTime value="20240306"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="130317dd-715b-69c9-e063-6394a90adc55"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Distribution</content>
                              </paragraph>
                              <paragraph>The mean (±SD) apparent volume of distribution of MPA in 12 healthy volunteers was approximately 3.6 (±1.5) L/kg. At clinically relevant concentrations, MPA is 97% bound to plasma albumin. The phenolic glucuronide metabolite of MPA (MPAG) is 82% bound to plasma albumin at MPAG concentration ranges that are normally seen in stable kidney transplant patients; however, at higher MPAG concentrations (observed in patients with kidney impairment or delayed kidney graft function), the binding of MPA may be reduced as a result of competition between MPAG and MPA for protein binding. Mean blood to plasma ratio of radioactivity concentrations was approximately 0.6 indicating that MPA and MPAG do not extensively distribute into the cellular fractions of blood.</paragraph>
                              <paragraph>
                                 <content styleCode="italics">In vitro</content>studies to evaluate the effect of other agents on the binding of MPA to human serum albumin (HSA) or plasma proteins showed that salicylate (at 25 mg/dL with human serum albumin) and MPAG (at ≥460 mcg/mL with plasma proteins) increased the free fraction of MPA. MPA at concentrations as high as 100 mcg/mL had little effect on the binding of warfarin, digoxin or propranolol, but decreased the binding of theophylline from 53% to 45% and phenytoin from 90% to 87%.

 </paragraph>
                           </text>
                           <effectiveTime value="20240306"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="130317dd-715c-69c9-e063-6394a90adc55"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Elimination</content>
                              </paragraph>
                              <paragraph>Mean (±SD) apparent half-life and plasma clearance of MPA are 17.9 (±6.5) hours and 193 (±48) mL/min following oral administration and 16.6 (±5.8) hours and 177 (±31) mL/min following intravenous administration, respectively.</paragraph>
                           </text>
                           <effectiveTime value="20240306"/>
                           <component>
                              <section>
                                 <id root="130317dd-715d-69c9-e063-6394a90adc55"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Metabolism</content>
                                    </paragraph>
                                    <paragraph>The parent drug, MMF, can be measured systemically during the intravenous infusion; however, approximately 5 minutes after the infusion is stopped or after oral administration, MMF concentrations are below the limit of quantitation (0.4 mcg/mL).</paragraph>
                                    <paragraph>Metabolism to MPA occurs pre-systemically after oral dosing. MPA is metabolized principally by glucuronyl transferase to form MPAG, which is not pharmacologically active.
 
  <content styleCode="italics">In vivo</content>, MPAG is converted to MPA during enterohepatic recirculation. The following metabolites of the 2-hydroxyethyl-morpholino moiety are also recovered in the urine following oral administration of MMF to healthy subjects: N-(2-carboxymethyl)-morpholine, N-(2-hydroxyethyl)-morpholine, and the N-oxide of N-(2-hydroxyethyl)-morpholine.

 </paragraph>
                                    <paragraph>Due to the enterohepatic recirculation of MPAG/MPA, secondary peaks in the plasma MPA concentration-time profile are usually observed 6 to 12 hours post-dose. Bile sequestrants, such as cholestyramine, reduce MPA AUC by interfering with this enterohepatic recirculation of the drug
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S10">Overdosage (10)</linkHtml>and
  
   <linkHtml href="#DI">Drug Interaction Studies</linkHtml>below
 
  </content>].

 </paragraph>
                                 </text>
                                 <effectiveTime value="20240306"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="130317dd-715e-69c9-e063-6394a90adc55"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Excretion</content>
                                    </paragraph>
                                    <paragraph>Negligible amount of drug is excreted as MPA (less than 1% of dose) in the urine. Orally administered radiolabeled MMF resulted in complete recovery of the administered dose, with 93% of the administered dose recovered in the urine and 6% recovered in feces. Most (about 87%) of the administered dose is excreted in the urine as MPAG. At clinically encountered concentrations, MPA and MPAG are usually not removed by hemodialysis. However, at high MPAG plasma concentrations (&gt;100 mcg/mL), small amounts of MPAG are removed.</paragraph>
                                    <paragraph>Increased plasma concentrations of MMF metabolites (MPA 50% increase and MPAG about a 3-fold to 6-fold increase) are observed in patients with renal insufficiency
 
  <content styleCode="italics">[see
  
   <linkHtml href="#Specific">Specific Populations</linkHtml>]
 
  </content>.

 </paragraph>
                                 </text>
                                 <effectiveTime value="20240306"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section ID="Specific">
                           <id root="130317dd-715f-69c9-e063-6394a90adc55"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Specific Populations</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20240306"/>
                           <component>
                              <section>
                                 <id root="130317dd-7160-69c9-e063-6394a90adc55"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Patients with Renal Impairment</content>
                                    </paragraph>
                                    <paragraph>The mean (±SD) pharmacokinetic parameters for MPA following the administration of oral MMF given as single doses to non-transplant subjects with renal impairment are presented in
 
  <content styleCode="bold">
                                          <linkHtml href="#Table9">Table 11</linkHtml>
                                       </content>.

 </paragraph>
                                    <paragraph>In a single-dose study, MMF was administered as a capsule or as an intravenous infusion over 40 minutes. Plasma MPA AUC observed after oral dosing to volunteers with severe chronic renal impairment (GFR &lt;25 mL/min/1.73 m
 
  <sup>2</sup>) was about 75% higher relative to that observed in healthy volunteers (GFR &gt;80 mL/min/1.73 m
 
  <sup>2</sup>). In addition, the single-dose plasma MPAG AUC was 3-fold to 6-fold higher in volunteers with severe renal impairment than in volunteers with mild renal impairment or healthy volunteers, consistent with the known renal elimination of MPAG. No data are available on the safety of long-term exposure to this level of MPAG.

 </paragraph>
                                    <paragraph>Plasma MPA AUC observed after single-dose (1 g) intravenous dosing to volunteers (n=4) with severe chronic renal impairment (GFR &lt;25 mL/min/1.73 m
 
  <sup>2</sup>) was 62.4 mcg∙h/mL (±19.3). Multiple dosing of MMF in patients with severe chronic renal impairment has not been studied.

 </paragraph>
                                 </text>
                                 <effectiveTime value="20240306"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="130317dd-7161-69c9-e063-6394a90adc55"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Patients with Delayed Graft Function or Nonfunction</content>
                                    </paragraph>
                                    <paragraph>In patients with delayed renal graft function post-transplant, mean MPA AUC(0-12h) was comparable to that seen in post-transplant patients without delayed renal graft function. There is a potential for a transient increase in the free fraction and concentration of plasma MPA in patients with delayed renal graft function. However, dose adjustment does not appear to be necessary in patients with delayed renal graft function. Mean plasma MPAG AUC(0-12h) was 2-fold to 3-fold higher than in post-transplant patients without delayed renal graft function
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S2.5">Dosage and Administration (2.5)</linkHtml>]
 
  </content>.

 </paragraph>
                                    <paragraph>In eight patients with primary graft non-function following kidney transplantation, plasma concentrations of MPAG accumulated about 6-fold to 8-fold after multiple dosing for 28 days. Accumulation of MPA was about 1-fold to 2-fold.</paragraph>
                                    <paragraph>The pharmacokinetics of MMF are not altered by hemodialysis. Hemodialysis usually does not remove MPA or MPAG. At high concentrations of MPAG (&gt;100 mcg/mL), hemodialysis removes only small amounts of MPAG.</paragraph>
                                 </text>
                                 <effectiveTime value="20240306"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="130317dd-7162-69c9-e063-6394a90adc55"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Patients with Hepatic Impairment</content>
                                    </paragraph>
                                    <paragraph>The mean (± SD) pharmacokinetic parameters for MPA following the administration of oral MMF given as single doses to non-transplant subjects with hepatic impairment is presented in
 
  <content styleCode="bold">
                                          <linkHtml href="#Table9">Table 11</linkHtml>
                                       </content>.

 </paragraph>
                                    <paragraph>In a single-dose (1 g oral) study of 18 volunteers with alcoholic cirrhosis and 6 healthy volunteers, hepatic MPA glucuronidation processes appeared to be relatively unaffected by hepatic parenchymal disease when pharmacokinetic parameters of healthy volunteers and alcoholic cirrhosis patients within this study were compared. However, it should be noted that for unexplained reasons, the healthy volunteers in this study had about a 50% lower AUC as compared to healthy volunteers in other studies, thus making comparisons between volunteers with alcoholic cirrhosis and healthy volunteers difficult. In a single-dose (1 g intravenous) study of 6 volunteers with severe hepatic impairment (aminopyrine breath test less than 0.2% of dose) due to alcoholic cirrhosis, MMF was rapidly converted to MPA. MPA AUC was 44.1 mcg∙h/mL (±15.5).</paragraph>
                                    <table ID="Table9" width="100%">
                                       <caption>Table 11 Pharmacokinetic Parameters for MPA [mean (±SD)] Following Single Doses of MMF Capsules in Chronic Renal and Hepatic Impairment</caption>
                                       <col width="40%" align="left" valign="top"/>
                                       <col width="15%" align="center" valign="top"/>
                                       <col width="15%" align="center" valign="top"/>
                                       <col width="15%" align="center" valign="top"/>
                                       <col width="15%" align="center" valign="top"/>
                                       <tbody>
                                          <tr styleCode="Botrule">
                                             <td colspan="5" align="center" styleCode="Lrule Rrule">
                                                <content styleCode="bold">Pharmacokinetic Parameters for Renal Impairment</content>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule"/>
                                             <td styleCode="Rrule" valign="middle">
                                                <content styleCode="bold">Dose</content>
                                             </td>
                                             <td styleCode="Rrule" valign="middle">
                                                <content styleCode="bold">T
     
      <sub>max</sub>
                                                   <br/>  (h)
    
     </content>
                                             </td>
                                             <td styleCode="Rrule" valign="middle">
                                                <content styleCode="bold">C
     
      <sub>max</sub>
                                                   <br/>  (mcg/mL)
    
     </content>
                                             </td>
                                             <td styleCode="Rrule" valign="middle">
                                                <content styleCode="bold">AUC
     
      <sub>(0-96h)</sub>
                                                   <br/>  (mcg∙h/mL)
    
     </content>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Healthy Volunteers 
     <br/>    GFR greater than 80 mL/min/1.73 m
    
     <sup>2</sup>
                                                <br/>    (n=6)
   
    </td>
                                             <td styleCode="Rrule">1 g</td>
                                             <td styleCode="Rrule">0.75 
     <br/>  (±0.27)
    </td>
                                             <td styleCode="Rrule">25.3 
     <br/>  (±7.99)
    </td>
                                             <td styleCode="Rrule">45.0 
     <br/>  (±22.6)
    </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Mild Renal Impairment 
     <br/>    GFR 50 to 80 mL/min/1.73 m
    
     <sup>2</sup>
                                                <br/>    (n=6)
   
    </td>
                                             <td styleCode="Rrule">1 g</td>
                                             <td styleCode="Rrule">0.75 
     <br/>  (±0.27)
    </td>
                                             <td styleCode="Rrule">26.0 
     <br/>  (±3.82)
    </td>
                                             <td styleCode="Rrule">59.9 
     <br/>  (±12.9)
    </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Moderate Renal Impairment 
     <br/>    GFR 25 to 49 mL/min/1.73 m
    
     <sup>2</sup>
                                                <br/>    (n=6)
   
    </td>
                                             <td styleCode="Rrule">1 g</td>
                                             <td styleCode="Rrule">0.75 
     <br/>  (±0.27)
    </td>
                                             <td styleCode="Rrule">19.0 
     <br/>  (±13.2)
    </td>
                                             <td styleCode="Rrule">52.9 
     <br/>  (±25.5)
    </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Severe Renal Impairment 
     <br/>    GFR less than 25 mL/min/1.73 m
    
     <sup>2</sup>
                                                <br/>    (n=7)
   
    </td>
                                             <td styleCode="Rrule">1 g</td>
                                             <td styleCode="Rrule">1.00 
     <br/>  (±0.41)
    </td>
                                             <td styleCode="Rrule">16.3 
     <br/>  (±10.8)
    </td>
                                             <td styleCode="Rrule">78.6 
     <br/>  (±46.4)
    </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td colspan="5" align="center" styleCode="Lrule Rrule">
                                                <content styleCode="bold">Pharmacokinetic Parameters for Hepatic Impairment</content>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule"/>
                                             <td styleCode="Rrule" valign="middle">
                                                <content styleCode="bold">Dose</content>
                                             </td>
                                             <td styleCode="Rrule" valign="middle">
                                                <content styleCode="bold">T
     
      <sub>max</sub>
                                                   <br/>  (h)
    
     </content>
                                             </td>
                                             <td styleCode="Rrule" valign="middle">
                                                <content styleCode="bold">C
     
      <sub>max</sub>
                                                   <br/>  (mcg/mL)
    
     </content>
                                             </td>
                                             <td styleCode="Rrule" valign="middle">
                                                <content styleCode="bold">AUC
     
      <sub>(0-48h)</sub>
                                                   <br/>  (mcg∙h/mL)
    
     </content>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Healthy Volunteers 
     <br/>    (n=6)
    </td>
                                             <td styleCode="Rrule">1 g</td>
                                             <td styleCode="Rrule">0.63 
     <br/>  (±0.14)
    </td>
                                             <td styleCode="Rrule">24.3 
     <br/>  (±5.73)
    </td>
                                             <td styleCode="Rrule">29.0 
     <br/>  (±5.78)
    </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Lrule Rrule">Alcoholic Cirrhosis 
     <br/>    (n=18)
    </td>
                                             <td styleCode="Rrule">1 g</td>
                                             <td styleCode="Rrule">0.85 
     <br/>  (±0.58)
    </td>
                                             <td styleCode="Rrule">22.4 
     <br/>  (±10.1)
    </td>
                                             <td styleCode="Rrule">29.8 
     <br/>  (±10.7)
    </td>
                                          </tr>
                                       </tbody>
                                    </table>
                                 </text>
                                 <effectiveTime value="20240306"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="130317dd-7163-69c9-e063-6394a90adc55"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Pediatric Patients</content>
                                    </paragraph>
                                    <paragraph>The pharmacokinetic parameters of MPA and MPAG have been evaluated in 55 pediatric patients (ranging from 1 year to 18 years of age) receiving mycophenolate mofetil oral suspension at a dose of 600 mg/m
 
  <sup>2</sup>twice daily (up to a maximum of 1 g twice daily) after allogeneic kidney transplantation. The pharmacokinetic data for MPA is provided in
 
  <content styleCode="bold">
                                          <linkHtml href="#Table10">Table 12</linkHtml>
                                       </content>.

 </paragraph>
                                    <table ID="Table12" width="100%">
                                       <caption>Table 12 Mean (±SD) Computed Pharmacokinetic Parameters for MPA by Age and Time After Allogeneic Kidney Transplantation</caption>
                                       <col width="20%" align="left" valign="top"/>
                                       <col width="5%" align="left" valign="top"/>
                                       <col width="15%" align="center" valign="top"/>
                                       <col width="10%" align="center" valign="top"/>
                                       <col width="10%" align="center" valign="top"/>
                                       <col width="10%" align="center" valign="top"/>
                                       <col width="10%" align="center" valign="top"/>
                                       <col width="10%" align="center" valign="top"/>
                                       <col width="10%" align="center" valign="top"/>
                                       <thead>
                                          <tr>
                                             <th styleCode="Lrule" valign="middle">Age Group</th>
                                             <th styleCode="Rrule" valign="middle">(n)</th>
                                             <th styleCode="Rrule" valign="middle">Time</th>
                                             <th colspan="2" styleCode="Rrule" valign="middle">T
    
     <sub>max</sub>
                                                <br/>  (h)
   
    </th>
                                             <th colspan="2" styleCode="Rrule" valign="middle">Dose Adjusted
    
     <footnote ID="t11fa">adjusted to a dose of 600 mg/m
                 2</footnote>C
    
     <sub>max</sub>
                                                <br/>  (mcg/mL)
   
    </th>
                                             <th colspan="2" styleCode="Rrule" valign="middle">Dose Adjusted
    
     <footnoteRef IDREF="t11fa"/>AUC
    
     <sub>0 to 12</sub>
                                                <br/>  (mcg∙h/mL)
   
    </th>
                                          </tr>
                                       </thead>
                                       <tbody>
                                          <tr>
                                             <td styleCode="Lrule"/>
                                             <td styleCode="Rrule"/>
                                             <td styleCode="Rrule">Early (Day 7)</td>
                                             <td/>
                                             <td styleCode="Rrule"/>
                                             <td/>
                                             <td styleCode="Rrule"/>
                                             <td/>
                                             <td styleCode="Rrule"/>
                                          </tr>
                                          <tr>
                                             <td styleCode="Lrule">1 to less than 2 yr</td>
                                             <td styleCode="Rrule">(6)
    
     <footnote ID="t11fd">a subset of 1 to &lt;6 yr</footnote>
                                             </td>
                                             <td styleCode="Rrule"/>
                                             <td>3.03</td>
                                             <td styleCode="Rrule">(4.70)</td>
                                             <td>10.3</td>
                                             <td styleCode="Rrule">(5.80)</td>
                                             <td>22.5</td>
                                             <td styleCode="Rrule">(6.66)</td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Lrule">1 to less than 6 yr</td>
                                             <td styleCode="Rrule">(17)</td>
                                             <td styleCode="Rrule"/>
                                             <td>1.63</td>
                                             <td styleCode="Rrule">(2.85)</td>
                                             <td>13.2</td>
                                             <td styleCode="Rrule">(7.16)</td>
                                             <td>27.4</td>
                                             <td styleCode="Rrule">(9.54)</td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Lrule">6 to less than 12 yr</td>
                                             <td styleCode="Rrule">(16)</td>
                                             <td styleCode="Rrule"/>
                                             <td>0.940</td>
                                             <td styleCode="Rrule">(0.546)</td>
                                             <td>13.1</td>
                                             <td styleCode="Rrule">(6.30)</td>
                                             <td>33.2</td>
                                             <td styleCode="Rrule">(12.1)</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule">12 to 18 yr</td>
                                             <td styleCode="Rrule">(21)</td>
                                             <td styleCode="Rrule"/>
                                             <td>1.16</td>
                                             <td styleCode="Rrule">(0.830)</td>
                                             <td>11.7</td>
                                             <td styleCode="Rrule">(10.7)</td>
                                             <td>26.3</td>
                                             <td styleCode="Rrule">(9.14)
    
     <footnote ID="K6268">n=20</footnote>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Lrule"/>
                                             <td styleCode="Rrule"/>
                                             <td styleCode="Rrule">Late (Month 3)</td>
                                             <td/>
                                             <td styleCode="Rrule"/>
                                             <td/>
                                             <td styleCode="Rrule"/>
                                             <td/>
                                             <td styleCode="Rrule"/>
                                          </tr>
                                          <tr>
                                             <td styleCode="Lrule">1 to less than 2 yr</td>
                                             <td styleCode="Rrule">(4)
    
     <footnoteRef IDREF="t11fd"/>
                                             </td>
                                             <td styleCode="Rrule"/>
                                             <td>0.725</td>
                                             <td styleCode="Rrule">(0.276)</td>
                                             <td>23.8</td>
                                             <td styleCode="Rrule">(13.4)</td>
                                             <td>47.4</td>
                                             <td styleCode="Rrule">(14.7)</td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Lrule">1 to less than 6 yr</td>
                                             <td styleCode="Rrule">(15)</td>
                                             <td styleCode="Rrule"/>
                                             <td>0.989</td>
                                             <td styleCode="Rrule">(0.511)</td>
                                             <td>22.7</td>
                                             <td styleCode="Rrule">(10.1)</td>
                                             <td>49.7</td>
                                             <td styleCode="Rrule">(18.2)</td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Lrule">6 to less than 12 yr</td>
                                             <td styleCode="Rrule">(14)</td>
                                             <td styleCode="Rrule"/>
                                             <td>1.21</td>
                                             <td styleCode="Rrule">(0.532)</td>
                                             <td>27.8</td>
                                             <td styleCode="Rrule">(14.3)</td>
                                             <td>61.9</td>
                                             <td styleCode="Rrule">(19.6)</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule">12 to 18 yr</td>
                                             <td styleCode="Rrule">(17)</td>
                                             <td styleCode="Rrule"/>
                                             <td>0.978</td>
                                             <td styleCode="Rrule">(0.484)</td>
                                             <td>17.9</td>
                                             <td styleCode="Rrule">(9.57)</td>
                                             <td>53.6</td>
                                             <td styleCode="Rrule">(20.3)
    
     <footnote ID="K6386">n=16</footnote>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Lrule"/>
                                             <td styleCode="Rrule"/>
                                             <td styleCode="Rrule">Late (Month 9)</td>
                                             <td/>
                                             <td styleCode="Rrule"/>
                                             <td/>
                                             <td styleCode="Rrule"/>
                                             <td/>
                                             <td styleCode="Rrule"/>
                                          </tr>
                                          <tr>
                                             <td styleCode="Lrule">1 to less than 2 yr</td>
                                             <td styleCode="Rrule">(4)
    
     <footnoteRef IDREF="t11fd"/>
                                             </td>
                                             <td styleCode="Rrule"/>
                                             <td>0.604</td>
                                             <td styleCode="Rrule">(0.208)</td>
                                             <td>25.6</td>
                                             <td styleCode="Rrule">(4.25)</td>
                                             <td>55.8</td>
                                             <td styleCode="Rrule">(11.6)</td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Lrule">1 to less than 6 yr</td>
                                             <td styleCode="Rrule">(12)</td>
                                             <td styleCode="Rrule"/>
                                             <td>0.869</td>
                                             <td styleCode="Rrule">(0.479)</td>
                                             <td>30.4</td>
                                             <td styleCode="Rrule">(9.16)</td>
                                             <td>61.0</td>
                                             <td styleCode="Rrule">(10.7)</td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Lrule">6 to less than 12 yr</td>
                                             <td styleCode="Rrule">(11)</td>
                                             <td styleCode="Rrule"/>
                                             <td>1.12</td>
                                             <td styleCode="Rrule">(0.462)</td>
                                             <td>29.2</td>
                                             <td styleCode="Rrule">(12.6)</td>
                                             <td>66.8</td>
                                             <td styleCode="Rrule">(21.2)</td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Lrule">12 to 18 yr</td>
                                             <td styleCode="Rrule">(14)</td>
                                             <td styleCode="Rrule"/>
                                             <td>1.09</td>
                                             <td styleCode="Rrule">(0.518)</td>
                                             <td>18.1</td>
                                             <td styleCode="Rrule">(7.29)</td>
                                             <td>56.7</td>
                                             <td styleCode="Rrule">(14.0)</td>
                                          </tr>
                                       </tbody>
                                    </table>
                                    <paragraph>The mycophenolate mofetil oral suspension dose of 600 mg/m
 
  <sup>2</sup>twice daily (up to a maximum of 1 g twice daily) achieved mean MPA AUC values in pediatric patients similar to those seen in adult kidney transplant patients receiving mycophenolate mofetil capsules at a dose of 1 g twice daily in the early post-transplant period. There was wide variability in the data. As observed in adults, early post-transplant MPA AUC values were approximately 45% to 53% lower than those observed in the later post-transplant period (&gt;3 months). MPA AUC values were similar in the early and late post-transplant period across the 1 to 18-year age range. 
  <br/>  A comparison of dose-normalized (to 600 mg/m2) MPA AUC values in 12 pediatric kidney transplant patients less than 6 years of age at 9 months post-transplant with those values in 7 pediatric liver transplant patients [median age 17 months (range: 10 to 60 months)] and at 6 months and beyond post-transplant revealed that, at the same dose, there were on average 23% lower AUC values in the pediatric liver compared to pediatric kidney patients. This is consistent with the need for higher dosing in adult liver transplant patients compared to kidney transplant patients to achieve the same exposure. 
  <br/>  In adult transplant patients administered the same dosage of mycophenolate mofetil, there is similar MPA exposure among kidney transplant and heart transplant patients. Based on the established similarity in MPA exposure between pediatric kidney transplant and adult kidney transplant patients at their respective approved doses, it is expected that MPA exposure at the recommended dosage will be similar in pediatric heart transplant and adult heart transplant patients.

 </paragraph>
                                 </text>
                                 <effectiveTime value="20240306"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="130317dd-7164-69c9-e063-6394a90adc55"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Male and Female Patients</content>
                                    </paragraph>
                                    <paragraph>Data obtained from several studies were pooled to look at any gender-related differences in the pharmacokinetics of MPA (data were adjusted to 1 g oral dose). Mean (±SD) MPA AUC(0 to 12h) for males (n=79) was 32.0 (±14.5) and for females (n=41) was 36.5 (±18.8) mcg∙h/mL while mean (±SD) MPA C
 
  <sub>max</sub>was 9.96 (±6.19) in the males and 10.6 (±5.64) mcg/mL in the females. These differences are not of clinical significance.

 </paragraph>
                                 </text>
                                 <effectiveTime value="20240306"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="130317dd-7165-69c9-e063-6394a90adc55"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Geriatric Patients</content>
                                    </paragraph>
                                    <paragraph>The pharmacokinetics of mycophenolate mofetil and its metabolites have not been found to be altered in geriatric transplant patients when compared to younger transplant patients.</paragraph>
                                 </text>
                                 <effectiveTime value="20240306"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section ID="DI">
                           <id root="130317dd-7166-69c9-e063-6394a90adc55"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph styleCode="underline">Drug Interaction Studies</paragraph>
                           </text>
                           <effectiveTime value="20240306"/>
                           <component>
                              <section>
                                 <id root="130317dd-7167-69c9-e063-6394a90adc55"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Acyclovir</content>
                                    </paragraph>
                                    <paragraph>Coadministration of MMF (1 g) and acyclovir (800 mg) to 12 healthy volunteers resulted in no significant change in MPA AUC and C
 
  <sub>max</sub>. However, MPAG and acyclovir plasma AUCs were increased 10.6% and 21.9%, respectively.

 </paragraph>
                                 </text>
                                 <effectiveTime value="20240306"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="130317dd-7168-69c9-e063-6394a90adc55"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Antacids with Magnesium and Aluminum Hydroxides</content>
                                    </paragraph>
                                    <paragraph>Absorption of a single dose of MMF (2 g) was decreased when administered to 10 rheumatoid arthritis patients also taking Maalox
 
  <sup>®</sup>TC (10 mL qid). The C
 
  <sub>max</sub>and AUC
 
  <sub>(0 to 24h)</sub>for MPA were 33% and 17% lower, respectively, than when MMF was administered alone under fasting conditions.

 </paragraph>
                                 </text>
                                 <effectiveTime value="20240306"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="130317dd-7169-69c9-e063-6394a90adc55"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Proton Pump Inhibitors (PPIs)</content>
                                    </paragraph>
                                    <paragraph>Coadministration of PPIs (e.g., lansoprazole, pantoprazole) in single doses to healthy volunteers and multiple doses to transplant patients receiving mycophenolate mofetil has been reported to reduce the exposure to MPA. An approximate reduction of 30 to 70% in the C
 
  <sub>max</sub>and 25% to 35% in the AUC of MPA has been observed, possibly due to a decrease in MPA solubility at an increased gastric pH.

 </paragraph>
                                 </text>
                                 <effectiveTime value="20240306"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="130317dd-716a-69c9-e063-6394a90adc55"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Cholestyramine</content>
                                    </paragraph>
                                    <paragraph>Following single-dose administration of 1.5 g MMF to 12 healthy volunteers pretreated with 4 g three times a day of cholestyramine for 4 days, MPA AUC decreased approximately 40%. This decrease is consistent with interruption of enterohepatic recirculation which may be due to binding of recirculating MPAG with cholestyramine in the intestine.</paragraph>
                                 </text>
                                 <effectiveTime value="20240306"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="130317dd-716b-69c9-e063-6394a90adc55"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Cyclosporine</content>
                                    </paragraph>
                                    <paragraph>Cyclosporine (Sandimmune
 
  <sup>®</sup>) pharmacokinetics (at doses of 275 to 415 mg/day) were unaffected by single and multiple doses of 1.5 g twice daily of MMF in 10 stable kidney transplant patients. The mean (±SD) AUC
 
  <sub>(0 to 12h)</sub>and C
 
  <sub>max</sub>of cyclosporine after 14 days of multiple doses of MMF were 3290 (±822) ng∙h/mL and 753 (±161) ng/mL, respectively, compared to 3245 (±1088) ng∙h/mL and 700 (±246) ng/mL, respectively, 1 week before administration of MMF.

 </paragraph>
                                    <paragraph>Cyclosporine A interferes with MPA enterohepatic recirculation. In kidney transplant patients, mean MPA exposure (AUC
 
  <sub>(0 to 12h)</sub>) was approximately 30 to 50% greater when MMF was administered without cyclosporine compared with when MMF was coadministered with cyclosporine. This interaction is due to cyclosporine inhibition of multidrug-resistance-associated protein 2 (MRP-2) transporter in the biliary tract, thereby preventing the excretion of MPAG into the bile that would lead to enterohepatic recirculation of MPA. This information should be taken into consideration when MMF is used without cyclosporine.

 </paragraph>
                                 </text>
                                 <effectiveTime value="20240306"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="130317dd-716c-69c9-e063-6394a90adc55"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Drugs Affecting Glucuronidation</content>
                                    </paragraph>
                                    <paragraph>Concomitant administration of drugs inhibiting glucuronidation of MPA may increase MPA exposure (e.g., increase of MPA AUC
 
  <sub>(0 to ∞)</sub>by 35% was observed with concomitant administration of isavuconazole).

 </paragraph>
                                    <paragraph>Concomitant administration of telmisartan and mycophenolate mofetil resulted in an approximately 30% decrease in MPA concentrations. Telmisartan changes MPA's elimination by enhancing PPAR gamma (peroxisome proliferator-activated receptor gamma) expression, which in turn results in an enhanced UGT1A9 expression and glucuronidation activity.</paragraph>
                                 </text>
                                 <effectiveTime value="20240306"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="130317dd-716d-69c9-e063-6394a90adc55"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Ganciclovir</content>
                                    </paragraph>
                                    <paragraph>Following single-dose administration to 12 stable kidney transplant patients, no pharmacokinetic interaction was observed between MMF (1.5 g) and intravenous ganciclovir (5 mg/kg). Mean (±SD) ganciclovir AUC and C
 
  <sub>max</sub>(n=10) were 54.3 (±19.0) mcg∙h/mL and 11.5 (±1.8) mcg/mL, respectively, after coadministration of the two drugs, compared to 51.0 (±17.0) mcg∙h/mL and 10.6 (±2.0) mcg/mL, respectively, after administration of intravenous ganciclovir alone. The mean (±SD) AUC and C
 
  <sub>max</sub>of MPA (n=12) after coadministration were 80.9 (±21.6) mcg∙h/mL and 27.8 (±13.9) mcg/mL, respectively, compared to values of 80.3 (±16.4) µg∙h/mL and 30.9 (±11.2) mcg/mL, respectively, after administration of MMF alone.

 </paragraph>
                                 </text>
                                 <effectiveTime value="20240306"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="130317dd-716e-69c9-e063-6394a90adc55"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Oral Contraceptives</content>
                                    </paragraph>
                                    <paragraph>A study of coadministration of mycophenolate mofetil (1 g twice daily) and combined oral contraceptives containing ethinylestradiol (0.02 mg to 0.04 mg) and levonorgestrel (0.05 mg to 0.20 mg), desogestrel (0.15 mg) or gestodene (0.05 mg to 0.10 mg) was conducted in 18 women with psoriasis over 3 consecutive menstrual cycles. Mean serum levels of LH, FSH and progesterone were not significantly affected. Mean AUC
 
  <sub>(0 to 24h)</sub>was similar for ethinylestradiol and 3-keto desogestrel; however, mean levonorgestrel AUC(0 to 24h) significantly decreased by about 15%. There was large inter-patient variability (%CV in the range of 60% to 70%) in the data, especially for ethinylestradiol.

 </paragraph>
                                 </text>
                                 <effectiveTime value="20240306"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="130317dd-716f-69c9-e063-6394a90adc55"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Sevelamer</content>
                                    </paragraph>
                                    <paragraph>Concomitant administration of sevelamer and MMF in adult and pediatric patients decreased the mean MPA C
 
  <sub>max</sub>and AUC
 
  <sub>(0 to 12h)</sub>by 36% and 26% respectively.

 </paragraph>
                                 </text>
                                 <effectiveTime value="20240306"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="130317dd-7170-69c9-e063-6394a90adc55"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Antimicrobials</content>
                                    </paragraph>
                                    <paragraph>Antimicrobials eliminating beta-glucuronidase-producing bacteria in the intestine (e.g. aminoglycoside, cephalosporin, fluoroquinolone, and penicillin classes of antimicrobials) may interfere with the MPAG/MPA enterohepatic recirculation thus leading to reduced systemic MPA exposure. Information concerning antibiotics is as follows:</paragraph>
                                    <list listType="unordered">
                                       <item>Trimethoprim/Sulfamethoxazole: Following single-dose administration of MMF (1.5 g) to 12 healthy male volunteers on day 8 of a 10-day course of trimethoprim 160 mg/sulfamethoxazole 800 mg administered twice daily, no effect on the bioavailability of MPA was observed. The mean (±SD) AUC and C
  
   <sub>max</sub>of MPA after concomitant administration were 75.2 (±19.8) mcg∙h/mL and 34.0 (±6.6) µg/mL, respectively, compared to 79.2 (±27.9) mcg∙h/mL and 34.2 (±10.7) mcg/mL, respectively, after administration of MMF alone.
 
  </item>
                                       <item>Norfloxacin and Metronidazole: Following single-dose administration of MMF (1 g) to 11 healthy volunteers on day 4 of a 5-day course of a combination of norfloxacin and metronidazole, the mean MPA AUC
  
   <sub>(0 to 48h)</sub>was significantly reduced by 33% compared to the administration of MMF alone (p&lt;0.05). The mean (±SD) MPA AUC
  
   <sub>(0 to 48h)</sub>after coadministration of MMF with norfloxacin or metronidazole separately was 48.3 (±24) mcg∙h/mL and 42.7 (±23) mcg∙h/mL, respectively, compared with 56.2 (±24) mcg∙h/mL after administration of MMF alone.
 
  </item>
                                       <item>Ciprofloxacin and Amoxicillin Plus Clavulanic Acid: A total of 64 mycophenolate mofetil-treated kidney transplant recipients received either oral ciprofloxacin 500 mg twice daily or amoxicillin plus clavulanic acid 375 mg three times daily for 7 or at least 14 days, respectively. Approximately 50% reductions in median trough MPA concentrations (pre-dose) from baseline (mycophenolate mofetil alone) were observed in 3 days following commencement of oral ciprofloxacin or amoxicillin plus clavulanic acid. These reductions in trough MPA concentrations tended to diminish within 14 days of antimicrobial therapy and ceased within 3 days of discontinuation of antibiotics.</item>
                                       <item>Rifampin: In a single heart-lung transplant patient, after correction for dose, a 67% decrease in MPA exposure (AUC
  
   <sub>(0 to 12h)</sub>) has been observed with concomitant administration of MMF and rifampin.
 
  </item>
                                    </list>
                                 </text>
                                 <effectiveTime value="20240306"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S13">
               <id root="130317dd-7171-69c9-e063-6394a90adc55"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20240306"/>
               <component>
                  <section ID="S13.1">
                     <id root="130317dd-7172-69c9-e063-6394a90adc55"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph>In a 104-week oral carcinogenicity study in mice, MMF in daily doses up to 180 mg/kg was not tumorigenic. The highest dose tested was 0.2 times the recommended clinical dose (2 g/day) in renal transplant patients and 0.15 times the recommended clinical dose (3 g/day) in cardiac transplant patients when corrected for differences in body surface area (BSA). In a 104-week oral carcinogenicity study in rats, MMF in daily doses up to 15 mg/kg was not tumorigenic. The highest dose was 0.035 times the recommended clinical dose in kidney transplant patients and 0.025 times the recommended clinical dose in heart transplant patients when corrected for BSA. While these animal doses were lower than those given to patients, they were maximal in those species and were considered adequate to evaluate the potential for human risk
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>]
 
  </content>.

 </paragraph>
                        <paragraph>The genotoxic potential of MMF was determined in five assays. MMF was genotoxic in the mouse lymphoma/thymidine kinase assay and the
 
  <content styleCode="italics">in vivo</content>mouse micronucleus assay. MMF was not genotoxic in the bacterial mutation assay, the yeast mitotic gene conversion assay or the Chinese hamster ovary cell chromosomal aberration assay.

 </paragraph>
                        <paragraph>MMF had no effect on fertility of male rats at oral doses up to 20 mg/kg/day. This dose represents 0.05 times the recommended clinical dose in renal transplant patients and 0.03 times the recommended clinical dose in cardiac transplant patients when corrected for BSA. In a female fertility and reproduction study conducted in rats, oral doses of 4.5 mg/kg/day caused malformations (principally of the head and eyes) in the first generation offspring in the absence of maternal toxicity. This dose was 0.01 times the recommended clinical dose in renal transplant patients and 0.005 times the recommended clinical dose in cardiac transplant patients when corrected for BSA. No effects on fertility or reproductive parameters were evident in the dams or in the subsequent generation.</paragraph>
                     </text>
                     <effectiveTime value="20240306"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S14">
               <id root="130317dd-7173-69c9-e063-6394a90adc55"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES</title>
               <effectiveTime value="20240306"/>
               <component>
                  <section ID="S14.1">
                     <id root="130317dd-7174-69c9-e063-6394a90adc55"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.1 Kidney Transplantation</title>
                     <effectiveTime value="20240306"/>
                     <component>
                        <section>
                           <id root="130317dd-7175-69c9-e063-6394a90adc55"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Adults</content>
                              </paragraph>
                              <paragraph>The three
 
  <content styleCode="italics">de novo</content>kidney transplantation studies compared two dose levels of oral mycophenolate mofetil (1 g twice daily and 1.5 g twice daily) with azathioprine (2 studies) or placebo (1 study) to prevent acute rejection episodes. One of the two studies with azathioprine (AZA) control arm also included anti-thymocyte globulin (ATGAM
 
  <sup>®</sup>) induction therapy. The geographic location of the investigational sites of these studies are included in
 
  <content styleCode="bold">
                                    <linkHtml href="#Table13">Table 13</linkHtml>
                                 </content>.

 </paragraph>
                              <paragraph>In all three
 
  <content styleCode="italics">de novo</content>kidney transplantation studies, the primary efficacy endpoint was the proportion of patients in each treatment group who experienced treatment failure within the first 6 months after transplantation. Treatment failure was defined as biopsy-proven acute rejection on treatment or the occurrence of death, graft loss or early termination from the study for any reason without prior biopsy-proven rejection.

 </paragraph>
                              <paragraph>Mycophenolate mofetil, in combination with corticosteroids and cyclosporine, reduced (statistically significant at 0.05 level) the incidence of treatment failure within the first 6 months following transplantation (
 
  <content styleCode="bold">
                                    <linkHtml href="#Table13">Table 13</linkHtml>).
 
  </content>Patients who prematurely discontinued treatment were followed for the occurrence of death or graft loss, and the cumulative incidence of graft loss and patient death combined are summarized in
 
  <content styleCode="bold">
                                    <linkHtml href="#Table14">Table 14</linkHtml>
                                 </content>. Patients who prematurely discontinued treatment were not followed for the occurrence of acute rejection after termination.

 </paragraph>
                              <table ID="Table13" width="100%">
                                 <caption>Table 13 Treatment Failure in De Novo Kidney Transplantation Studies</caption>
                                 <col width="30%" align="left" valign="top"/>
                                 <col width="23%" align="center" valign="top"/>
                                 <col width="23%" align="center" valign="top"/>
                                 <col width="24%" align="center" valign="top"/>
                                 <tfoot>
                                    <tr>
                                       <td align="left" colspan="4">*Does not include death and graft loss as reason for early termination.</td>
                                    </tr>
                                 </tfoot>
                                 <tbody>
                                    <tr>
                                       <td styleCode="Lrule Rrule">
                                          <content styleCode="bold">USA Study</content>
                                       </td>
                                       <td styleCode="Rrule">
                                          <content styleCode="bold">Mycophenolate mofetil 
      <br/>  2 g/day
     </content>
                                       </td>
                                       <td styleCode="Rrule">
                                          <content styleCode="bold">Mycophenolate mofetil 
      <br/>  3 g/day
     </content>
                                       </td>
                                       <td styleCode="Rrule">
                                          <content styleCode="bold">AZA 
      <br/>  1 to 2 mg/kg/day
     </content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">
                                          <content styleCode="bold">(N=499 patients)</content>
                                       </td>
                                       <td styleCode="Rrule">
                                          <content styleCode="bold">(n=167 patients)</content>
                                       </td>
                                       <td styleCode="Rrule">
                                          <content styleCode="bold">(n=166 patients)</content>
                                       </td>
                                       <td styleCode="Rrule">
                                          <content styleCode="bold">(n=166 patients)</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule"/>
                                       <td colspan="3" styleCode="Rrule">All 3 groups received anti-thymocyte globulin induction, cyclosporine and corticosteroids</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">All treatment failures</td>
                                       <td styleCode="Rrule">31.1%</td>
                                       <td styleCode="Rrule">31.3%</td>
                                       <td styleCode="Rrule">47.6%</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Early termination without prior acute rejection</td>
                                       <td styleCode="Rrule">9.6%</td>
                                       <td styleCode="Rrule">12.7%</td>
                                       <td styleCode="Rrule">6.0%</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Biopsy-proven rejection episode on treatment</td>
                                       <td styleCode="Rrule">19.8%</td>
                                       <td styleCode="Rrule">17.5%</td>
                                       <td styleCode="Rrule">38.0%</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">
                                          <content styleCode="bold">Europe/Canada/Australia Study</content>
                                       </td>
                                       <td styleCode="Rrule">
                                          <content styleCode="bold">Mycophenolate mofetil 
      <br/>  2 g/day
     </content>
                                       </td>
                                       <td styleCode="Rrule">
                                          <content styleCode="bold">Mycophenolate mofetil 
      <br/>  3 g/day
     </content>
                                       </td>
                                       <td styleCode="Rrule">
                                          <content styleCode="bold">AZA 
      <br/>  100 to 150 mg/day
     </content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">
                                          <content styleCode="bold">(N=503 patients)</content>
                                       </td>
                                       <td styleCode="Rrule">
                                          <content styleCode="bold">(n=173 patients)</content>
                                       </td>
                                       <td styleCode="Rrule">
                                          <content styleCode="bold">(n=164 patients)</content>
                                       </td>
                                       <td styleCode="Rrule">
                                          <content styleCode="bold">(n=166 patients)</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule"/>
                                       <td colspan="3" styleCode="Rrule">No induction treatment administered; all 3 groups received cyclosporine and corticosteroids</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">All treatment failures</td>
                                       <td styleCode="Rrule">38.2%</td>
                                       <td styleCode="Rrule">34.8%</td>
                                       <td styleCode="Rrule">50.0%</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Early termination without prior acute rejection</td>
                                       <td styleCode="Rrule">13.9%</td>
                                       <td styleCode="Rrule">15.2%</td>
                                       <td styleCode="Rrule">10.2%</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Biopsy-proven rejection episode on treatment</td>
                                       <td styleCode="Rrule">19.7%</td>
                                       <td styleCode="Rrule">15.9%</td>
                                       <td styleCode="Rrule">35.5%</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">
                                          <content styleCode="bold">Europe Study</content>
                                       </td>
                                       <td styleCode="Rrule">
                                          <content styleCode="bold">Mycophenolate mofetil 
      <br/>  2 g/day
     </content>
                                       </td>
                                       <td styleCode="Rrule">
                                          <content styleCode="bold">Mycophenolate mofetil 
      <br/>  3 g/day
     </content>
                                       </td>
                                       <td styleCode="Rrule">
                                          <content styleCode="bold">Placebo</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">
                                          <content styleCode="bold">(N=491 patients)</content>
                                       </td>
                                       <td styleCode="Rrule">
                                          <content styleCode="bold">(n=165 patients)</content>
                                       </td>
                                       <td styleCode="Rrule">
                                          <content styleCode="bold">(n=160 patients)</content>
                                       </td>
                                       <td styleCode="Rrule">
                                          <content styleCode="bold">(n=166 patients)</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule"/>
                                       <td colspan="3" styleCode="Rrule">No induction treatment administered; all 3 groups received cyclosporine and corticosteroids.</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">All treatment failures</td>
                                       <td styleCode="Rrule">30.3%</td>
                                       <td styleCode="Rrule">38.8%</td>
                                       <td styleCode="Rrule">56.0%</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Early termination without prior acute rejection</td>
                                       <td styleCode="Rrule">11.5%</td>
                                       <td styleCode="Rrule">22.5%</td>
                                       <td styleCode="Rrule">7.2%</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Biopsy-proven rejection episode on treatment</td>
                                       <td styleCode="Rrule">17.0%</td>
                                       <td styleCode="Rrule">13.8%</td>
                                       <td styleCode="Rrule">46.4%</td>
                                    </tr>
                                 </tbody>
                              </table>
                              <paragraph>No advantage of mycophenolate mofetil at 12 months with respect to graft loss or patient death (combined) was established (
 
  <content styleCode="bold">
                                    <linkHtml href="#Table14">Table 14</linkHtml>
                                 </content>). Numerically, patients receiving mycophenolate mofetil 2 g/day and 3 g/day experienced a better outcome than controls in all three studies; patients receiving mycophenolate mofetil 2 g/day experienced a better outcome than mycophenolate mofetil 3 g/day in two of the three studies. Patients in all treatment groups who terminated treatment early were found to have a poor outcome with respect to graft loss or patient death at 1 year.

 </paragraph>
                              <table ID="Table14" width="100%">
                                 <caption>Table 14 De Novo Kidney Transplantation Studies Cumulative Incidence of Combined Graft Loss or Patient Death at 12 Months</caption>
                                 <col width="30%" align="left" valign="top"/>
                                 <col width="23%" align="center" valign="top"/>
                                 <col width="23%" align="center" valign="top"/>
                                 <col width="24%" align="center" valign="top"/>
                                 <thead>
                                    <tr>
                                       <th styleCode="Lrule Rrule" valign="middle">Study</th>
                                       <th styleCode="Rrule">Mycophenolate mofetil 
     <br/>  2 g/day
    </th>
                                       <th styleCode="Rrule">Mycophenolate mofetil 
     <br/>  3 g/day
    </th>
                                       <th styleCode="Rrule">Control (AZA or Placebo)</th>
                                    </tr>
                                 </thead>
                                 <tbody>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">USA</td>
                                       <td styleCode="Rrule">8.5%</td>
                                       <td styleCode="Rrule">11.5%</td>
                                       <td styleCode="Rrule">12.2%</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Europe/Canada/Australia</td>
                                       <td styleCode="Rrule">11.7%</td>
                                       <td styleCode="Rrule">11.0%</td>
                                       <td styleCode="Rrule">13.6%</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Europe</td>
                                       <td styleCode="Rrule">8.5%</td>
                                       <td styleCode="Rrule">10.0%</td>
                                       <td styleCode="Rrule">11.5%</td>
                                    </tr>
                                 </tbody>
                              </table>
                           </text>
                           <effectiveTime value="20240306"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="130317dd-7176-69c9-e063-6394a90adc55"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Pediatrics - De Novo Kidney transplantation PK Study with Long Term Follow-Up</content>
                              </paragraph>
                              <paragraph>One open-label, safety and pharmacokinetic study of mycophenolate mofetil oral suspension 600 mg/m
 
  <sup>2</sup>twice daily (up to 1 g twice daily) in combination with cyclosporine and corticosteroids was performed at centers in the United States (9), Europe (5) and Australia (1) in 100 pediatric patients (3 months to 18 years of age) for the prevention of renal allograft rejection. Mycophenolate mofetil was well tolerated in pediatric patients
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S6.1">Adverse Reactions (6.1)</linkHtml>]
 
  </content>, and the pharmacokinetics profile was similar to that seen in adult patients dosed with 1 g twice daily mycophenolate mofetil capsules
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>].
 
  </content>The rate of biopsy-proven rejection was similar across the age groups (3 months to &lt;6 years, 6 years to &lt;12 years, 12 years to 18 years). The overall biopsy-proven rejection rate at 6 months was comparable to adults. The combined incidence of graft loss (5%) and patient death (2%) at 12 months post-transplant was similar to that observed in adult kidney transplant patients.

 </paragraph>
                           </text>
                           <effectiveTime value="20240306"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S14.2">
                     <id root="130317dd-7177-69c9-e063-6394a90adc55"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.2 Heart Transplantation</title>
                     <text>
                        <paragraph>A double-blind, randomized, comparative, parallel-group, multicenter study in primary
 
  <content styleCode="italics">de novo</content>heart transplant recipients was performed at centers in the United States (20), in Canada (1), in Europe (5) and in Australia (2). The total number of patients enrolled (ITT population) was 650; 72 never received study drug and 578 received study drug (Safety Population). Patients received mycophenolate mofetil 1.5 g twice daily (n=289) or AZA 1.5 to 3 mg/kg/day (n=289), in combination with cyclosporine (Sandimmune
 
  <sup>®</sup>or Neoral
 
  <sup>®</sup>) and corticosteroids as maintenance immunosuppressive therapy. The two primary efficacy endpoints were: (1) the proportion of patients who, after transplantation, had at least one endomyocardial biopsy-proven rejection with hemodynamic compromise, or were re-transplanted or died, within the first 6 months, and (2) the proportion of patients who died or were re-transplanted during the first 12 months following transplantation. Patients who prematurely discontinued treatment were followed for the occurrence of allograft rejection for up to 6 months and for the occurrence of death for 1 year.

 </paragraph>
                        <paragraph>The analyses of the endpoints showed:</paragraph>
                        <list listType="unordered">
                           <item>Rejection: No difference was established between mycophenolate mofetil and AZA with respect to biopsy-proven rejection with hemodynamic compromise.</item>
                           <item>Survival: Mycophenolate mofetil was shown to be at least as effective as AZA in preventing death or re-transplantation at 1 year (see
  
   <content styleCode="bold">
                                 <linkHtml href="#Table15">Table 15</linkHtml>
                              </content>).
 
  </item>
                        </list>
                        <table ID="Table15" width="100%">
                           <caption>Table 15 De Novo Heart Transplantation Study Rejection at 6 Months/Death or Re-transplantation at 1 Year</caption>
                           <col width="34%" align="left" valign="top"/>
                           <col width="16%" align="center" valign="middle"/>
                           <col width="17%" align="center" valign="middle"/>
                           <col width="16%" align="center" valign="middle"/>
                           <col width="17%" align="center" valign="middle"/>
                           <thead>
                              <tr>
                                 <th styleCode="Lrule Rrule"/>
                                 <th colspan="2" styleCode="Rrule Botrule">All Patients (ITT)</th>
                                 <th colspan="2" styleCode="Rrule Botrule">Treated Patients</th>
                              </tr>
                              <tr>
                                 <th styleCode="Lrule Rrule"/>
                                 <th styleCode="Rrule">AZA 
     <br/>  N = 323
    </th>
                                 <th styleCode="Rrule">Mycophenolate mofetil 
     <br/>  N = 327
    </th>
                                 <th styleCode="Rrule">AZA 
     <br/>  N = 289
    </th>
                                 <th styleCode="Rrule">Mycophenolate mofetil 
     <br/>  N = 289
    </th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Biopsy-proven rejection with hemodynamic compromise at 6 months
    
     <footnote ID="K7453">Hemodynamic compromise occurred if any of the following criteria were met: pulmonary capillary wedge pressure ≥20 mm or a 25% increase; cardiac index &lt;2.0 L/min/m
             2 or a 25% decrease; ejection fraction ≤30%; pulmonary artery oxygen saturation ≤60% or a 25% decrease; presence of new S
             3 gallop; fractional shortening was ≤20% or a 25% decrease; inotropic support required to manage the clinical condition.
            </footnote>
                                 </td>
                                 <td styleCode="Rrule">121 (38%)</td>
                                 <td styleCode="Rrule">120 (37%)</td>
                                 <td styleCode="Rrule">100 (35%)</td>
                                 <td styleCode="Rrule">92 (32%)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">Death or retransplantation at 1 year</td>
                                 <td styleCode="Rrule">49 (15.2%)</td>
                                 <td styleCode="Rrule">42 (12.8%)</td>
                                 <td styleCode="Rrule">33 (11.4%)</td>
                                 <td styleCode="Rrule">18 (6.2%)</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20240306"/>
                  </section>
               </component>
               <component>
                  <section ID="S14.3">
                     <id root="130317dd-7178-69c9-e063-6394a90adc55"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.3 Liver Transplantation</title>
                     <text>
                        <paragraph>A double-blind, randomized, comparative, parallel-group, multicenter study in primary hepatic transplant recipients was performed at centers in the United States (16), in Canada (2), in Europe (4) and in Australia (1). The total number of patients enrolled was 565. Per protocol, patients received mycophenolate mofetil 1 g twice daily intravenously for up to 14 days followed by mycophenolate mofetil 1.5 g twice daily orally or AZA 1 to 2 mg/kg/day intravenously followed by AZA 1 to 2 mg/kg/day orally, in combination with cyclosporine (Neoral
 
  <sup>®</sup>) and corticosteroids as maintenance immunosuppressive therapy. The actual median oral dose of AZA on study was 1.5 mg/kg/day (range of 0.3 to 3.8 mg/kg/day) initially and 1.26 mg/kg/day (range of 0.3 to 3.8 mg/kg/day) at 12 months. The two primary endpoints were: (1) the proportion of patients who experienced, in the first 6 months post-transplantation, one or more episodes of biopsy-proven and treated rejection or death or re-transplantation, and (2) the proportion of patients who experienced graft loss (death or re-transplantation) during the first 12 months post-transplantation. Patients who prematurely discontinued treatment were followed for the occurrence of allograft rejection and for the occurrence of graft loss (death or re-transplantation) for 1 year.

 </paragraph>
                        <paragraph>In combination with corticosteroids and cyclosporine, mycophenolate mofetil demonstrated a lower rate of acute rejection at 6 months and a similar rate of death or re-transplantation at 1 year compared to AZA (
 
  <content styleCode="bold">
                              <linkHtml href="#Table16">Table 16</linkHtml>
                           </content>).

 </paragraph>
                        <table ID="Table16" width="100%">
                           <caption>Table 16 De Novo Liver Transplantation Study Rejection at 6 Months/Death or Retransplantation at 1 Year</caption>
                           <col width="50%" align="left" valign="middle"/>
                           <col width="25%" align="center" valign="middle"/>
                           <col width="25%" align="center" valign="middle"/>
                           <thead>
                              <tr>
                                 <th styleCode="Lrule Rrule"/>
                                 <th styleCode="Rrule">AZA 
     <br/>  N = 287
    </th>
                                 <th styleCode="Rrule">Mycophenolate mofetil 
     <br/>  N = 278
    </th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Biopsy-proven, treated rejection at 6 months (includes death or re-transplantation)</td>
                                 <td styleCode="Rrule">137 (47.7%)</td>
                                 <td styleCode="Rrule">107 (38.5%)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">Death or re-transplantation at 1 year</td>
                                 <td styleCode="Rrule">42 (14.6%)</td>
                                 <td styleCode="Rrule">41 (14.7%)</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20240306"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S15">
               <id root="130317dd-7179-69c9-e063-6394a90adc55"/>
               <code code="34093-5" codeSystem="2.16.840.1.113883.6.1" displayName="REFERENCES SECTION"/>
               <title>15 REFERENCES</title>
               <text>
                  <paragraph>1. "OSHA Hazardous Drugs." OSHA.
 
  <content styleCode="italics">http://www.osha.gov/SLTC/hazardousdrugs/index.html</content>
                  </paragraph>
               </text>
               <effectiveTime value="20240306"/>
            </section>
         </component>
         <component>
            <section ID="S16">
               <id root="130317dd-717a-69c9-e063-6394a90adc55"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <text>
                  <paragraph>Mycophenolate Mofetil Capsules, USP are available containing 250 mg of mycophenolate mofetil, USP.</paragraph>
                  <paragraph>The 250 mg capsules are light blue/ peach, size ‘1’ hard gelatin capsules, printed in black with ‘GC1’ on body containing white to off white powder.</paragraph>
                  <paragraph>NDC: 70518-2835-00</paragraph>
                  <paragraph>NDC: 70518-2835-01</paragraph>
                  <paragraph>PACKAGING: 100 in 1 BOX</paragraph>
                  <paragraph>PACKAGING: 1 in 1 POUCH</paragraph>
                  <paragraph/>
                  <paragraph>Storage</paragraph>
                  <paragraph>Store at 25°C (77°F); excursions permitted to 15°C to 30°C (59°F to 86°F).</paragraph>
                  <paragraph/>
                  <paragraph>Repackaged and Distributed By:</paragraph>
                  <paragraph>Remedy Repack, Inc.</paragraph>
                  <paragraph>625 Kolter Dr. Suite #4 Indiana, PA 1-724-465-8762</paragraph>
                  <paragraph/>
               </text>
               <effectiveTime value="20240306"/>
            </section>
         </component>
         <component>
            <section ID="S17">
               <id root="130317dd-717b-69c9-e063-6394a90adc55"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <effectiveTime value="20240306"/>
               <component>
                  <section>
                     <id root="130317dd-717c-69c9-e063-6394a90adc55"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>Advise the patient to read the FDA-approved patient labeling (
 
  <linkHtml href="#MG">Medication Guide and Instructions for Use</linkHtml>).

 </paragraph>
                     </text>
                     <effectiveTime value="20240306"/>
                  </section>
               </component>
               <component>
                  <section ID="S17.1">
                     <id root="130317dd-717d-69c9-e063-6394a90adc55"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>17.1 Embryofetal Toxicity</title>
                     <effectiveTime value="20240306"/>
                     <component>
                        <section>
                           <id root="130317dd-717e-69c9-e063-6394a90adc55"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Pregnancy loss and malformations</content>
                              </paragraph>
                              <list listType="unordered">
                                 <item>Inform females of reproductive potential and pregnant women that use of mycophenolate mofetil during pregnancy is associated with an increased risk of first trimester pregnancy loss and an increased risk of congenital malformations. Advise that they must use an acceptable form of contraception
  
   <content styleCode="italics">[see
   
    <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>,
   
    <linkHtml href="#S8.1">Use in Specific Populations (8.1</linkHtml>,
   
    <linkHtml href="#S8.3">8.3)</linkHtml>]
  
   </content>.
 
  </item>
                                 <item>Encourage pregnant women to enroll in the Pregnancy Exposure Registry. This registry monitors pregnancy outcomes in women exposed to mycophenolate
  
   <content styleCode="italics">[see
   
    <linkHtml href="#S8.1">Use in Specific Populations (8.1)</linkHtml>].
  
   </content>
                                 </item>
                              </list>
                           </text>
                           <effectiveTime value="20240306"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="130317dd-717f-69c9-e063-6394a90adc55"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Contraception</content>
                              </paragraph>
                              <list listType="unordered">
                                 <item>Discuss pregnancy testing, pregnancy prevention and planning with females of reproductive potential
  
   <content styleCode="italics">[see
   
    <linkHtml href="#S8.3">Use in Specific Populations (8.3)</linkHtml>].
  
   </content>
                                 </item>
                                 <item>Females of reproductive potential must use an acceptable form of birth control during the entire mycophenolate mofetil therapy and for 6 weeks after stopping mycophenolate mofetil, unless the patient chooses abstinence. Mycophenolate mofetil may reduce effectiveness of oral contraceptives. Use of additional barrier contraceptive methods is recommended
  
   <content styleCode="italics">[see
   
    <linkHtml href="#S8.3">Use in Specific Populations (8.3)</linkHtml>].
  
   </content>
                                 </item>
                                 <item>For patients who are considering pregnancy, discuss appropriate alternative immunosuppressants with less potential for embryofetal toxicity. Risks and benefits of mycophenolate mofetil should be discussed with the patient.</item>
                                 <item>Advise sexually active male patients and/or their partners to use effective contraception during the treatment of the male patient and for at least 90 days after cessation of treatment. This recommendation is based on findings of animal studies
  
   <content styleCode="italics">[see
   
    <linkHtml href="#S8.3">Use in Specific Populations (8.3)</linkHtml>,
   
    <linkHtml href="#S13.1">Nonclinical Toxicology (13.1)</linkHtml>]
  
   </content>.
 
  </item>
                              </list>
                           </text>
                           <effectiveTime value="20240306"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S17.2">
                     <id root="130317dd-7180-69c9-e063-6394a90adc55"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>17.2 Development of Lymphoma and Other Malignancies</title>
                     <text>
                        <list listType="unordered">
                           <item>Inform patients that they are at increased risk of developing lymphomas and other malignancies, particularly of the skin, due to immunosuppression
  
   <content styleCode="italics">[see
   
    <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>]
  
   </content>.
 
  </item>
                           <item>Advise patients to limit exposure to sunlight and ultraviolet (UV) light by wearing protective clothing and use of broad-spectrum sunscreen with high protection factor.</item>
                        </list>
                     </text>
                     <effectiveTime value="20240306"/>
                  </section>
               </component>
               <component>
                  <section ID="S17.3">
                     <id root="130317dd-7181-69c9-e063-6394a90adc55"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>17.3 Increased Risk of Serious Infections</title>
                     <text>
                        <paragraph>Inform patients that they are at increased risk of developing a variety of infections due to immunosuppression. Instruct them to contact their physician if they develop any of the signs and symptoms of infection explained in the Medication Guide.
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S5.3">Warnings and Precautions (5.3)</linkHtml>]
 
  </content>.

 </paragraph>
                     </text>
                     <effectiveTime value="20240306"/>
                  </section>
               </component>
               <component>
                  <section ID="S17.4">
                     <id root="130317dd-7182-69c9-e063-6394a90adc55"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>17.4 Blood Dyscrasias</title>
                     <text>
                        <paragraph>Inform patients that they are at increased risk for developing blood adverse effects such as anemia or low white blood cells. Advise patients to immediately contact their healthcare provider if they experience any evidence of infection, unexpected bruising, or bleeding, or any other manifestation of bone marrow suppression
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S5.4">Warnings and Precautions (5.4)</linkHtml>]
 
  </content>.

 </paragraph>
                     </text>
                     <effectiveTime value="20240306"/>
                  </section>
               </component>
               <component>
                  <section ID="S17.5">
                     <id root="130317dd-7183-69c9-e063-6394a90adc55"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>17.5 Gastrointestinal Tract Complications</title>
                     <text>
                        <paragraph>Inform patients that mycophenolate mofetil can cause gastrointestinal tract complications including bleeding, intestinal perforations, and gastric or duodenal ulcers. Advise the patient to contact their healthcare provider if they have symptoms of gastrointestinal bleeding, or sudden onset or persistent abdominal pain
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S5.5">Warnings and Precautions (5.5)</linkHtml>]
 
  </content>.

 </paragraph>
                     </text>
                     <effectiveTime value="20240306"/>
                  </section>
               </component>
               <component>
                  <section ID="S17.6">
                     <id root="130317dd-7184-69c9-e063-6394a90adc55"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>17.6 Acute Inflammatory Syndrome</title>
                     <text>
                        <paragraph>Inform patients that acute inflammatory reactions have been reported in some patients who received mycophenolate mofetil. Some reactions were severe, requiring hospitalization. Advise patients to contact their physician if they develop fever, joint stiffness, joint pain or muscle pains
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S5.7">Warnings and Precautions (5.7)</linkHtml>]
 
  </content>.

 </paragraph>
                     </text>
                     <effectiveTime value="20240306"/>
                  </section>
               </component>
               <component>
                  <section ID="S17.7">
                     <id root="130317dd-7185-69c9-e063-6394a90adc55"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>17.7 Immunizations</title>
                     <text>
                        <paragraph>Inform patients that mycophenolate mofetil can interfere with the usual response to immunizations. Before seeking vaccines on their own, advise patients to discuss first with their physician
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S5.8">Warnings and Precautions (5.8)</linkHtml>]
 
  </content>.

 </paragraph>
                     </text>
                     <effectiveTime value="20240306"/>
                  </section>
               </component>
               <component>
                  <section ID="S17.8">
                     <id root="130317dd-7186-69c9-e063-6394a90adc55"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>17.8 Administration Instructions</title>
                     <text>
                        <list listType="unordered">
                           <item>Advise patients not to crush mycophenolate mofetil tablets and not to open mycophenolate mofetil capsules.</item>
                           <item>Advise patients to avoid inhalation or contact of the skin or mucous membranes with the powder contained in mycophenolate mofetil capsules and with the oral suspension. If such contact occurs, they must wash the area of contact thoroughly with soap and water. In case of ocular contact, rinse eyes with plain water.</item>
                           <item>Advise patients to take a missed dose as soon as they remember, except if it is closer than 2 hours to the next scheduled dose; in this case they should continue to take mycophenolate mofetil at the usual times.</item>
                        </list>
                     </text>
                     <effectiveTime value="20240306"/>
                  </section>
               </component>
               <component>
                  <section ID="S17.9">
                     <id root="130317dd-7187-69c9-e063-6394a90adc55"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>17.9 Blood Donation</title>
                     <text>
                        <paragraph>Advise patients not to donate blood during therapy and for at least 6 weeks following discontinuation of mycophenolate mofetil
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S5.8">Warnings and Precautions (5.11)</linkHtml>]
 
  </content>.
 
  <content styleCode="italics">.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240306"/>
                  </section>
               </component>
               <component>
                  <section ID="S17.10">
                     <id root="130317dd-7188-69c9-e063-6394a90adc55"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>17.10 Semen Donation</title>
                     <text>
                        <paragraph>Advise males of childbearing potential not to donate semen during therapy and for 90 days following discontinuation of mycophenolate mofetil.
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S5.8">Warnings and Precautions (5.12)</linkHtml>]
 
  </content>.

 </paragraph>
                     </text>
                     <effectiveTime value="20240306"/>
                  </section>
               </component>
               <component>
                  <section ID="S17.11">
                     <id root="130317dd-7189-69c9-e063-6394a90adc55"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>17.11 Potential to Impair Driving and Use of Machinery</title>
                     <text>
                        <paragraph>Advise patients that mycophenolate mofetil can affect the ability to drive or operate machines. Patients should avoid driving or operating machines if they experience somnolence, confusion, dizziness, tremor or hypotension during treatment with mycophenolate mofetil.
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S5.14">Warnings and Precautions (5.14)</linkHtml>]
 
  </content>.

 </paragraph>
                        <paragraph>The brands listed are trademarks of their respective owners.</paragraph>
                     </text>
                     <effectiveTime value="20240306"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="id_link_13032067-69d5-6790-e063-6394a90aaf26">
               <id root="13032067-69d4-6790-e063-6394a90aaf26"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <text>
                  <paragraph>Repackaged and Distributed By:</paragraph>
                  <paragraph>Remedy Repack, Inc.</paragraph>
                  <paragraph>625 Kolter Dr. Suite #4 Indiana, PA 1-724-465-8762</paragraph>
               </text>
               <effectiveTime value="20240306"/>
            </section>
         </component>
         <component>
            <section ID="MG">
               <id root="13032067-69d6-6790-e063-6394a90aaf26"/>
               <code code="42231-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL MEDGUIDE SECTION"/>
               <text>
                  <table width="100%">
                     <colgroup>
                        <col align="left" valign="top" width="3%"/>
                        <col align="left" valign="top" width="30%"/>
                        <col align="left" valign="top" width="17%"/>
                        <col align="left" valign="top" width="3%"/>
                        <col align="left" valign="top" width="14%"/>
                        <col align="left" valign="top" width="13%"/>
                        <col align="left" valign="top" width="20%"/>
                     </colgroup>
                     <tbody>
                        <tr>
                           <td/>
                           <td/>
                           <td/>
                           <td/>
                           <td/>
                           <td/>
                           <td/>
                        </tr>
                        <tr styleCode="Botrule">
                           <td align="center" colspan="7" styleCode="Lrule Rrule">
                              <content styleCode="bold">Dispense with Medication Guide available at www.accordhealthcare.us/medication-guides</content>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td align="center" colspan="7" styleCode="Lrule Rrule">
                              <content styleCode="bold">MEDICATION GUIDE</content>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td align="center" colspan="7" styleCode="Lrule Rrule">
                              <content styleCode="bold">Mycophenolate Mofetil Capsules 250 mg
      <br/>
			Mycophenolate Mofetil Tablets 500 mg
      <br/>
			(MYE koe FEN oh late MOE fe til)
     </content>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="7" styleCode="Lrule Rrule">Read the Medication Guide that comes with mycophenolate mofetil capsules and tablets before you start taking it and each time you refill your prescription. There may be new information. This Medication Guide does not take the place of talking with your doctor about your medical condition or treatment.</td>
                        </tr>
                        <tr>
                           <td colspan="7" styleCode="Lrule Rrule">
                              <content styleCode="bold">What is the most important information I should know about mycophenolate mofetil capsules and tablets?
      <br/>
			Mycophenolate mofetil capsules and tablets can cause serious side effects, including:
      <br/>
			Increased risk of loss of a pregnancy (miscarriage) and higher risk of birth defects.
     </content>Females who take mycophenolate mofetil during pregnancy have a higher risk of miscarriage during the first 3 months (first trimester), and a higher risk that their baby will be born with birth defects.
			
     <list listType="unordered">
                                 <item>
                                    <content styleCode="bold">If you are a female who can become pregnant</content>, your doctor must talk with you about acceptable birth control methods (contraceptive counseling) to use while taking mycophenolate mofetil. You should have 1 pregnancy test immediately before starting mycophenolate mofetil capsules and tablets and another pregnancy test 8 to 10 days later. Pregnancy tests should be repeated during routine follow-up visits with your doctor. Talk to your doctor about the results of all of your pregnancy tests.
       <br/>
				You must use acceptable birth control during your entire mycophenolate mofetil treatment and for 6 weeks after stopping mycophenolate mofetil capsules and tablets, unless at any time you choose to avoid sexual intercourse (abstinence) with a man completely. Mycophenolate mofetil decreases blood levels of the hormones in birth control pills that you take by mouth. Birth control pills may not work as well while you take mycophenolate mofetil, and you could become pregnant. If you take birth control pills while using mycophenolate mofetil you must also use another form of birth control. Talk to your doctor about other birth control methods that you can use while taking mycophenolate mofetil capsules and tablets.
      </item>
                                 <item>
                                    <content styleCode="bold">If you are a sexually active male whose female partner can become pregnant while you are taking mycophenolate mofetil capsules and tablets,</content>use effective contraception during treatment and for at least 90 days after stopping mycophenolate mofetil capsules and tablets.
      </item>
                                 <item>
                                    <content styleCode="bold">If you plan to become pregnant</content>, talk with your doctor. Your doctor will decide if other medicines to prevent rejection may be right for you.
      </item>
                                 <item>
                                    <content styleCode="bold">If you become pregnant while taking mycophenolate mofetil capsules and tablets, do not stop taking mycophenolate mofetil capsules and tablets. Call your doctor right away.</content>You and your doctor may decide that other medicines to prevent rejection may be right for you. You and your doctor should report your pregnancy to the Mycophenolate Pregnancy Registry either:
				
       <list listType="unordered">
                                       <item>By phone at 1-800-617-8191 
         <content styleCode="bold">or</content>
                                       </item>
                                       <item>By visiting the REMS website at 
         <content styleCode="bold">www.mycophenolateREMS.com</content>
                                       </item>
                                    </list>
				The purpose of this registry is to gather information about the health of you and your baby.
      </item>
                              </list>
                              <content styleCode="bold">Increased risk of getting certain cancers.</content>People who take mycophenolate mofetil capsules and tablets have a higher risk of getting lymphoma, and other cancers, especially skin cancer. Tell your doctor if you have:
    </td>
                        </tr>
                        <tr>
                           <td colspan="3" styleCode="Lrule">
                              <list listType="unordered">
                                 <item>unexplained fever, prolonged tiredness, weight loss or lymph node swelling</item>
                                 <item>a brown or black skin lesion with uneven borders, or one part of the lesion does not look like the other</item>
                              </list>
                           </td>
                           <td colspan="4" styleCode="Rrule">
                              <list listType="unordered">
                                 <item>a change in the size and color of a mole</item>
                                 <item>a new skin lesion or bump</item>
                                 <item>any other changes to your health</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="7" styleCode="Lrule Rrule">
                              <content styleCode="bold">Increased risk of getting certain cancers.</content>People who take mycophenolate mofetil capsules and tablets have a higher risk of getting lymphoma, and other cancers, especially skin cancer. Tell your doctor if you have:
    </td>
                        </tr>
                        <tr>
                           <td colspan="3" styleCode="Lrule">
                              <list listType="unordered">
                                 <item>unexplained fever, prolonged tiredness, weight loss or lymph node swelling</item>
                                 <item>a brown or black skin lesion with uneven borders, or one part of the lesion does not look like the other</item>
                              </list>
                           </td>
                           <td colspan="4" styleCode="Rrule">
                              <list listType="unordered">
                                 <item>a change in the size and color of a mole</item>
                                 <item>a new skin lesion or bump</item>
                                 <item>any other changes to your health</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="7" styleCode="Lrule Rrule">
                              <content styleCode="bold">Increased risk of getting serious infections.</content>Mycophenolate mofetil capsules and tablets weakens the body's immune system and affects your ability to fight infections. Serious infections can happen with mycophenolate mofetil capsules and tablets and can lead to hospitalizations and death. These serious infections can include:
			
     <list listType="unordered">
                                 <item>
                                    <content styleCode="bold">Viral infections.</content>Certain viruses can live in your body and cause active infections when your immune system is weak. Viral infections that can happen with mycophenolate mofetil capsules and tablets include:
				
       <list listType="unordered">
                                       <item>Shingles, other herpes infections, and cytomegalovirus (CMV). CMV can cause serious tissue and blood infections.</item>
                                       <item>BK virus. BK virus can affect how your kidney works and cause your transplanted kidney to fail.</item>
                                       <item>Hepatitis B and C viruses. Hepatitis viruses can affect how your liver works. Talk to your doctor about how hepatitis viruses may affect you.</item>
                                       <item>COVID-19</item>
                                    </list>
                                 </item>
                                 <item>
                                    <content styleCode="bold">A brain infection called Progressive Multifocal Leukoencephalopathy (PML).</content>In some patients, mycophenolate mofetil capsules and tablets may cause an infection of the brain that may cause death. You are at risk for this brain infection because you have a weakened immune system. Call your doctor right away if you have any of the following symptoms:
      </item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule"/>
                           <td colspan="2">
                              <list listType="unordered" styleCode="Disc">
                                 <item>Weakness on one side of the body</item>
                                 <item>You do not care about things that you usually care about (apathy)</item>
                              </list>
                           </td>
                           <td/>
                           <td colspan="3" styleCode="Rrule">
                              <list listType="unordered" styleCode="Disc">
                                 <item>You are confused or have problems thinking</item>
                                 <item>You can not control your muscles</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="7" styleCode="Lrule Rrule">
                              <list listType="unordered">
                                 <item>
                                    <content styleCode="bold">Fungal infections</content>. Yeasts and other types of fungal infections can happen with mycophenolate mofetil capsules and tablets and can cause serious tissue and blood infections (See " 
       <content styleCode="bold">
                                       <linkHtml href="#Effects">What are the possible side effects of mycophenolate mofetil capsules and tablets?</linkHtml>
                                    </content>" 
       <content styleCode="bold">).</content>
                                 </item>
                              </list>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="7" styleCode="Lrule Rrule">See " 
     <content styleCode="bold">
                                 <linkHtml href="#Effects">What are the possible side effects of mycophenolate mofetil capsules and tablets?</linkHtml>
                              </content>" for information about other serious side effects.
    </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="7" styleCode="Lrule Rrule">
                              <content styleCode="bold">What is Mycophenolate mofetil capsules and tablets?</content>
                              <list listType="unordered">
                                 <item>Mycophenolate mofetil capsules and tablets are a prescription medicine to prevent rejection (antirejection medicine) in people who have received a kidney, heart or liver transplant. Rejection is when the body's immune system perceives the new organ as a "foreign" threat and attacks it.</item>
                                 <item>Mycophenolate mofetil capsules and tablets is used with other medicines containing cyclosporine and corticosteroids.</item>
                              </list>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="7" styleCode="Lrule Rrule">
                              <content styleCode="bold">Who should not take Mycophenolate mofetil capsules and tablets?
      <br/>
			Do not take mycophenolate mofetil capsules and tablets if you are allergic to mycophenolate mofetil or any of the ingredients in mycophenolate mofetil capsules and tablets.
     </content>See the end of this Medication Guide for a complete list of ingredients in mycophenolate mofetil capsules and tablets.
    </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="7" styleCode="Lrule Rrule">
                              <content styleCode="bold">What should I tell my doctor before taking Mycophenolate mofetil capsules and tablets?
      <br/>
			Tell your doctor about all of your medical conditions, including if you:
     </content>
                              <list listType="unordered">
                                 <item>have any digestive problems, such as ulcers.</item>
                                 <item>have Lesch-Nyhan syndrome, Kelley-Seegmiller syndrome or another rare inherited deficiency hypoxanthine-guanine phosphoribosyl-transferase (HGPRT). You should not take mycophenolate mofetil capsules and tablets if you have one of these disorders.</item>
                                 <item>plan to receive any vaccines. People taking mycophenolate mofetil capsules and tablets should not receive live vaccines. Some vaccines may not work as well during treatment with mycophenolate mofetil capsules and tablets.</item>
                                 <item>are pregnant or plan to become pregnant. See " 
       <content styleCode="bold">
                                       <linkHtml href="#Important">What is the most important information I should know about mycophenolate mofetil capsules and tablets?</linkHtml>" 
       </content>
                                 </item>
                                 <item>are breastfeeding or plan to breastfeed. It is not known if mycophenolate mofetil passes into breast milk. You and your doctor will decide if you will take mycophenolate mofetil capsules and tablets or breastfeed.</item>
                              </list>
                              <content styleCode="bold">Tell your healthcare provider about all the medicines you take,</content>including prescription and over-the-counter medicines, vitamins and herbal supplements. Some medicines may affect the way mycophenolate mofetil capsules and tablets works, and mycophenolate mofetil capsules and tablets may affect how some medicines work.
     <br/>
			Especially tell your doctor if you take:
			
     <list listType="unordered">
                                 <item>birth control pills (oral contraceptives). See " 
       <content styleCode="bold">
                                       <linkHtml href="#Important">What is the most important information I should know about mycophenolate mofetil capsules and tablets?</linkHtml>
                                    </content>"
      </item>
                                 <item>sevelamer (Renagel 
       <sup>®</sup>, Renvela™). These products should be taken at least 2 hours after taking mycophenolate mofetil capsules and tablets.
      </item>
                                 <item>acyclovir (Zovirax 
       <sup>®</sup>), valacyclovir (Valtrex 
       <sup>®</sup>), ganciclovir (CYTOVENE 
       <sup>®</sup>-IV, Vitrasert 
       <sup>®</sup>), valganciclovir (VALCYTE 
       <sup>®</sup>).
      </item>
                                 <item>rifampin (Rifater 
       <sup>®</sup>, Rifamate 
       <sup>®</sup>, Rimactane 
       <sup>®</sup>, Rifadin 
       <sup>®</sup>).
      </item>
                                 <item>antacids that contain magnesium and aluminum (mycophenolate mofetil capsules and tablets and the antacid should not be taken at the same time).</item>
                                 <item>proton pump inhibitors (PPIs) (Prevacid 
       <sup>®</sup>, Protonix 
       <sup>®</sup>).
      </item>
                                 <item>sulfamethoxazole/trimethoprim (BACTRIM™, BACTRIM DS™).</item>
                                 <item>norfloxacin (Noroxin 
       <sup>®</sup>) and metronidazole (Flagyl 
       <sup>®</sup>, Flagyl 
       <sup>®</sup>ER, Flagyl 
       <sup>®</sup>IV, Metro IV, Helidac 
       <sup>®</sup>, Pylera™).
      </item>
                                 <item>ciprofloxacin (Cipro 
       <sup>®</sup>, Cipro 
       <sup>®</sup>XR, Ciloxan 
       <sup>®</sup>, Proquin 
       <sup>®</sup>XR) and amoxicillin plus clavulanic acid (Augmentin 
       <sup>®</sup>, Augmentin XR™).
      </item>
                                 <item>azathioprine (Azasan 
       <sup>®</sup>, Imuran 
       <sup>®</sup>).
      </item>
                                 <item>cholestyramine (Questran Light 
       <sup>®</sup>, Questran 
       <sup>®</sup>, Locholest Light, Locholest, Prevalite 
       <sup>®</sup>).
      </item>
                              </list>
			Know the medicines you take. Keep a list of them to show to your doctor or nurse and pharmacist when you get a new medicine. Do not take any new medicine without talking with your doctor.
    </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="7" styleCode="Lrule Rrule">
                              <content styleCode="bold">How should I take Mycophenolate mofetil capsules and tablets?</content>
                              <list listType="unordered">
                                 <item>Take mycophenolate mofetil capsules and tablets exactly as prescribed.</item>
                                 <item>Do not stop taking mycophenolate mofetil capsules and tablets or change the dose unless your doctor tells you to.</item>
                                 <item>If you miss a dose of mycophenolate mofetil capsules and tablets, or you are not sure when you took your last dose, take your prescribed dose of mycophenolate mofetil capsules and tablets as soon as you remember. If your next dose is less than 2 hours away, skip the missed dose and take your next dose at your normal scheduled time. Do not take 2 doses at the same time. Call your doctor if you are not sure what to do.</item>
                                 <item>Take mycophenolate mofetil capsules and tablets on an empty stomach, unless your doctor tells you otherwise.</item>
                                 <item>
                                    <content styleCode="bold">Do not</content>crush mycophenolate mofetil tablets.
      </item>
                                 <item>
                                    <content styleCode="bold">Do not</content>open or crush mycophenolate mofetil capsules.
      </item>
                                 <item>If you are not able to swallow mycophenolate mofetil tablets or capsules, your doctor may prescribe mycophenolate mofetil oral suspension. This is a liquid form of mycophenolate mofetil. Your pharmacist will mix the medicine before you pick it up from a pharmacy.</item>
                                 <item>Do not mix mycophenolate mofetil oral suspension with any other medicine. Mycophenolate mofetil oral suspension should not be mixed with any type of liquids before taking the dose. See the 
       <linkHtml href="#IFU">Instructions for Use</linkHtml>at the end of this Medication Guide for detailed instructions about how to take mycophenolate mofetil oral suspension the right way.
      </item>
                                 <item>
                                    <content styleCode="bold">Do not</content>breathe in (inhale) or let Mycophenolate mofetil powder or oral suspension come in contact with your skin or mucous membranes.
				
       <list listType="unordered">
                                       <item>If you accidentally get the powder or oral suspension on the skin, wash the area well with soap and water.</item>
                                       <item>If you accidentally get the powder or oral suspension in your eyes or other mucous membranes, flush with plain water.</item>
                                    </list>
                                 </item>
                                 <item>If you take too much mycophenolate mofetil, call your doctor or the poison control center right away.</item>
                              </list>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="7" styleCode="Lrule Rrule">
                              <content styleCode="bold">What should I avoid while taking Mycophenolate mofetil capsules and tablets?</content>
                              <list listType="unordered">
                                 <item>Avoid becoming pregnant. See 
       <content styleCode="bold">" 
        <linkHtml href="#Important">What is the most important information I should know about mycophenolate mofetil capsules and tablets?</linkHtml>" 
       </content>
                                 </item>
                                 <item>Limit the amount of time you spend in sunlight. Avoid using tanning beds or sunlamps. People who take mycophenolate mofetil capsules and tablets have a higher risk of getting skin cancer. (See 
       <content styleCode="bold">" 
        <linkHtml href="#Important">What is the most important information I should know about mycophenolate mofetil capsules and tablets?</linkHtml>" 
       </content>) Wear protective clothing when you are in the sun and use a broad-spectrum sunscreen with a high protection factor. This is especially important if your skin is very fair or if you have a family history of skin cancer.
      </item>
                                 <item>You should not donate blood while taking mycophenolate mofetil capsules and tablets and for at least 6 weeks after stopping mycophenolate mofetil capsules and tablets.</item>
                                 <item>You should not donate sperm while taking mycophenolate mofetil capsules and tablets and for 90 days after stopping mycophenolate mofetil capsules and tablets.</item>
                              </list>
			Mycophenolate mofetil capsules and tablets may influence your ability to drive and use machines (See 
     <content styleCode="bold">" 
      <linkHtml href="#Effects">What are the possible side effects of mycophenolate mofetil capsules and tablets?</linkHtml>") 
     </content>. If you experience drowsiness, confusion, dizziness, tremor, or low blood pressure during treatment with mycophenolate mofetil capsules and tablets, you should be cautious about driving or using heavy machines.
    </td>
                        </tr>
                        <tr>
                           <td colspan="7" styleCode="Lrule Rrule">
                              <content styleCode="bold">What are the possible side effects of mycophenolate mofetil capsules and tablets?</content>
                              <br/>
			Mycophenolate mofetil capsules and tablets 
     <content styleCode="bold">may cause serious side effects, including:</content>
                              <list listType="unordered">
                                 <item>See 
       <content styleCode="bold">" 
        <linkHtml href="#Important">What is the most important information I should know about mycophenolate mofetil capsules and tablets?</linkHtml>" 
       </content>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Low blood cell counts.</content>People taking high doses of mycophenolate mofetil capsules and tablets each day may have a decrease in blood counts, including:
				
       <list listType="unordered">
                                       <item>
                                          <content styleCode="bold">white blood cells, especially neutrophils.</content>Neutrophils fight against bacterial infections. You have a higher chance of getting an infection when your white blood cell count is low. This is most common from 1 month to 6 months after your transplant.
        </item>
                                       <item>
                                          <content styleCode="bold">red blood cells.</content>Red blood cells carry oxygen to your body tissues. You have a higher chance of getting severe anemia when your red blood cell count is low.
        </item>
                                       <item>
                                          <content styleCode="bold">platelets</content>. Platelets help with blood clotting.
        </item>
                                    </list>
				Your doctor will do blood tests before you start taking mycophenolate mofetil and during treatment with mycophenolate mofetil capsules and tablets to check your blood cell counts.Tell your doctor right away if you have any signs of infection (see 
       <content styleCode="bold">" 
        <linkHtml href="#Important">What is the most important information I should know about mycophenolate mofetil capsules and tablets?</linkHtml>" 
       </content>), including any unexpected bruising or bleeding. Also, tell your doctor if you have unusual tiredness, lack of energy, dizziness or fainting.
      </item>
                              </list>
                              <content styleCode="bold">Stomach problems.</content>Stomach problems including intestinal bleeding, a tear in your intestinal wall (perforation) or stomach ulcers can happen in people who take mycophenolate mofetil capsules and tablets. Bleeding can be severe and you may have to be hospitalized for treatment. Call your doctor right away if you have sudden or severe stomach-area pain or stomach-area pain that does not go away, or if you have diarrhea.
     <br/>
                              <content styleCode="bold">Inflammatory reactions.</content>Some people taking mycophenolate mofetil may have an inflammatory reaction with fever, joint stiffness, joint pain, and muscle pain. Some of these reactions may require hospitalization. This reaction could happen within weeks to months after your treatment with mycophenolate mofetil starts or if your dose is increased. Call your doctor right away if you experience these symptoms.
     <br/>
                              <content styleCode="bold">The most common side effects of mycophenolate mofetil capsules and tablets include:</content>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" styleCode="Lrule">
                              <list listType="unordered">
                                 <item>diarrhea</item>
                                 <item>blood problems including low white and red blood cell counts</item>
                                 <item>infections</item>
                                 <item>blood pressure problems</item>
                                 <item>fast heartbeat</item>
                                 <item>swelling of the lower legs, ankles and feet</item>
                              </list>
                           </td>
                           <td colspan="4" styleCode="Rrule">
                              <list listType="unordered">
                                 <item>changes in laboratory blood levels, including high levels of blood sugar (hyperglycemia)</item>
                                 <item>stomach problems including diarrhea, constipation, nausea and vomiting</item>
                                 <item>rash</item>
                                 <item>nervous system problems such as headache, dizziness and tremor</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="7" styleCode="Lrule Rrule">
                              <content styleCode="bold">Side effects that can happen more often in children than in adults taking mycophenolate mofetil capsules and tablets include:</content>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" styleCode="Lrule">
                              <list listType="unordered">
                                 <item>stomach area pain</item>
                                 <item>fever</item>
                                 <item>infection</item>
                                 <item>pain</item>
                                 <item>blood infection (sepsis)</item>
                                 <item>diarrhea</item>
                              </list>
                           </td>
                           <td colspan="4" styleCode="Rrule">
                              <list listType="unordered">
                                 <item>vomiting</item>
                                 <item>sore throat</item>
                                 <item>colds (respiratory tract infections)</item>
                                 <item>high blood pressure</item>
                                 <item>low white blood cell count</item>
                                 <item>low red blood cell count</item>
                              </list>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="7" styleCode="Lrule Rrule">These are not all of the possible side effects of mycophenolate mofetil capsules and tablets. Tell your doctor about any side effect that bothers you or that does not go away.
     <br/>
                              <content styleCode="bold">Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088</content>. You may also report side effects to www.accordhealthcare.us or call Accord Healthcare Inc. at 1-866-941-78753.
    </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="7" styleCode="Lrule Rrule">
                              <content styleCode="bold">How should I store mycophenolate mofetil capsules and tablets?</content>
                              <list listType="unordered">
                                 <item>Store mycophenolate mofetil capsules and tablets at room temperature, between 59°F to 86°F (15°C to 30°C).</item>
                                 <item>Keep mycophenolate mofetil tablets in the light-resistant container that it comes in.</item>
                              </list>
                              <content styleCode="bold">Keep mycophenolate mofetil capsules and tablets and all medicines out of the reach of children.</content>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="7" styleCode="Lrule Rrule">
                              <content styleCode="bold">General information about the safe and effective use of mycophenolate mofetil capsules and tablets.</content>
                              <br/>
			Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use mycophenolate mofetil capsules and tablets for a condition for which it was not prescribed. Do not give mycophenolate mofetil capsules and tablets to other people, even if they have the same symptoms that you have. It may harm them.
     <br/>
			This Medication Guide summarizes the most important information about mycophenolate mofetil capsules and tablets. If you would like more information, talk with your doctor. You can ask your doctor or pharmacist about mycophenolate mofetil capsules and tablets that is written for health professionals.
    </td>
                        </tr>
                        <tr>
                           <td colspan="7" styleCode="Lrule Rrule">
                              <content styleCode="bold">What are the ingredients in mycophenolate mofetil capsules and tablets?
      <br/>
			Active ingredient:
     </content>mycophenolate mofetil
     <br/>
                              <content styleCode="bold">Inactive ingredients:
      <br/>
			Mycophenolate mofetil 250 mg capsules:
     </content>croscarmellose sodium, magnesium stearate, povidone (K-90), microcrystalline cellulose, hydroxypropyl cellulose and talc. The capsule shells contain FD&amp;C blue #2, gelatin, red iron oxide, sodium lauryl sulfate, titanium dioxide, and yellow iron oxide. The imprinting ink contains shellac, iron oxide black and potassium hydroxide.
     <br/>
                              <content styleCode="bold">Mycophenolate mofetil 500 mg tablets:</content>iron oxide black, croscarmellose sodium, FD&amp;C blue #2 aluminum lake, hydroxypropyl cellulose, hypromellose, magnesium stearate, microcrystalline cellulose, polyethylene glycol 400, povidone (K-90), iron oxide red, talc, and titanium dioxide.
     <br/>
                              <br/>
                              <br/>
			The brands listed are trademarks of their respective owners.
     <br/>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>This Medication Guide has been approved by the US Food and Drug Administration Revised: 10/2023</paragraph>
                  <paragraph>Repackaged By / Distributed By: RemedyRepack Inc.</paragraph>
                  <paragraph>625 Kolter Drive, Indiana, PA 15701</paragraph>
                  <paragraph>(724) 465-8762</paragraph>
               </text>
               <effectiveTime value="20240306"/>
            </section>
         </component>
         <component>
            <section ID="id_link_13033623-8ca4-6e1d-e063-6294a90a0881">
               <id root="13033623-8ca3-6e1d-e063-6294a90a0881"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph>DRUG: mycophenolate mofetil</paragraph>
                  <paragraph>GENERIC: mycophenolate mofetil</paragraph>
                  <paragraph>DOSAGE: CAPSULE</paragraph>
                  <paragraph>ADMINSTRATION: ORAL</paragraph>
                  <paragraph>NDC: 70518-2835-0</paragraph>
                  <paragraph>NDC: 70518-2835-1</paragraph>
                  <paragraph>COLOR: blue</paragraph>
                  <paragraph>SHAPE: CAPSULE</paragraph>
                  <paragraph>SCORE: No score</paragraph>
                  <paragraph>SIZE: 19 mm</paragraph>
                  <paragraph>IMPRINT: GC1</paragraph>
                  <paragraph>PACKAGING: 1 in 1 POUCH</paragraph>
                  <paragraph>OUTER PACKAGING: 100 in 1 BOX</paragraph>
                  <paragraph>ACTIVE INGREDIENT(S):</paragraph>
                  <list listType="unordered">
                     <item>MYCOPHENOLATE MOFETIL 250mg in 1</item>
                  </list>
                  <paragraph>INACTIVE INGREDIENT(S):</paragraph>
                  <list listType="unordered">
                     <item>CROSCARMELLOSE SODIUM</item>
                     <item>MAGNESIUM STEARATE</item>
                     <item>CELLULOSE, MICROCRYSTALLINE</item>
                     <item>POVIDONE K90</item>
                     <item>HYDROXYPROPYL CELLULOSE (90000 WAMW)</item>
                     <item>TALC</item>
                     <item>FD&amp;C BLUE NO. 2</item>
                     <item>GELATIN</item>
                     <item>FERRIC OXIDE RED</item>
                     <item>SODIUM LAURYL SULFATE</item>
                     <item>TITANIUM DIOXIDE</item>
                     <item>FERRIC OXIDE YELLOW</item>
                     <item>SHELLAC</item>
                     <item>POTASSIUM HYDROXIDE</item>
                     <item>FERROSOFERRIC OXIDE</item>
                  </list>
                  <paragraph>
                     <renderMultiMedia referencedObject="Remedy_Label"/>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="img_13032314-2556-68dc-e063-6394a90a8c11"/>
                  </paragraph>
               </text>
               <effectiveTime value="20240306"/>
               <component>
                  <observationMedia ID="Remedy_Label">
                     <text>Remedy_Label</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="Remedy_Label.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="img_13032314-2556-68dc-e063-6394a90a8c11">
                     <text>MM2</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="Mycophenolate Mofetil 250mg_70518-2835-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>